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Cognitive dysfunction occurs during the cholestatic liver disease Primary biliary 
Cholangitis (PBC). Patients experience with short-term memory and concentration deficit, 
termed ‘brain fog’. This can be debilitating and severely affect quality of life, with no 
beneficial treatments (Newton, Hollingsworth et al. 2008) 
 
In this thesis, using the murine Bile Duct Ligation (BDL) model and in vitro modelling with 
human neuronal cells, I investigated the effects of cholestasis on the blood-brain barrier 
(BBB) and resultant changes within the brain. This study focussed on the hippocampus 
due to its crucial role in learning and memory. Changes to BBB could be observed from 
day 6, including astrocyte detachment, and permeability using MRI. By day 10 mice had 
visual spatial memory deficits, neuroinflammation was seen within the hippocampus, and 
changes were observed in gamma frequency oscillations. Interestingly, neurons in the 
hippocampus possessed features of senescence in cholestatic mice (telomere associated 
DNA damage, and P21+ RNA), highlighting parallels in pathology between the liver (where 
senescence is known to occur during cholestasis) and the brain. This effect was mirrored 
during in vitro studies, where neurons treated with PBC patient serum (to simulate 
pathological exposure to bile acids) also displayed increased sen-B-gal, a feature of 
senescence.   
 
In another strand, I examined the ability of both approved (ursodeoxycholic acid, 
Obeticholic Acid) and experimental (Bezafibrate) therapies to modify cognitive processes. 
Only Obeticholic Acid provides a potential therapeutic due to its in vivo and in vitro effects. 
Strikingly, OCA improve cognition and reduces neuronal senescence in BDL mice and in 
vitro when neurons are pre-treated before serum treatments.  
 
Therefore, the data presented in this thesis implicates senescence as a key pathological 
feature of cholestatic disease not just in the liver but also in brain where it has been 
previously linked to poor cognition (Baker, Wijshake et al. 2011, Fielder, Tweedy et al. 
2020). Further investigation of early intervention with OCA may prove beneficial to 
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Bile duct ligation (BDL) 
Bile Duct Resection (BDR) 
Bile acid (BA) 
Obeticholic Acid (OCA) 
Ursodeoxycholic Acid (UDCA) 
non-alcoholic steatohepatitis (NASH) 
Bezafibrates (BF) 
Open Field (OF) 
Blood-brain barrier (BBB) 
Neurovascular Unit (NVU) 
Brain Microvascular Endothelial Cells (BMECs) 
Hepatic Encephalopathy (HE) 
Sucrose rich artificial cerebral-spinal fluid (SaCSF) 
Artificial cerebral-spinal fluid (aCSF) 
Carbachol (Cb) 
Micromolar (μM) 
Room temperature (RT) 
phosphocreatine responses (PCr) 
cardio pulmonary exercise testing (CPET), 
quality of life (QOL) 
resting-state functional magnetic resonance imaging (rsfMRI) 
Diffusion Tensor Imaging Magnetic Resonance Imaging (DTI-MRI) 
interferon gamma (IFN- γ)  
lipopolysaccharide (LPS) 
Arginase1 (arg1) 
Nitric oxide synthase (iNOS) 
 Rotations per minute (RPM) 
 Glial acidic fibrillary protein (GFAP) 
Electron microscopy (EM) 
Fluorescence Activated Cell Sorting (FACs) 
 v 
Biliary Epithelial Cells (BECs)  
Ductular Reaction (DR) 
Phosphate Buffered Saline (PBS) 
Distilled water (dH20) 
Parvalbumin (PV) 
Peroxisome Proliferator-Activated Receptor (PARR) 
Aspartate Transaminase (AST) 
Alanine Transaminase (ALT) 
Alkaline Phosphatase (ALP) 
Cytochrome P450 cholesterol 7A1-hydroxylase (CYP7A1)  
Cytochrome sterol 27-hydroxylase (CYP27A1) 
Carbontetrachloride (CCL4) 
α-naphthylisothiocyanate (ANIT) 
apical sodium-dependent bile acid transporter (ASBT) 
Pregnane X receptor (PXR) 
Farnesoid X Receptor (FXR) 
tumour necrosis factor-α (TNF-α) 
interleukins 4 and 10 (IL4, IL10) 
transforming growth factor beta (TGF-β) 
Takeda G protein Coupled receptor (TGR5) 
Lithocholic Acid (LCA) 
Taurocholic acid (TCA) 
Glycoursodeoxycholic acid (GUDCA) 
chenodeoxycholic acid (CDCA) 
monozygotic (MZ) 
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1. Chapter One - General Introduction 
 The Normal Functional Anatomy of the Human Liver 
and Biliary Tree 
1.1.1. Liver 
 
The organ of the liver is primarily responsible for several processes including 
detoxification, energy homeostasis, cholesterol and fat processing in conjunction 
with the biliary system. It also represents the largest visceral organ by volume, 
spanning the upper abdomen (Rogers and Dintzis 2012).  
 
The liver is comprised of four lobes, in order of size; the right, the left, the caudate 
and the quadrate lobe. The lobes have complex interlinking functionality. The major 
blood supply (70%) of the liver comes from the portal vein. The portal vein is 
mirrored by the bile ducts which run in parallel throughout, giving rise to the classic 
‘portal triad’ formation seen in liver histology first reported by Ludwig (Ludwig 
1987).  
 
The portal triad is the centre of the functional units of the liver; named lobules or 
hepatic acinus. These comprise of aforementioned portal triad (a bile duct, portal 
vein and hepatic artery) with bridging formation of hepatocytes. This construction 
causes a graded oxygen content across different areas of the lobule, partitioning 
areas of the liver into metabolic zones (figure 1). These zones are crucial for the 
normal functioning of the liver. The zones represent flexible metabolic attributes of 
hepatocytes, and can be modified and shifted into either a more oxygen dependent 
or glycolytic state along with other metabolic modifications. 
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Figure 1. The metabolic and functional organisation of the liver. 
1.1.2. The Biliary Tree 
The biliary tree in humans is a complex system of interlobular, septal and major ducts 
intersected at one end with the Canals of Hering and the other the extrahepatic bile 
ducts, delivering bile to the gallbladder. Bile has many roles in the body, most famously 
it is the major pathway for cholesterol degradation.  
In this pathway bile acids are formed as end-products of degraded cholesterol and must 
be excreted via the intestines through to the faeces. The normal composition of the bile 
is 97% water, 0.7% bile acids, 0.2% bilirubin, 0.51% fats (cholesterol, fatty acids, and 
lecithin) (Barrett and Ganong 2012). Bile is made in the liver by the hepatocytes and 
secreted into the bile canaliculi via the apical membrane. Adjacent hepatocytes have 
adjoining apical membranes separated via tight junctions(Anderson and Van Itallie 
1995). This both sticks hepatocytes together and ensures the bile acids don’t diffuse 
from the bile flow. During cholestatic injury, distressed hepatocytes can change their 
bile secretion patterns, disrupting the tight junction and leading to perturbed flow, 
resulting in bidirectional bile flow back into the intercellular space and out into the liver 
(Boyer 1983). 
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Bile secretion differs depending on the area of the lobule in which the hepatocyte 
resides. Hepatocytes from the periportal regions are exposed to and produce  higher 
concentrations of bile salts, resulting in a larger size of canaliculi in these regions (Layden 
and Boyer 1978). Once within the biliary tree, tracts are lined with cholangiocytes (also 
termed biliary epithelial cells) -the major cell type lining the biliary epithelium. 
Smaller ducts are lined by between 4-5 cholangiocytes, while larger ducts can be lined 
by up to 40 (Glaser, Francis et al. 2006). Classically, cholangiocytes are mitotically 
dormant however they have been shown to proliferate in response to noxious stimuli 
such as carbontetrachloride (CCL4) (LeSage, Benedetti et al. 1999), α-
naphthylisothiocyanate (ANIT), or cholestasis (Glaser, Lam et al. 2010). It is thought that 
smaller cholangiocytes (lining small ducts) have a larger proliferative capacity than larger 
cholangiocytes (lining large ducts). Cholangiocyte proliferation, termed ductular 
reaction (DR) also occurs during cholestatic biliary disease in humans (Sell 1998).  
1.1.3. Differences in the Liver and Biliary Tree between 
humans and rodents 
Rodents provide a good model species for study of the liver and biliary tree. However, 
there are some key differences in the structural organisation. In mice, livers spans the 
entire subdiaphragmatic space and accounts for 6% of total body weight, 3x as much as 
humans (Rogers and Dintzis 2012). Rodents also have fewer intermediary ducts, 
possessing mainly large and small ducts (Alpini, Roberts et al. 1996). 
Another key difference in rats is the absence of the gall bladder, first reported in 1922 
(McMaster 1922). While the cause of this is not known it is thought that due to the 
nature of a rat’s diet (low fats) and the way in which they continuously forage for food 
a gallbladder is not evolutionarily necessary, and the liver is able to produce sufficient 
bile without a need for storage. 
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 Bile Salts Function, Composition and Regulation 
As aforementioned, the bile is partly made up of bile acids. These have long been 
described as digestive detergents, acting as detergents to emulsify circulating fat 
globules. While these bile acids do have a primary role in the breakdown of cholesterol 
(over half of cholesterol is broken down this way (Insull 2006)),  they are also bioactive 
steroids hormones with key roles in processes such as energy homeostasis.  
Bile acids are produced solely in the liver, by hepatocyte undergoing a series of catabolic 
reactions producing bile from cholesterol under the power of the enzyme cholesterol 
7α-hydroxylase (CYP7A1). Due to their control of cholesterol homeostasis the levels of 
bile acids in the enterohepatic circulation is tightly regulated, through the transcription 
of CYP7A1 (Russell & Setchell, 1992) (Pullinger, Eng et al. 2002). CYP7A1 is the rate 
limiting enzyme in the classical pathway of bile acid synthesis, leading to the repression 
of bile acid synthesis via negative feedback loops.  
The primary bile acids in humans cholic acid (CA) and chenodeoxycholic acid (CDCA) are 
ordinarily synthesised by hepatocytes under CYP7A1 in the classical pathway. More 
rarely their synthesis can be initiated by mitochondrial CYP7A1, which is found in other 
cell types in the liver including macrophages (Hylemon, Zhou et al. 2009).  
 
After synthesis in the liver, bile acids are secreted and absorbed into the intestine (figure 
2). The main transporter responsible for bile acid transport from the apical (canicular) 
membrane is BSEP (Childs, Yeh et al. 1995). The importance of BSEP was discovered in 
progressive familial intrahepatic cholestasis subtype 2 (PFIC-2) patients. A lack of 
functional BSEP in these patients leads to severe decrease in normal bile acid 
concentration (1% of normal), highlighting BSEP as the major canalicular bile acid 
transport mechanism (Strautnieks, Kagalwalla et al. 1997). 
 
Upon reaching the large intestine primary bile acids undergo further processing via 
deconjugation and dehydroxylation by gut bacteria. This processing forms secondary 
bile acids such as chenodeoxycholic acid (CDCA) conversion to lithocholic acid (LA) 
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(Ridlon, Kang et al. 2006). Unconjugated bile acids can be absorbed passively in the 
ileum, and conjugated bile acids are actively transported by bile acid transporters 
(Wilson, Lindsey et al. 1968) back to the liver. In humans, bile acids are stored primarily 
in the gallbladder, and are released after each meal. 
 
In the gallbladder bile acids and cholesterols along with phospholipids and micelles, 
which solubilise cholesterols and also reduce bile acid toxicity. This allows bile acids to 
facilitate absorption of dietary vitamins and lipids in the small intestine. Upon release 
into the intestines, bile acids are then reabsorbed into the ileum and taken back to the 
liver (via portal tract) for re-excretion into the bile by the hepatocytes. In the ileum 
terminal bile acids are absorbed into the enterocyte actively by the apical sodium-
dependent bile acid transporter (ASBT) and secreted back to portal circulation via 
basolateral Ostα/Ostβ transporters, which have a key role in preventing accumulating 
bile acid toxicity (Ferrebee, Li et al. 2018) and are a major basolateral bile acid transport 
system in the intestine and many other epithelial cells (Dawson, Hubbert et al. 2005). 
Hepatocytes take up bile acids by Na+-taurocholate co-transporting polypeptide (NTCP) 


















The bile acids found in mammalian species are so called ‘modern’ C24 bile acids. These 
bile acids form the majority of the human bile pool and consist of chains 24 carbon 
atoms long (Hofmann, Sjövall et al. 1992). The bile acid pools of other more ‘primitive’ 
vertebrates such as sharks or amphibians are commonly 25, 26 or 27 carbon atoms in 
length. Mammalian bile acids are conjugated with glycine or taurine, in humans at a 
ratio of about 4:1 (Warren, Chalmers et al. 2006). 
 
 Key Bile Acid Receptors and their Specific Roles 
1.3.1. Farnesoid X Receptor (FXR) 
 
Farnesoid X Receptor (FXR) is a nuclear bile acid receptor with functions in metabolism, 
and a pivotal role in regulating liver inflammation and regeneration (Meng, Wang et al. 
2010, Zhang, Wang et al. 2012). It is expressed in a variety of tissues such as liver, 
adipose tissue, pancreas, kidney and the vascular wall (Huber, Murphy et al. 2002). 
Figure 2. Active mechanisms of bile acid transport through the liver and biliary system. 
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Several papers indicate that FXR has a key role in gene regulation of hepatic bile acid 
synthesis, bile acid secretion from the gall bladder, absorption into the intestine and 
hepatic bile acid uptake, thus highlighting its role in mechanisms of bile acid homeostasis 
throughout its cycle (Kuipers, Claudel et al. 2004). 
 
FXR can be activated by both free and conjugated bile acids. Hydrophobic bile acids are 
more potent agonists.  Chenodeoxycholic acid (CDCA) is the natural compound of 
highest affinity (EC50 ~ 10 μM) (Wang, Chen et al. 1999) and deoxycholic acid and 
lithocholic acid bind with weaker affinity. Hydrophilic bile acids such as muricholic acid 
and ursodeoxycholic acid cannot activate FXR (Li, Jadhav et al. 2013). Intercept’s artificial 
compound Obeticholic Acid can activate FXR with a potency 100x stronger than CDCA 
(De Magalhaes Filho, Downes et al. 2016). 
 
1.3.1.1. Regulation of Bile Acid Synthesis by Farnesoid X 
Receptor 
 
Bile acid synthesis is largely controlled by the transcriptional regulation of CYP7A1, the 
main rate limiting step in bile synthesis in the liver (Chiang 2009). It is also well known 
that bile acids are responsible for repressing CYP7A1 gene expression, generating an 
effective negative feedback loop. This feedback mechanism allows the liver to 
effectively increase or decrease bile acid synthesis and the resulting pool, maintaining 
constant levels. 
 
Inhibition feedback of CYP7A1 is controlled by FXR. This nuclear receptor is expressed in 
both hepatocyte and enterocytes, and induces small heterodimer partner (SHP), to 
repress transcriptional regulator liver-related homologue-1 (LRH-1). This in turn binds to 
the CYP7A1 promotor, inhibiting CYP7A1 synthesis and reducing bile acid production 
(Heuman, Hylemon et al. 1989, Goodwin, Jones et al. 2000). Inhibition is induced via a 
cascade mediated by small heterodimer partner (SHP) and various transcription factors 
which bind the bile acid response elements in the promoter region of CYP7A1 (Stroup, 
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Crestani et al. 1997). Other cytochrome 450 enzymes involved in BA synthesis can also 
be regulated in this way, for example CYP8B1 (Yang, Zhang et al. 2002). 
 
However, SHP deficient mice are still able to repress CYP7A1 expression, through bile 
acid stimulation and through FXR agonism.  This therefore suggests other FXR mediated 
feedback regulation of CYP7A1 must exist in place of SHP knockout (Kerr, Saeki et al. 
2002). Concurrently, FXR has also been shown to induce fibroblast growth factor-15 
(FGF-15) (FGF-19 in murine), which can also affect CYP7A1 transcription, highlighting a 
role for FXR as a master regulator of bile acid synthesis. FGF-15 infusion in mouse 
studies, either directly into circulation or specifically in liver tissue caused repression of 
CYP7A1 mRNA (Inagaki, Choi et al. 2005).  
 
Conversely, when mice lack functional FXR, bile acid synthesis is upregulated, CYP7A1 
expression increased, and pool size increased (Sinal, Tohkin et al. 2000)  illustrating the 
importance of FXR in inhibition of bile acid synthesis. 
 
1.3.1.2. Role of Farnesoid X Receptor in Lipid Metabolism 
 
It has long been known that bile acid sequestrants reduce total and low-density 
lipoprotein in the plasma. Patients on bile acid supplements decrease their high-density 
lipoprotein whereas cholestyramine treatment (bile acid sequestrant) can increase HDL 
cholesterol levels (Shepherd, Packard et al. 1979). 
 
1.3.2. Takeda G Protein 5 Receptor 
 
TGR5 is a G-protein coupled receptor, also named G-protein bile acid-activated receptor 
(GP-BAR1). TGR5 is widely expressed in many tissues, including the intestine, 
gallbladder, liver, and brain (Maruyama et al., 2002). In the liver TGR5 is expressed 
mainly in Kupffer cells and sinusoidal cells, with no TGR5 expression in hepatocytes 
(Keitel, Donner, Winandy, Kubitz, & Haussinger, 2008; Keitel et al., 2007). When 
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activated, TGR5 stimulates cAMP synthesis, leading via intracellular signalling cascades 
to increases in nitrous oxide and the complex phosphorylation of CD95 (Reinehr & 
Haussinger, 2004). This reduces bile acid- induced apoptosis in the sinusoidal cells, which 
are regularly exposed to high levels of bile acids from the portal circulation post-meals. 
 
 Primary Biliary Cholangitis (PBC) 
 
Primary Biliary Cholangitis (PBC) is an autoimmune liver disease of the bile duct. Immune 
system attack causes destruction of the intrahepatic bile ducts, selectively targeting 
intrahepatic cholangiocytes. The disease also causes progressive cholestasis of the liver, 
defined as ‘decrease in bile flow due to impaired secretion by hepatocytes or 
obstruction of intra/extra-hepatic bile ducts. Ultimately the build-up of bile acids in the 
hepatic circulation leads to inflammation and fibrosis of the liver, which can advance to 
cirrhosis at the later stages of the disease. In 26% of cases this leads to liver failure within 
10 years of diagnosis (Washington 2007). 
  
Clinically, PBC is a heterogeneous disease, causing difficulties in diagnosis and 
treatment. Patient presentation can range from asymptomatic and slow progressing 
cholestasis diagnosed only from abnormal liver biochemistry to advanced cirrhosis 
(Long, Scheuer et al. 1977, Crowe, Christensen et al. 1985). It is clear that PBC represents 
a variety of patients, with as spectrum of disease states reflecting ongoing dynamic 
processes of bodily wide and local organ injury. 
 
1.4.1. Anti-Mitochondrial and Anti-Nuclear Antibodies 
 
The pathophysiology of PBC was identified in the 1980s as a loss of tolerance to 
ubiquitous mitochondrial autoantigens the E2 subunit at the mitochondrial pyruvate 
dehydrogenase complex (PDC-E2), causing targeted injury at the small ducts. This leads 
to an autoimmune response driven by mitochondrial autoantigen intolerance, primarily 
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within the liver causing inflammatory response (cholangitis), progressing to cholestasis 
(prohibition/ disruption of bile flow) and on to cirrhosis of the liver. The presence of anti-
mitochondrial antigens (AMA) is largely used for clinical diagnosis, however these are 
present only in 90-95% of cases (Hirschfield 2011). It is thought that AMAs are the most 
specific immune marker of any autoimmune disease. 
 
AMAs specifically recognise the lipoylated domains on immunodominant epitopes 
where lipoic acid is attached at the lysine group (K) 173. T cells and B cells both possess 
the lipoylated K173 group, leading to CD4 T cell being enriched 100-150-fold in the liver 
and lymph nodes. CD8 T cells (PDC-E2 specific) in the liver also possess this domain and 
so are upregulated by 10 fold (Kita , Lian  et al. 2002, Kita, Matsumura et al. 2002).  
 
AMA negative patients show no obvious differences from AMA positive patients, and 
present similarly based on criteria of age, sex and liver (Lindgren, Glaumann et al. 2009). 
This goes against the paradigm of AMA positivity as central to PBC diagnosis and 
progression, and has sparked debate on the true pathogenesis of PBC.  
 
More recently, other autoantibodies have been linked with the disease. Antinuclear 
antibodies (ANAs) are autoantibodies attacking the nuclear fraction of the cell, and 
occur in around 50% of patients. They are clinically significant, and can be prognostic 
indicators (their presence informs of more severe disease) (Nakamura, Takii et al. 2006, 
Nakamura, Kondo et al. 2007). However, the pathogenic significance of these is unclear.  
 
Clinical laboratories typically use fluorescence microscopy to detect changes in the 
nucleus, such as dotted nuclei or rimmed patterns. Specific components linked with 
nuclear pore complex gp120 and sp100 have been implicated in prognostic testing. 
Recent studies have shown that higher titres of AMA specific antibodies anti-gp210 and 
anti-sp100 can be associated with more advanced disease (Gatselis, Zachou et al. 2013), 
whereas only mildly elevated anti-sp100 titres were associated with a better long term 
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prognosis. More recently these biomarkers of progression have been investigated in 
trials (Huang, Han et al. 2019). 
 
1.4.2. Histology and Immune Response 
 
PBC is an organ specific autoimmune disease, with the small hepatic ducts the main 
target of autoimmune attack. The disease has a complex interplay of genetics or 
environmental factors with the adaptive immune system contributing to disease onset 
and progression. 
 
PBC has a very distinct histology, categorised into four stages. First comes periportal 
inflammation with ductular lesions, moving on to secondary increased periportal lesions 
and hepatitis. The third stage is defined by loss of normal hepatic architecture and 
bridging fibrosis, followed by cirrhosis of the liver at stage four. These stages are often 
accompanied by ‘florid lesions’ - areas of intense inflammatory response and resulting 
necrosis (Ludwig, Dickson et al. 1978). The inflammatory infiltrate resulting in the lesions 
is heterogeneous, consisting of large numbers of lymphocytes that are closely 
associated with distressed and necrotic BECs, as well as both resident and infiltrating 
macrophage populations (Kobayashi, Kakuda et al. 2014). This large-scale inflammation 
leads to occlusion at the ducts and portal veins accompanied by ductular reaction. Figure 
3 below from (Smyk, Rigopoulou et al. 2012) gives examples of histological staging. 
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1.4.3. Ductular Reaction  
Ductular reaction is a key pathological feature of PBC. It is defined as an expansion and 
proliferation at the duct, via expansion of ductules or by differentiation of hepatic 
progenitor cells (HPC) into biliary structures. Ductular reaction requires two key 
interlinked processes; the proliferation of the epithelium at the duct and the aggravation 
by bile acids leading to fibrosis. Both mesenchymal and inflammatory cell accompany 
the expansion of BECs that surround the biliary tract. HPC expansion exists as a 
compensatory mechanism in the event of liver damage, when hepatocytes become 
distressed (Roskams 2003). In association with this ductular reaction, hepatic stellate 
cells become activated and proliferate, depositing extra cellular matrix in a fibrotic 
Figure 3. Figure is taken from (Smyk, Rigopoulou et al. 2012). The four histological stages of PBC begin with 
inflammatory infiltrate leading to extensive periportal inflammation and ductular reaction. Stage 3 is bridging fibrosis 
through the tissue finally followed in stage 4 by cirrhosis. 
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response(Milani, Herbst et al. 1990). It remains unclear which of these events occur first, 
however the combination results in an expanded and distorted duct. 
 
BECs play a key role in ductular rearrangement. During PBC BECs begin to express a 
reactive phenotype of a combination of chemokines and cytokines along with 
angiogenic factors similar to during liver development which encourage proliferation 
(Strazzabosco and Fabris 2012). Phenotypic changes to these cells create paracrine 
connections with stromal cells such as hepatic stellate cells and Kupffer cells (Fabris and 
Strazzabosco 2011). 
 
1.4.4. Adaptive Immune Response in PBC 
 
Adaptive immune response in PBC is thought to be activated as a consequence of 
autoimmune response. The triggers resulting in the autoimmune response remain 
unclear, however molecular mimicry has been suggested. PDC-E2 reactive T cell lines 
(the primary PBC autoantigen) have been shown to be cross reactive with E.Coli 
peptides, which may provide some insight into the pathogenesis of PBC (Shimoda, 
Nakamura et al. 2000). 
 
1.4.4.1. CD8 T Cells 
Overall, CD8+ T cells are key in the pathogenesis of PBC. They infiltrate the portal regions 
throughout disease progression in ample numbers (Kita , Lian  et al. 2002) and infact a 
PBC phenotype can be induced by transfer of CD8 T cells from dnTGF-βRII mouse model 
of PBC in to wild type C57/Bl6 mouse strain (Yang, Lian et al. 2008). Other PBC emulating 
mouse models show the development of lesions is paired with huge CD8 T cell 
infiltration (Wakabayashi, Yoshida et al. 2009). 
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1.4.4.2. CD4 T Cells 
CD4 T cells also infiltrate the peri-portal hepatic regions both in PBC and in animal 
models. Increased CD4 T cells can be seen accumulating specifically within the portal 
tracts (Lan, Salunga et al. 2009) compared to other regions of the liver. Other studies 
show that  Th1 cells mediate initial immune response, which is then perpetuated by 
Th17 cells in established disease (Yang, Ma et al. 2014).  
 
Other T cells populations have also been investigated in PBC. The presence of IL-6 in the 
bile duct suggests that Th2 cell cytokines lead to cell damage by antibody dependent 
cytotoxicity (Yasoshima, Kono et al. 1998).  
 
1.4.5. Aetiology and Risk Factors 
 
As with many autoimmune diseases, PBC has a complex and heterogeneous inheritance. 
There is a high level of predominance in women (approx. 10:1 in the UK), and is 
particularly common in postmenopausal women. Though it is less common in men, male 
patients tend to present at an younger age and have a more severe disease phenotype 
(Carbone, Mells et al. 2013), and were less likely to show response once they began 
treatment with UDCA.  
 
Reasons for the high female predominance in PBC are scarce. Women who develop PBC 
at a younger age also show a clear reduction in response to first line treatment UDCA 
(Carbone, Mells et al. 2013) like men. As cholestasis is seen in pregnancy, it seems likely 
that this effect could be influenced by the effects of female sex hormones such as 
oestrogen, the receptors for which are expressed on liver populations such as 
cholangiocytes (Alvaro, Invernizzi et al. 2004).  
 
Another hypothesis is that PBC may be influenced by changes in sex chromosomes. X 
linked disease such as Turner’s syndrome can have autoimmune symptoms causing 
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chronic cholestasis, and additionally several key immune tolerance genes such as FOXP3 
are coded for by the X chromosome (Powell, Buist et al. 1982). Women with PBC also 
have frequent X chromosome monosomy, suggestive of X chromosome instability 
(Invernizzi, Miozzo et al. 2004).  
 
1.4.5.1. Genetic Risk and Risk alleles 
 
There is some monozygotic (MZ) twin concordance in PBC, suggesting an element of 
genetic inheritance (Selmi, Mayo et al. 2004). However, studies in discordant MZ twin 
pairs show there are marked differences in epigenetic modifications such as DNA 
methylation and additional copy number variants resulting from duplications or 
rearrangement (Selmi, Cavaciocchi et al. 2014).  
 
The prevalence of PBC risk in first degree relatives of those with the condition is 
approximately 0.72% and 1.2% (Hirschfield and Invernizzi 2011). However, this becomes 
much higher if female to female relatives (such as mother-daughter) are investigated 
(Lazaridis, Juran et al. 2007). 
 
In the past decade, Genome Wide Association Studies (GWAS) have led to some 
progress in mapping the genetic susceptibility to the disease. Susceptibility loci have 
been identified are mainly within the Human Leukocyte Antigen complex (HLA). This is 
encoded on the major histocompatibility complex and is responsible for regulation of 
the human immune response. Both Canadian (Hirschfield, Liu et al. 2009) and Italian 
(Liu, Invernizzi et al. 2010) GWAS have confirmed susceptibility loci for PBC falling within 
the HLA, and two main genes outside of the HLA IL12A and IL12RB2 both of which 





1.4.5.2. Environmental Factors 
 
There have been several environmental factors reported as influencing the 
pathogenesis of PBC. The prevalence of PBC is markedly different in different countries 
and regions. Within the UK incidence of PBC is highest in the North East (Prince, 
Chetwynd et al. 2001) and South Wales (Metcalf and James 1997). There could be a 
number of reasons for this; firstly, PBC is more prevalent in areas of socioeconomic 
deprivation. The North East is a typically deprived region, which can cause large scale 
differences in demographic and produces many confounding variables, making it tricky 
to discern specific risk factors for PBC development. Historically, it is a coal mining 
region, as is South Wales, likely leading to the large-scale environmental release of 
chemical compounds. Areas of Coal mining activity have been found to be associated 
with PBC diagnosis hotspots in the North East of England (Dyson, Blain et al. 2019). 
However other risk factors such as smoking (Gershwin, Selmi et al. 2005), have long been 
reported higher in lower socioeconomic groups (Hiscock, Bauld et al. 2012). 
 
Xenobiotics have been at the forefront of environmental candidates for the triggering 
of PBC, largely because of their associations with several other autoimmune diseases 
such as systemic sclerosis. There are several candidates for xenobiotic compounds in 
PBC from compounds present in cigarettes as mentioned above, to compounds found 
in pesticides, food additives, and hair dyes (Amano, Leung et al. 2005). There is also 
evidence to suggest that the auto-immune reaction may be due to the activation of the 
immune system following pathogenic response. Several pathogens have been 
investigated from Escherichia coli (Burroughs, Rosenstein et al. 1984) (a bacteria 
commonly implicated in UTIs). A summary of genetic and environmental risk factors can 





Figure 4.Environmental and genetic risk factors in the development of PBC. 
1.4.5.3. Diagnosis and Symptoms 
 
At the time of diagnosis, a large portion of patients are asymptomatic (20-61%) (Prince, 
Chetwynd et al. 2004). Patients with PBC can remain symptomless for up to 10 years, 
however once symptoms appear time until transplant is around 10 years (Washington 
2007). Better testing procedures and AMA testing have improved the likelihood of early 
diagnosis. 
 
The introduction of large-scale qualitative methodology such as the PBC-40 
questionnaire has highlighted the associations of certain symptom presentation and low 
quality of life scores. The most common symptoms at presentation are pruritus and 
fatigue. However, these are often the most debilitating, causing patients to stay in their 
homes and affecting daily function 
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1.4.5.4. Pruritis 
Pruritus causes uncomfortable itching in patients. It can range from mild and tolerable 
to immobilising, leading to sleep disturbance, depression and reduced quality of life. The 
itch generally occurs in a diurnal pattern, with an intense late evening itching period. 
Possible causes of the itching sensation include accumulation of bile acids in the tissues 
and/or stimulation of brain centres involved in sensation, which may have evolved as a 
protective reflex against noxious stimulation in the body. Despite how common and how 
severe this itching can be, the exact pathophysiology of pruritis remains unclear. 
Evidence shows that when bile acids are injected subcutaneously, a pruritis itch occurs, 
supporting the hypothesis of tissue bile acid accumulation (Varadi 1974). Additionally, 
bile acid monologue drug treatments such as ursodeoxycholic acid (UDCA) do little to 
cessate these pruritic symptoms (Ricci, Hofmann et al. 1998).  
There is evidence to suggest that itch has an interlinked neurological pathology. Opioid 
antagonists and serotonin reuptake inhibitors such as nalextrone and sertraline both 
have mild anti pruritic activity. However, the most potent anti-pruritic effect and 
therefore the most common prescribed treatment is rifampicin the Pregnane X receptor 
(PXR) agonist (EASL 2009), suggesting that much of the itch originates in the liver and 
that bile acids have a large contribution to the overall symptomatology.  
1.4.5.5. Fatigue  
 
Fatigue is one of the most common and debilitating symptoms of PBC. A complex 
symptom set, it is reported to occur in anywhere between 40-80% pf patients (Witt-
Sullivan, Heathcote et al. 1990, Goldblatt, Taylor et al. 2002, Poupon, Chrétien et al. 
2004). Of those experiencing fatigue 68% have spells lasting over 6 months(Cauch-
Dudek, Abbey et al. 1998), and 20% experience debilitating fatigue leaving them unable 
to work (Dyson, Wilkinson et al. 2016). As well as working fatigue can also severely 
impact other factors such as mental health, family and social life. Studies using the UK-
PBC cohort have shown that fatigue is the symptom which causes the greatest impact 
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on perceived quality of life for patients (Mells, Pells et al. 2013), making it an important 
target for therapy. 
 
However, no therapy as currently used impacts fatigue, including first- and second-line 
therapies UDCA (Heathcote, Cauch-Dudek et al. 1994) and OCA (Nevens, Andreone et 
al. 2016). Even liver transplantation in end stage disease does nothing to improve fatigue  
(Carbone, Bufton et al. 2013).  
 
The pathophysiology of fatigue, as with many of the other symptoms remains poorly 
understood. Fatigue can be broadly characterised in two components; peripheral and 
central fatigue. Peripheral fatigue is often described as loss of energy and is related to 
muscle weakness. It has been shown that fatigued PBC patients are quicker to tire upon 
repeated hand grip testing. Interestingly, fatigue is correlative with rate of grip strength 
decline on repeat testing (Goldblatt, James et al. 2001). 
 
Muscle acidosis may be a contributing factor, and has been found to be caused by 
mitochondrial dysregulation in the muscle of patients. Studies have shown fatigued 
patients have a higher ratio of phosphocreatine responses (PCr) to ATP in both working 
arm muscle (Hollingsworth, Newton et al. 2008) and cardiac muscle (Jones, 
Hollingsworth et al. 2010). Using cardio pulmonary exercise testing (CPET), PBC patients 
were found to have significantly lower anaerobic threshold than controls. Changes in 
aerobic anaerobic metabolism in fatigued patients contribute to muscle acidosis.  
Intramuscular acidosis leads to increased muscle fatigue during sustained activity, 
resulting in reduced contractile force and longer recovery times (Allen, Lannergren et al. 
1995). 
 
The central component is often self-described by patients as ‘brain fog’ and has several 
neurophysiological changes resulting in depression sleep disturbance and cognitive 
abnormalities. It is likely that central fatigue is intricately interlinked with cognitive 
symptoms in PBC. Fatigued patients have been found to have delayed sleep timing 
 20 
leading to disturbed sleep and excessive daytime somnolence (Montagnese, Nsemi et 
al. 2013).  
 
1.4.5.6. Cognitive Symptoms 
 
Cognitive impairments are most often reported as problems relating to concentration 
and memory. These occur in many patients, with 80% reporting mild cognitive 
impairment and 50% showing moderate to severe issues with concentration and 
memory (Newton, Hollingsworth et al. 2008). They have a large negative impact on 
patient quality of life, leaving patients unable to function normally (Hale, Newton et al. 
2012). Despite this, cognitive deficits are often under diagnosed, and written off as 
fatigue based. One of the main issues face by patients with cognitive symptoms is that 
they do not correlate with disease progression (Newton, Bhala et al. 2006), or to 
histological markers of liver disease severity (Newton, Hollingsworth et al. 2008) and is 
not reversed by transplantation.  
 
1.4.5.6.1. Inclusion of Cognitive Symptoms Within the PBC-
40 
 
Because of this ambiguity, most quality of life (QOL) research in PBC until 2005 had been 
focussed on fatigue despite the fact that there is evidence of a separate mechanisms of 
cognitive deficit with abnormalities seen in attentional, concentration and psychomotor 
testing (Tarter, Hegedus et al. 1987, Floreani, Marchiori et al. 1995). The invention and 
subsequent inclusion in clinical assessment of scoring systems such as the PBC-40 
(Jacoby, Rannard et al. 2005) have allowed the definitive separation of fatigue and 
cognitive deficit as symptoms by providing specific cognition based questions in the 
assessment.   
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Cognitive symptoms have been separately categorised and is addressed by six questions 
in the PBC-40 questionnaire ‘In the last 4 weeks: 
• I had to make a lot of effort to remember things 
• I had difficulty remembering things from one day to the next 
• My concentration span was short because of PBC 
• I had difficulty keeping up with conversations 
• I found it difficult to concentrate on anything 
• I found it difficult to remember what I wanted to do’ (Jacoby, Rannard et al. 
2005) 
 
1.4.5.6.2. Human Brain Imaging Studies in PBC 
 
This kind of recognition has led to more in depth analysis of the effects of PBC both 
physiologically on the brain itself and on the day-to-day functional capacity of patients. 
White matter lesions (WML) have been identified in patients, from early stages of the 
disease, suggesting there is damage foci in the brain of patients, perhaps in areas of high 
neuroinflammatory susceptibility (Newton, Hollingsworth et al. 2008). The density of 
lesions was found to be correlated with severity of cognitive deficit in these studies, and 
deficits were also associated with autonomic dysfunction (measured in systolic blood 
pressure) where lower blood pressure was associated with cognitive dysfunction. Lesion 
density was found to be greater in the frontal lobe, an area important in higher level 
executive function. 
 
In addition to physical changes to the brain, functional magnetic resonance studies of 
deep grey matter structures in the brains of PBC patients (Mosher, Swain et al. 2017) 
have revealed changes in the functional connectivity of patients. Using 20 patients and 
21 matched controls Mosher et al studied resting state functional connectivity in several 
deep brain structures (the hippocampus, amygdala, thalamus and putamen) via resting-
state functional magnetic resonance imaging (rsfMRI). The signals created by rsfMRI are 
synchronous in functional brain networks, either within or between brain regions.  
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The study shows PBC patients exhibit several rsFC changes in key brain regions. They 
report an increased rsFC within the putamen, amygdala, hippocampus and thalamus. As 
suggested by the authors, this could be as a result of chronic immune cell infiltration 
resulting in connectivity changes within the brain (D'Mello, Le et al. 2009). Changes such 
as these in key functional areas modulating memory and adaptive function 
(hippocampus, amygdala) could feasibly be responsible for the changes in cognition 
experienced by patients.  
 
Mosher et al also found altered rsFC in the connections between the putamen and the 
motor cortex. In light of previous studies linking changes in motor cortex excitability with 
fatigue symptoms, it is likely that the shift in rsFC is related to fatigue symptoms. 
However, similar shift in rsFC between the putamen and regions important in 
attentional control (IFG) and working memory (superior frontal gyrus, inferior parietal 
gyrus) are more likely to be functionally related to cognitive deficits, highlighting the 
functional separation of the two symptoms. The researchers were also able to correlate 
these rsFC changes in the deep brain to performance in working memory tasks, fatigue 
and itch. 
 
Subsequent follow up studies have investigated more closely the hippocampal structure 
and found reduced hippocampal volume in PBC patients (Mosher, Swain et al. 2018). As 
concluded by the study, this is likely correlative with neuroinflammation and resultant 
oxidative stress within and surrounding the hippocampus, due to iron deposition. In 
depth analysis of key hippocampal sub-structures revealed significant changes to the 
subiculum, CA4 and dentate gyrus. As the patients in this particular study are only on 
average 6 years after diagnosis, brain structural changes begin early in the disease 
process.  
 
Sophisticated functional imaging techniques such as Diffusion Tensor Imaging Magnetic 
Resonance Imaging (DTI-MRI) have unveiled changes to fractional anisotropy in  patients 
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to significant levels in the thalamus (Grover, Southern et al. 2016). The thalamus is an 
important relay centre in the brain, and therefore may be implicated in the executive 
function and attentional deficit reported by patients. In conjunction the study reported 
change in T1 weighted MRI showing abnormalities in all brain regions studied including 
the thalamus, caudate putamen, and global pallidus.  
 
Other groups who have used DTI have also found few differences. A German study from 
2018 reported no significant changes to DTI in any brain regions in PBC patients (Zenouzi, 
von der Gablentz et al. 2018). However, this study also found few changes in cognition 
score, and only selected functional deficit based not in working memory or executive 
function domains, but in verbal fluency measurements.  
 
1.4.5.7. Overlap between Fatigue and Cognitive Symptoms 
 
Studies such as these and more highlight the complex interlinking mechanisms of fatigue 
and cognitive dysfunctions in PBC. Peripheral fatigue can often occur separately, 
whereas the symptoms of central fatigue are more complex, as they are closely 
associated with cognitive dysfunction, and likely have overlapping pathologies. This is 
highlighted by studies such as Mosher et al 2017 showing connectivity changes in key 
functional areas such as the hippocampus can be correlated with both working memory 
tasks and fatigue. 
 
Differences in sampling and patient selection can cause a high variability in cognitive 
studies. Due to the huge variety in symptoms experienced by patients and the overlap 
between fatigue and cognitive domains, it becomes difficult to tease apart functional 
differences associated with different brain regions and contributing to different 
symptoms. The aforementioned German study targeted a highly fatigued patient set, 
with little cognitive symptoms, whereas the study by Grover et al stratified patients 
based on cognitive domains in the PBC-40 questionnaire.  Another complicating issue is 
the interplay between pre cirrhotic cognitive changes in PBC, and the development of 
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post cirrhotic hepatic encephalopathy. Though pre cirrhotic symptoms and their 
pathology is less studied, publications such as these corroborate evidence of cognitive 
symptoms outside of classic late stage hepatic encephalopathy. This highlights the need 
for further study of the mechanistic basis of cognitive dysfunction in cholestatic liver 
diseases such as PBC. 
 
 Hepatic Encephalopathy (HE) 
 
Hepatic encephalopathy (HE) is a severe and debilitating brain condition rising from end-
stage cirrhotic liver disease, occurring in around 40% of cirrhotic patients (Poordad 
2007). He begins at minimal stage (stage 1) with mild confusion and changes to verbal 
fluency and impaired sleep-wake cycle and progresses through to severe HE (stage3-4), 
resulting in confusion, and ultimately the patient becomes comatose (Amodio, 
Montagnese et al. 2004). HE is a well-established prognostic indicator for PBC, and one 
patients rarely recover from – stage 4 HE is associated with high mortality rates (Wong, 
Gish et al. 2014, Bajaj, O’Leary et al. 2017).  
 
1.5.1. Pathogenesis of HE  
1.5.2. Hyper-ammonia  
 
The hepatology community has outlined hyper ammonia as the classical cause of HE. 
Ordinarily the healthy liver is responsible for much of the processing of ammonia during 
the urea cycle. The liver transforms ammonia into urea which is split between the kidney 
and intestines for disposal through urine, and further transformation and faecal 
expulsion respectively. The intestine also creates most of the ammonia found in the 
bodily circulation through the deamination of amino acids, releasing it back into the 
portal circulation for transport to the liver. The liver uptakes around 85% of produced 
ammonia (fig 4). In cirrhotic conditions, the stressed hepatocytes in the liver are unable 
to process ammonia. This causes a build-up of ammonia that is unable to be transformed 
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and excreted. This causes an overload of ammonia in portal circulation. However due to 
overloading of the liver, portal hypertension occurs, leading to a much larger 




Figure 5. Ammonia circulation in healthy and cirrhotic liver. 
 
A high concentration of circulating ammonia can lead to permeability at the blood brain 
barrier through induced changes at tight junctions (Ott and Larsen 2004). Usually 
cerebral ammonia is detoxified via glutamine synthetase expressed by astrocytes, and 
converted into glutamine. Accumulation of glutamine within astrocytes leads to swelling 
which is causative of oedema (Wright, Davies et al. 2007).  
 Treatments for PBC 
 
Treatments are thoroughly reviewed as introduction in Chapter 4 (page 96). 
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 The Blood-Brain Barrier in Health and Disease 
 
The blood brain barrier forms a protective environment between the brain and the rest 
of the body. It allows the free movement of water and permeable molecules and also 
allows some molecules by active transport. Lipid solubility plays a large role in the 
passage of molecules through the blood brain barrier and is affected by many factors 
such as charge and tertiary structure (Banks 2009).  
 
The BBB is organised into neurovascular units (NVU), as first described by Harder et al in 
2002 (Harder, Zhang et al. 2002). NVUs consist of the brain capillary endothelium, 
pericytes (Lai and Kuo 2005) along with associated astrocytic end-feet and neurons 
(Cohen, Ehret et al. 1995) as seen in figure 6. Each component is intricately linked with 
the other, establishing one whole functional unit. NVUs provide a highly efficient 
system, regulated by gap junctions and ion channels to enable the transport of ions and 
neuro-modulatory molecules between the blood and the brain (Gordon, Choi et al. 
2008). 
 
Figure 6. A) Anatomical layout of the Blood-brain barrier, with astrocytes forming attachment both  to the 
vessel and neurons. B) Cross sectional diagram of a blood vessel indicating astrocyte end-feet, pericyte 




The role of the astrocyte at the blood brain barrier was first questioned in Camilo Golgi’s 
famous work (reprint can be found here (Golgi, Bentivoglio et al. 2001) originally 
published in 1886), where he noted the close proximity of astrocyte end-feet with the 
cerebrovasculature. After this it was not re-examined until much later by Davson and 
Oldendorf (Davson and Oldendorf 1967). It is now known that astrocytes play an 
important role in maintaining separation of the central nervous system and the rest of 
the bodily circulation, including regulation of ionic flow, nutrients and macromolecules 
into the CNS. 
 
Initial descriptions of astrocytes vastly underestimated their role, pinning them as 
neuronal and structural support cells both within the NVU and wider brain functions. 
This was questioned by Cornell-Bell, who went on to show the astrocytes express 
glutamate sensitive ion channels, and are able to propagate calcium waves within their 
own cytoplasm but also to each other, promoting long-range communication (Cornell-
Bell, Finkbeiner et al. 1990).  
 
Astrocytes are incredibly versatile and are able to communicate with both blood vessels 
and neurons simultaneously. They are involved in bidirectional communication at the 
synapse, expressing G-protein coupled receptors that can sense neurotransmitters and 
stimulate the appropriate gliotransmitter response (reviewed here (Santello, Calì et al. 
2012). By release of these gliotransmitters, astrocytes are able to modulate synaptic 
communication. 
 
Gliotransmission means astrocytes are able to communicate efficiently not just with 
neurons but with cells such as pericytes and endothelial cells at the barrier. This allows 
modification of processes such as vasodilation in accordance with neuronal activity in 
order to maintain intricate balance of energy consumption by neurons and the delivery 





Pericytes sit closely associated with endothelial cells and provide them with structural 
support. Pericytes are essential to NVU function as they sit between the brain 
parenchyma and the blood vessels facilitating communication between the two. More 
recently interest in pericytes has grown, and in the last ten years key discoveries have 
been made about their function, such as their ability to regulate the BBB through 
signalling factors, influencing both the tight junctions of endothelial cells and the 
attachment of astrocyte end-feet (Armulik, Genové et al. 2010). It has since been 
reported that reduced pericyte number can cause increased BBB permeability through 
tight junction loss (Sengillo, Winkler et al. 2013), and pericytes control the flow of 
molecules between the blood stream and the brain, solidifying them as key modulators 
of BBB function.  
 
Additionally, pericytes also have roles in the neuroinflammatory response – they can 
express inflammatory cytokines and present their antigens to immune cells, recruit 
them to allow their passage into the brain (Rustenhoven, Jansson et al. 2017). In 
response to inflammatory cytokines such as IL-1B or TNF- α inflammatory signals are 
released along with matrix metalloproteinase 9 (MMP-9) which can directly lead to BBB 
breakdown (Herland, van der Meer et al. 2016).  
 
1.7.3. Evidence of BBB dysfunction in cholestatic liver 
disease 
 
Over the past 10 years, support has been building for the hypothesis that the circulation 
of toxic bile acid and related molecules could facilitate BBB breakdown and allow 
neurological changes. Proof of bile acid related BBB breakdown is scarce and much is 
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limited to in vitro modelling of human cells. These studies largely focus on the tight 
junction aspects of BBB integrity.  
 
In these experiments treatment with unconjugated bilirubin (UCB) led to a bi-phasic 
response, of which the second phase caused the reduction in zonula occludens (ZO)-1 
and β-catenin levels, thus leading to reduction of tight junctions and cell-to-cell contacts 
(Palmela, Sasaki et al. 2012). Similar effects were also seen by the group using LPS, or a 
combination of both LPS and UCB (Cardoso, Kittel et al. 2012). These changes could 
potentially increase para-cellular permeability and allow bile acid entry into the brain in 
pathogenic conditions.  
 
Bile acids themselves seem to exert pleiotropic effects at the barrier. In vitro follow up 
to the above studies shows pre-treatment with hydrophilic bile acids UDCA or 
glycoursodeoxycholic acid (GUDCA) confer protection against UCB induced barrier 
permeability (Palmela, Correia et al. 2015). Later studies indicate that both hydrophobic 
bile acids such as chenodeoxycholic acid (CDCA) and hydrophilic bile acids such as 
deoxycholic acid (DCA), but not UDCA can permeabilize the BBB. This study not only 
provides early evidence that cholestasis can be detrimental to BBB function, but that 
individual bile acids such as CDCA and DCA can mediate this effect and are able to 
permeabilize the BBB both in vitro and in vivo (Quinn, McMillin et al. 2014). Seemingly, 
the effects of bile acids at the barrier are more complex than being able to state a 
positive or negative effect, rather they are likely to have complex interactions, based on 




Neuroinflammation is an inflammatory response within the brain, mediated by 
cytokines chemokines or other neuro-reactive molecules produced largely by either 
infiltrating immune cells or resident neuroglia (microglia and astrocytes).  
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1.8.1. Microglia  
 
The microglia are the resident macrophage type cell of the brain. They are responsible 
many of the innate immune functions within the brain, including immune regulation by 
cytokine production and in immunosurveillance and phagocytic engulfment. Generally, 
they comprise around 10% of the cell population (Lawson, Perry et al. 1992)and mirror 
many of the characteristics of their cousins the macrophage, namely myeloid lineage 
(Ginhoux, Greter et al. 2010) and their slow turnover (Lawson, Perry et al. 1992).  
 
Even when in their resting state, microglia are constantly surveilling the surrounding 
area for any miniscule changes in homeostasis. They respond to disruptions in ions such 
as potassium and ATP molecules released from damaged cells (Davalos, Grutzendler et 
al. 2005), as well as  directly to immune threats (virus, bacteria, or foreign stimuli). They 
become activated and change their shape, with a swollen soma and retracted processes. 
This change is associated with increased expression of calcium binding protein Iba1 (Ito, 
Imai et al. 1998), which is often used for immunohistological measurement. 
 
Reactive microglia can be broadly classified into distinctive states of reactivity; an 
inflammatory and neurotoxic state known as M1 and a resolutory and neuroprotective 
state known as M2 (Boche, Perry et al. 2013). However, even cells within these 
phenotypes can display diverse characteristics and undergo phenotype switching. M1 
microglia can be activated via both interferon gamma (IFN- γ) and lipopolysaccharide 
(LPS) signalling, and release pro inflammatory cytokines such as tumour necrosis factor-
α (TNF-α), IL-6 etc (full list in Figure 7). M2 phenotype microglia can be induced by 
interleukins 4 and 10 (IL4, IL10) and release anti-inflammatory molecules IL-10 and 
transforming growth factor beta (TGF-β) (Colton, Mott et al. 2006, Boche, Perry et al. 
2013). These two phenotype of microglia can be stratified by the presence of a series of 




Figure 7. Differential activation states of microglia and their associated cytokine outputs. 
 Besides inflammation, microglia also have emerging roles in memory and learning 
through a process called synaptic pruning. During development, weaker synapses are 
regularly phagocytosed by microglia as the brain matures (Paolicelli, Bolasco et al. 2011). 
More recently, this process has also been implicated in synapse loss in 




As well as their active role at the blood-brain barrier, astrocytes also have diverse 
functions in neuroinflammation and modulation of neuronal signalling. They make up 
around 35% of all cells in the central nervous system, and are key regulators of 
pathogenic immune response and response to neuronal injury.  
 
Astrocytes are able to detect and respond to a number of inflammatory stimuli. As a 
part of their response to CNS injury they become activated, and form a scar known as 
gliosis or astrogliosis. This is protective, and ensures any inflammatory stimuli or 
neurotoxic compounds remain trapped at the injury site. Before the point of scar 
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formation, many morphological and phenotypic changes occur, including activation, a 
process which leads to increased expression of astrocyte distinctive markers such as glial 
fibrillary acid protein (GFAP) and vimentin. Increases in GFAP have been robustly linked 
to support of neuronal activity in a number of pathological states including epilepsy 
(Steward, Torre et al. 1992).  
 
Similarly to microglia, differential activation phenotypes have been discovered in 
astrocytes. These have been as A1 neurotoxic astrocytes and A2 resolutory astrocytes, 
in keeping with the common nomenclature generated for microglia. A1 astrocytes can 
be induced by classically activated microglia (M1) through the secretion of inflammatory 
factors (IL-1α, TNF α) and complement factors such as C1q. Once in the A1 activation 
state, astrocytes lose the ability to support healthy neuronal activities such as 
synaptogenesis and instead induce the neuronal cell death (Liddelow, Guttenplan et al. 
2017). As with M1 microglia, the number of A1 astrocytes is increased in age, particularly 
in hippocampal and striatal regions with these regions seeing both a larger number of 
A1 associated genes, and a higher fold of upregulation (Clarke, Liddelow et al. 2018). 
The particular neurotoxin inducing neuronal death is yet to be identified (as in Figure 8). 
 
A2 phenotype astrocytes are protective, and are induced in models such as middle 
cerebral artery occlusion (MCAO), where astrocytes play a key role in the regeneration 
of tissue following ischaemia. This was initially proposed by Sofroniew (Sofroniew 2009) 
who observed in conditions of ischaemia, astrocytes play a key role in BBB repair, 
reducing immune cell infiltration and limiting neuron damage. Astrocytes were 
extensively profiled from the MCAO model by Ben Barres and colleagues. They found 
release of key neurotrophic factors from astrocytes in the MCAO model, including 
leukaemia inhibitory factor (LIF), Cardiotrophin-like cytokine factor 1 (CLCF1) and 
thrombospondins (Zamanian, Xu et al. 2012), which are capable of helping to repair lost 
synapses (Eroglu, Allen et al. 2009).  
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 Cellular Senescence 
 
Cellular senescence is a complex process leading to a loss of replicative capacity in 
somatic cells. It was first described in 1961 by Hayflick and Moorhead (Hayflick and 
Moorhead 1961). When exposed to stress (endogenous or exogenous), a cell may 
activate a cascade which produces a senescence phenotype, meaning a cell can no 
longer divide and loses its function. This state is phenotypically distinct from other states 
such as quiescence, or terminal differentiation (Munoz-Espin and Serrano 2014, R. 
Pacheco-Rivera 2017).  
 
Senescent cells become unresponsive to stimulation and demonstrate a distinctive 
metabolic and epigenetic phenotype. Senescence is implicated in a variety of standard 
age related and pathological processes including in liver cancers and cholestatic disease 
such as PBC (Sasaki, Ikeda et al. 2005). There are several differing biological processes 
associated with cellular senescence, the replicative senescence described by Hayflick 
being just one of them(Munoz-Espin and Serrano 2014). This means that there is no 
definitive marker of senescence, as this can differ between organ and pathology. 
 
1.9.1. Telomere Dysfunction and Replicative Senescence 
Most mitotic cells have a limited replicative capacity before they enter a state of 
senescence. This is also known to occur in vitro, indeed this is how it was first observed 
by Hayflick and Moorhead, leading to the coining of the term ‘Hayflick’s limit’, which 
states that a normal human fetal cell population will divide successfully between 40 – 
60 times before entering a senescent state (Hayflick and Moorhead 1961).  
 
Telomeres are found at the end of the chromosomes and cap the encoding regions of 
the genome (Campisi and d'Adda di Fagagna 2007, R. Pacheco-Rivera 2017). This forms 
a barrier which protects the integrity and genomic stability of chromosomes. Telomeres 
are formed of the protein complex named Shelterin (de Lange 2005, R. Pacheco-Rivera 
2017). Telomerase activity adds telomere repeat sequences onto the end of telomeres, 
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therefore ensuring that they maintain their length (Munoz-Lorente, Cano-Martin et al. 
2019). Without the action of telomerase, telomeres shorten with each cell division until 
a point at which DNA damage response (DDR) becomes triggered, ultimately leading to 
senescence. Telomere shortening has been found to be directly correlative with the 
induction of cellular senescence (Harley, Futcher et al. 1990). This has been 
demonstrated in mice, where longer telomeres are associated with increased lifespan 
and healthier ageing (Munoz-Lorente, Cano-Martin et al. 2019).  
 
Somatic cells do not express telomerases, therefore limiting their replication and 
causing naturally occurring age related replicative senescence (R. Pacheco-Rivera 2017). 
Telomeres are shortened by around 50-200 base pairs per replication (Harley, Futcher 
et al. 1990, Herbig, Jobling et al. 2004, Campisi and d'Adda di Fagagna 2007). This loss 
inevitably destabilises the Shelterin complex, dislodging it and resulting in the exposed 
telomeric ends being recognised as a DNA break and activating the DDR (de Lange 2005, 
Victorelli and Passos 2017). These induced senescent cell accumulate throughout 
lifespan and can contribute to age related disease onset. Additionally, there are several 
genetic disorders resulting from telomerase mutations, including within the liver 
(Calado, Regal et al. 2009). 
 
1.9.2. DNA damage and Oncogene Induced Senescence 
 
The DDR can also occur as a result of other insults which lead to premature cellular 
senescence in response to noxious stimuli. Breaks in DNA, either single or double strand 
break drive chromosome instability, resulting in the phosphorylation of gamma H2AX 
histone via activation and binding of ATM and ATR protein kinases (d'Adda di Fagagna, 
Reaper et al. 2003, Herbig, Jobling et al. 2004).  
 
ATM also works to phosphorylate essential checkpoint kinases checkpoint-1 (CHK1) and 
checkpoint-2 (CHK2), which trigger a cascade leading to cell-cycle arrest (d'Adda di 
Fagagna, Reaper et al. 2003, Hernandez-Segura, Nehme et al. 2018). This and other 
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pathways drive cellular senescence. Key drivers of cell cycle arrest include cyclin 
dependent kinase (CDK) inhibitors p16, p15 and p21 (Hernandez-Segura, Nehme et al. 
2018). Ordinarily, CDK’s phosphorylate proteins at different stages of the cell cycle, 
tightly regulating arrest and growth. The key parallel pathways involved in the induction 
of cell cycle arrest are p53-p21 and p16-Rb (d'Adda di Fagagna, Reaper et al. 2003). 
 
P53 as a key tumour suppressor and ‘guardian of the genome’, conserving genomic 
stability. When DDR is activated multi-site phosphorylation of P53 and MDM2 
degradation suppress P53  (Zhang, Xiong et al. 1998), leading to activation of P21. As a 
CDK inhibitor P21 functions to promote cell cycle arrest at G1/S phase. Pro-senescent 
P21 can also be activated in a P53 independent manner, through TGF-b signalling (Datto, 
Li et al. 1995). The p53/P21 pathway is paramount to the senescence response. 
Inhibition of P21 is able to prevent the occurrence of senescence entirely (Brown, Wei 
et al. 1997, Dirac and Bernards 2003). Several interlinking processes, such as telomere 
shortening, cellular or oxidative stress, all lead to the process of P53 activation through 
the DDR, ultimately evoking senescence. 
 
Another key CDK inhibitor P16, also plays a key role in senescence induction. Ordinarily 
P16 regulates the cell cycle through inhibiting Rb phosphorylation (Herbig, Jobling et al. 
2004) and accelerating the cycle through to S phase. Several different methods of 
senescence induction such as telomere shortening have been shown to effect P16, 
either epigenetically or via interference with Rb protein (Smogorzewska and de Lange 
2002). There is also evidence implicating the 16/Rb pathway in oxidative stress-induced 
senescence through MAPK which is induced by reactive oxygen species (ROS). 
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1.9.3. Reactive Oxygen Species (ROS) 
 
Reactive oxygen species (ROS) are a product of cellular oxygen metabolism, occurring 
naturally in the body. Certain types of ROS such as superoxides are highly reactive 
molecules that can exert varying biological effects. Ordinarily ROS species are highly 
regulated in the body and sequestered by naturally occurring antioxidants (R. Pacheco-
Rivera 2017). Therefore, cells with higher anti-oxidant capacity also tend to show a 
higher threshold for replicative senescence and slower telomere shortening (Kornienko, 
Smirnova et al. 2019).  Telomeres are highly susceptible to oxidative damage, likely due 
to displacement of shelterin complexes by ROS, leaving telomeres vulnerable (von 
Zglinicki, Saretzki et al. 1995, Coluzzi, Leone et al. 2019). 
 
1.9.4. Senescence Associated Secretory Phenotype (SASP) 
A major hallmark of senescence is the senescence associated secretory phenotype, or 
SASP. The name SASP refers to the collection of chemo and cytokines secreted from 
senescent cells (Maciel-Baron, Morales-Rosales et al. 2016). The secretion of SASP from 
a senescent cell can also influence the behaviour of surrounding cells, inducing 
senescence through paracrine signalling. SASP is difficult to define as a specific secretory 
signature, given that it can vary greatly between organ and the cell type in question, as 
well as the induction stimuli (Maciel-Baron, Morales-Rosales et al. 2016). Despite this, 
some core components remain conserved, such as IL-6, IL-8 and TGF- β, which can be 
observed in a fairly consistent manner across cell types. It seems likely therefore that 
the SASP allows communication between distressed and senescent cells and co-
ordinates the immune response (Krizhanovsky, Yon et al. 2008, Ogrodnik, Miwa et al. 
2017, R. Pacheco-Rivera 2017). 
 
1.9.5. Senescence in Liver Disease 
Senescence is a pathological hallmark of cholestatic liver disease. In 2005, the Japanese 
Yakanuma group discovered a common senescence phenotype was found to occur in 
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the liver during DR, with surrounding biliary epithelial cells (BECs) becoming senescent 
In PBC patients  (Sasaki, Ikeda et al. 2005). In the context of cholestasis BECs also incur 
DNA damage and telomere shortening (Sasaki, Ikeda et al. 2008), both known causes of  
cellular senescence (Collado, Blasco et al. 2007). This led to several key discoveries 
including the realisation that senescence occurs in many liver diseases rising from 
persistent injury and DR (Sasaki, Ikeda et al. 2010), and in many cases can drive the 
pathology of these conditions(Ogrodnik, Miwa et al. 2017). 
 
Hepatocytes also frequently become senescent following liver injury, and can contribute 
to the DR phenotype and resulting fibrosis (Lu, Bird et al. 2015). This process can lead to 
sustained inflammation and exacerbation of disease phenotype.  
 
In turn the induction of senescence in hepatic cell types leads to the release of 
inflammatory cytokines, known as the senescence associated secretory phenotype or 
SASP. SASP can have a large effect on the microenvironment, triggering the induction of 
senescence in nearby cells (Nelson, Wordsworth et al. 2012).  This effect is induced 
through both paracrine and autocrine signalling. Within the liver, key SASP chemokines 
include several TGFb family ligands such as VEGF, CCL2 and CCL20, as well as IL-6 and IL-
8 which are sustained across cell types (Acosta, Banito et al. 2013). CCL2 is known to 
have a key role in macrophage recruitment through receptor CCR2 (Gregory, Morand et 
al. 2006), and also acts to sustain senescence through its CXCR2 receptor (Acosta, 
O'Loghlen et al. 2008). 
 
1.9.6. Senescence in Neurons 
 
The cellular process of senescence occurs throughout every organ in the body. Within 
the brain it has been found that senescence like phenotypes do occur in neurons during 
normal ageing processes (Jurk, Wang et al. 2012), despite them being post mitotic. In 
ageing mice, several markers of senescence (B-galactosidase, P21) and senescence 
associated signalling (IL-6, ROS) were found in various neuronal populations. At 32 
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months these features occurred in 40–80% of Purkinje neurons and 20–40% of cortical 
and hippocampal neurons.  
 
So far, little is known about the impact of senescence features and low grade 
‘inflammaging’ (often attributed to SASP chemokines IL-6 and IL-8) on neuropathology 
such as degenerative diseases.  Astrocytes are a key brain cell population, and have been 
long associated with the pathology of several neurodegenerative diseases (Maragakis 
and Rothstein 2006). In stressed conditions astrocytes have been found to undergo 
changes in their function such as cell cycle arrest, reduced telomere length, P16, P21 
and P53 expression and other key senescence processes both in vitro (Bitto, Sell et al. 
2010), and in vivo in patients with Alzheimer’s disease (Bhat, Crowe et al. 2012). 
Astrocytes have been found to be more susceptible to oxidative stress induced 
senescence than other cell types such as fibroblasts, suggesting that senescence may be 
more common in the brain than other organs. As these stressed astrocytes cease to 
function, they can pass on this phenotypic switch to the neurons they are co-cultured 
with. This induces glutamatergic distress, signalling changes and cell death (Limbad, 














 Aims of the PhD 
 
The aims of this PhD are as follows: 
 
• Utilize the BDL model to assess the effects of cholestatic disease on several 
parameters – liver damage, cognition and fatigue, the function and morphology 
of the blood brain barrier, changes within the hippocampus including neuron 
cell loss, neuroinflammation, senescence. 
 
• Using the BDL model, assess functional changes in the hippocampus through 
local field potential electrophysiology to look at changes in network gamma 
frequency oscillation. 
 
• Utilize the BDL model to assess the effects of 1st line (UDCA), 2nd line (OCA), and 
experimental (bezafibrate) therapy on liver, cognitive and CNS changes 
observed in mice following BDL. 
 
• Use in vitro neuronal cell models to investigate changes in neurons exposed to 
BDL or PBC patient serum and elucidate mechanisms of neuronal dysfunction. 
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All mice used in these studies were of C57/Bl6 genotype, male and purchased from 
Envigo. All procedures were in accordance with the UK Animals (Scientific Procedures) 
Act 1986 and European Union directive 2010/63EU and in accordance with the arrive 
guidelines. 
 
 Bile Duct Ligation (BDL) Surgery  
 
 BDL surgery was performed when animals were 8-12 weeks and at least 25g in weight. 
BDL surgery involves the gall bladder being tied and cut, preventing flow of the bile and 
causing cholestasis. All mice were humanely euthanised at 10 days post-surgery and 
organs harvested as outlined in figure 8 below. Bile Duct Ligation (BDL) is a common 
model for progressive cholestatic liver disease in mice, which transitions through three 
phases. Phase 1. In the early phase, bile leaking into the liver causes biliary and hepatic 
injury and inflammation, which typically peaks around days 3-5. Phase 2. Cholestatic 
liver damage persists initiating a progressive ductular reaction and fibrogenic response, 
days 5 - ~14.  Phase 3, which is not studied here, causes advanced fibrosis and then 
cirrhosis with possible onset of ascites, typically from days 14-21 (Abshagen, König et al. 
2015). 
 
 When drug treatments were used, these were integrated into the surgery schedule 
either prophylactically from 3 days prior to surgery or therapeutically from 3 days post-
surgery. Mice received buprenorphine post-operative pain relief, were monitored and 
clinically scored daily and were kept at 25°C in a heated cabinet. Drug treatments were 
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given at the following concentrations:  Obeticholic Acid (OCA) 0.03%, Ursodeoxycholic 
Acid (UDCA) 0.5%, Bezafibrates (BF) 0.5% w/v. 
 
For all studies with behavioural testing, treatments were integrated into powdered 
chow diet under the assumption that each mouse would eat 3g of chow per day. For the 
flow cytometry experiments, mice were oral gavaged with either control or drug 
dispensed in a volume of 100µl per mouse per day. Behavioural studies followed plan 
outlined below (Figure 9), where mice underwent Open Field testing on day 9 and Y 
maze testing on day 10 post-surgery. Surgery was performed by Prof Fiona Oakley. 
 
Figure 9. Experimental Drug Dosing schedule BDL mice. 
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 Behavioural Testing 
2.3.1. Open Field 
Open field testing was used to assess locomotor activity  in mice (Seibenhener and 
Wooten 2015). Poor locomotor activity in mice can be related to  fatigue. Fatigue is in 
some cases associated with poor cognition in PBC patients and therefore is of interest 
in this thesis. Open field testing involves allowing the mouse to move freely around on 
a samsung tablet contained securely in a specially constructed box. A software is used 
to record the animals free movement for 5 minutes, with a reduction in movement 
indicative of fatigue in the animal.  
 
Mice were moved into behavioural testing room at least 1 hour prior to testing, and all 
BDL animals placed onto heated pads. Animals were then individually placed into a 
testing area measuring 25.66 x 17.53cm onto a Samsung Galaxy Tab 2 10.1 for 5 minutes. 
Steps and distance travelled were recorded using MouseTrapp© software. 
 
2.3.2.  Y Maze 
In order to compare the BDL model to the human cognitive deficit, the Y-maze was 
selected. This is a hippocampal dependent task measuring  visual spatial memory 
(Kraeuter, Guest et al. 2019). This task was selected with discussion between Dave 
Jones, who described the clinical phenotype seen in patients and mouse behavioural 
expert Claire Richardson in order to select the most appropriate test to assess spatial 
and hippocampal dependent memory, which form part of the patient phenotype.  
 
Mice were moved into behavioural testing room at least 1 hour prior to testing, and all 
BDL animals placed onto heated pads. Y maze arena had three arms of 40cm identified 
as A1 A2 A3, each with a differentiating marker at the end of the arm. Mice were 
assigned different start arms in a rotating allocation. In the T1 phase mice were placed 
into the maze with only two arms open for 5 minutes to explore the arena. The mice 
were then removed to a clean cage for 1 minute (fresh cage used per cage of mice). Then 
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in T2 mice were returned to the maze in the starting position with the novel arm opened 
for 2 minutes, and allowed to explore. A camera was set up above the maze to record 
movements and the video files analysed via Ethovision software. Animals who showed 
no movement were excluded from analysis. (UDCA study; BDL n=1, pro-UDCA BDL n=1, 
Ther-UDCA BDL n=1. OCA study; BDL n=2, pro-OCA-BDL n=2 BDL, Ther-OCA n=1, Beza 
study Beza n=2). 
 
 Liver Histology 
2.4.1. Terminal Tissue Collection 
At the point of harvest livers histology is taken from 3 transverse sections. These are 
taken from the large lobe, the bi-lobulated lobe and the triangular lobe. The spleen is 
used as a positive control in IHC. For histological analysis, each lobe was sampled and 
tissues were fixed with 10% formalin for 24 hours. After this time, they were switched 
to 70% ethanol, embedded in paraffin and sliced to 5µm.  
 
2.4.2. Picrosirius Red 
Protocol for Picrosirius red is first described in (Wright, Issa et al. 2001). Tissue dewaxed 
in 2x 5 minutes in clearene, 5 minutes in 100% ethanol and 5 minutes in 70% ethanol. 
Slides were then transferred to distilled water for 3x 3 minutes. Tissues were moved to 
0.2% phosphomolybdic acid in distilled water (DI) for 5 minutes and then washed for 3x 
3 minutes with DI water before being placed into 0.1% Sirius red F3B in picric acid 
solution for 90 minutes. They were washed again 3x 3 minutes in DI water and changed 
to a 0.01M hydrochloric acid (HCL) solution for 2 minutes, washed 3x again and 
dehydrated through ascending alcohol concentrations into clearene for 5 minutes 
before being mounted in pertex mounting media.  
 
2.4.3. General Liver IHC Procedure on FFPE tissue 
This protocol was adapted from (Oakley, Meso et al. 2005). Adaptions to the protocol 
for individual stains are listed below in table 1, and section 2.4.4). Tissues underwent 
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dewaxing protocol as described above. Endogenous peroxidases were blocked using 2% 
hydrogen peroxide solution in methanol for 15 minutes and slides washed in PBS. 
Antigen retrieval was performed using the method outlined in table 1 diluted in water 
and heated in the microwave for 20 minutes, removed and allowed to cool. After being 
washed with PBS slides were mounted into a sequenza and blocked sequentially with 
avidin and biotin for 20 minutes each. Blocking was performed with 1:5 dilution relevant 
serum (outlined in table 1 below) in PBS for 20 minutes before primary antibody was 
applied for an hour at room temperature. 
 
The slides were washed 3x in PBS and incubated with secondary antibody for 2 hours 
before being washed in PBS 3x and Vector ABC tertiary applied for 1 hour. Slides were 
washed again 3x in PBS before 100µl DAB reaction mixture was applied to each slide for 
1-5 minutes each. After a brief PBS wash tissue was counterstained in Meyers 
Haemotoxylin and washed in running tap and Scot’s water before being dehydrated as 
stated above and mounted using pertex mounting medium. 
 
Table 1. Antibodies and block procedure used for each antibody for liver histology 
Stain Primary Antibody Secondary Antibody Block + Antigen 
Retrieval  









20% Pig Serum 
Citrate 
microwave 
Cytokeratin 19 – 
ductular expansion 
Rb polyclonal to 
Cytokeratin19  
1:250 





20% Pig Serum 
Citrate 
microwave 










20% Pig Serum 
1mM EDTA soln 
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2.4.4. Stain Specific Modifications in Liver Histology 
For P21 staining in liver tissue was pre-boiled in dH20 for 10 minutes before the EDTA 
antigen retrieval step.  
 
2.4.5. Imaging and Analysis for Liver 
Image analysis was performed using a Nikon Eclipse Upright Brightfield microscope and 
NIS-Elements BR analysis software. For all liver IHC analysis images are taken at 100x 
magnification and 4 images taken per lobe, totalling 12 images per animal. Large vessels 
were excluded from analysis. Optical density was calculated using a threshold that was 
established on several images before being applied to the whole cohort. A percentage 
of stained area was calculated from this for PSR, α-SMA and CK19 stains. For p21 an 
object count threshold was established and applied to all tissues. 
 
 Mesoscale Discovery (MSD) 
Levels of IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, KC/GRO, TNF-α in the serum of 
sham and BDL mice were detected using the V-PLEX Proinflammatory Panel 1 Mouse Kit 
(K15048D). 
 Liver Enzymes 
Alanine aspartate transferase (AST) and alkaline phosphatase (ALP) were measured 
using standard protocols in the clinical pathology department at the Royal Victoria 
Infirmary. 
 Brain Histology 
Brain histology was performed on fixed paraffin embedded sections at 5µm thickness. 
Protocol was adapted from (Lin, Patel et al. 2017) Tissues were dewaxed as per liver 
protocol above (section 2.4.3). Slides were washed with PBS and microwaved for 20 
minutes with Vector labs citrate-based antigen unmasking solution (H-3300-250) diluted 
in water. After cooling, tissue permeabilization was performed with 0.25% triton X-100 
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in PBS for 15 minutes before slides were blocked for 2 hours with 5% donkey serum 
block. Slides were incubated with primary antibody overnight at 4°C, at the 
concentrations shown below (table 2). 
 
 On the second day slides were washed 3x over an hour with 0.1% Triton-X100 in PBS 
and the secondary antibody applied in block solution at the dilutions indicated below. 
Tissue was washed a final time with 3x 0.1% PBST before DAPI was applied in blocking 
solution for 10 minutes at 1:1000 concentration. Slides were mounted using 
Vectorshield prolong gold anti fade mounting media (P36930). 
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2.7.1. Brain Histology Analysis 
In order to obtain images of the whole dentate gyrus, 3 images were taken per animal 
(figure 10A). Counts were taken only from within the granule cell layers of the dentate 
gyrus as highlighted in figure 10D, in order to minimise the differences in sampling and 
dentate gyrus size between animals. Cell type counts are represented as a percentage 
of total cells. Total cells were calculated by counting DAPI positive cells in cell counter 
extension in Matlab version 2012b. Each cell type was then calculated as a percentage 
of DAPI + cells. 
 
Figure 10. Counting strategy for histology in the dentate gyrus. A) Zoomed out image showing the whole 
structure of the DG at 10x. B) in order to capture images of a high quality, 3x 20x images were taken per 
animal, capturing the whole DG structure C-E) show example images. Counts were taken within the 
densely populated granule cell layer region highlighted in D. 
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2.7.2. Brain P21 RNA-ish 
RNA-ISH was performed after RNAscope protocol from Advanced Cell Diagnostics Inc. 
(ACD). Tissues underwent dewaxing protocol as described above. Endogenous 
peroxidases were blocked using 2% hydrogen peroxide solution in methanol for 15 
minutes and slides washed in PBS. Slides were washed with PBS and slides heated for 30 
minutes. Following this slides were washed in dH20 and 100% ethanol and air dried. 
Sections were treated with protease plus for 30 minutes at 40°C, washed with H2O and 
incubated with p21 probe for 2 hours at 40°C.  
 
Slides were washed in H20 and incubated with AMP1 for 30 minutes at 40°C, washed 
with wash buffer and incubated with AMP2 for 15 minutes at 40°C. This was repeated 
with wash buffer and AMP3 for 30 minutes, then washed and AMP4 for 15 minutes, 
both at 40°C. With washes in between AMP5 and AMP6 were applied, for 30 and 15 
minutes respectively at room temperature. Finally, RNAscope 2.5 HD Reagent kit-RED 
was used for chromogenic labelling. After counterstaining with haematoxylin, sections 
were dehydrated, mounted with Pertex and coverslipped.           
                                                            
2.7.3. Immuno-triple Fish for Telomere staining 
This protocol is first described in (Hewitt, Jurk et al. 2012). Slides were heated and 
rehydrated through alcohol as previously outlined and underwent a sodium citrate 
antigen retrieval. Non-specific binding was blocked with 30 minutes incubation in 1:60 
Goat serum. Slides were blocked with Avidin and Biotin before being wash and 
incubated with γ-H2A.X antibody (table 2) overnight at 4°C at a 1:250 dilution. Slides 
were washed 3x with PBS and incubated with biotinylated secondary antibody for 30 
minutes diluted in block with Goat serum at a 1:200 concentration. Sections were 
washed in PBS and incubated with Avidin DCS (vectorlab) at 1:500 concentration for 30 
minutes. 
 
After γ-H2A.X IF, slides were washed three times in PBS, crosslinked with 4% 
paraformaldehyde for 20 minutes and dehydrated in graded ethanol. Sections were 
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denatured for 10 min at 80°C in hybridization buffer (70% formamide (Sigma UK), 25 mM 
MgCl2, 0.1 M Tris (pH 7.2), 5% blocking reagent (Roche, Germany)) containing 
2.5 μg ml−1 Cy-3-labelled telomere-specific (CCCTAA) probe (Panagene), followed by 
hybridization for 2 hour at RT in the dark.   
 
 Slides were washed with 70% formamide in 2 × SSC for 15 minutes, followed by washes 
in 2 × SSC and PBS for 10 minutes. Sections were incubated with DAPI, mounted and 
imaged. In-depth Z-stacking was used (a minimum of 40 optical slices with × 63 
objective) followed by Huygens (SVI) deconvolution. Number of TAF per cell was 
assessed by quantification of partially or fully overlapping (in the same optical slice) 
signals from telomere probe and γ-H2A.X in slice-by-slice analysis, 100 cells per animal 
or as many neurons as present.  
 
2.7.4. Super Resolution Imaging 
Immunofluorescent staining was undertaken as described above. In order to stain the 
astrocytic attachment to blood vessels sections were co-stained with anti-GFAP rabbit 
polyclonal antibody and endothelial wall antibody (RecA) (table 2). Sections were 
imaged using a Leica SP8 confocal (inverted) gSTED 3D Super resolution microscope. 
 
2.7.5. Electron Microscopy 
At point of harvest hippocampi were sub-dissected and finely chopped. Tissue was fixed 
in 2% glutaraldehyde 0.1M cacodylate buffer overnight, and then post fixed in 1% 
osmium tetroxide before being dehydrated in acetone and embedded in epoxy resin. 
The blocks sectioned ultrathin and sliced both longitudinally and transversely and 
stained with uranyl acetate and lead citrate and imaged on a Philips CM100 TEM with 
tungsten filament.  
 
For analysis, 10 blood vessel images were taken per animal. Astrocyte coverage was 
calculated using imageJ. Images were set using the ingrained scale on the image, the 
relative diameter of the whole vessel, and the astrocyte coverage was calculated as a 
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percentage by dividing whole diameter by astrocyte coverage and multiplying by 100. 
Endothelial thickness was measured on the same ten images per animal. For each vessel 
endothelial thickness was sampled at 10 places, evenly spaced around the vessel, and 
averaged to account for variability in thickness of the vessel. For both measurements 
the final number for the animal (n=4 per group) total was calculated as an average of 
the 10 images captured for that animal.  
 
 Flow Cytometry 
A panel of fluorescently labelled antibodies was designed in order to determine the 
specific expression of Farnesoid X Receptor on brain microvascular endothelial cells 
(BMEC) in the hippocampus. Flow cytometry in the brain, and the selection of Sca1 as a 
marker of microvascular endothelial cells was adapted from (Wylot, Konarzewska et al. 
2015, Au - Martin, Au - El-Behi et al. 2017). 
 
Additionally, we characterised the ARG1 (M2) and iNOS (M1) phenotype of resident and 
infiltrating immune cells. Antibody mixtures were prepared in a total volume of 30μl of 
FACs buffer (with or without a permeabilisation agent depending on the presence of the 
proteins internally or externally). The antibody concentrations are described in Table 3.  
 
Mice were euthanised humanely, perfused through the left ventricle and the brain 
removed. The left and right hippocampus was sub-dissected out and placed in Hanks 
Buffered Saline Solution (without calcium and magnesium, HBSS (-)). The brain sample 
was finely chopped and a digestion cocktail containing 1ml PBS, 123µl Liberase (low 
thermolysin grade from Roche) and 200µl DNase and placed in an incubator at 37°C for 
45 minutes. The digested brain was then put through a 70µm cell strainer and rinsed 
through with HBSS (-) to ensure collection of all tissue. Cells were centrifuged for 6 
minutes at 400g and supernatant discarded and cells re-suspended in 5ml HBSS. Cells 
had 30% Percoll (diluted in PBS) slowly underlaid. They were centrifuged for 30 minutes 
at 900g with 0 brake so the interphase is not disrupted. The fat and myelin layer should 
settle at the top of the liquid interphase and be pipetted gently off. Other cell fractions 
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remain in a pellet at the bottom of the tube. Pellet is re-suspended in 200ul PBS and 
transferred to a 96 well round bottom plate. 
 
Cells are span at 1500rpm for 2 minutes and supernatant discarded before 50ul 
Live/Dead stain mix is added (if being used). Cells incubated with L/D at 4°C for 15 
minutes before spun at 1500rpm and 200ul FACs buffer (PBS and 1% Fetal calf serum) 
added to each well.  To stain intracellular proteins, the cells undergo a 2-step staining 
procedure.  
 
First the cells were incubated with the cell surface antibodies for 30 minutes at 4°C 
(CD45, Sca1, CD31, CD11b, F4/80). They are then washed in FACs buffer and fixed and 
permeabilised for 15 minutes each at 4°C. Fixation was achieved by incubating the cells 
in 4% paraformaldehyde and permabilisation step done using 1x Perm wash (BD 
Biosciences). 
 
Intracellular antibodies were diluted to the required concentration (outlined in table 3) 
in 1X Perm Wash diluted in FACs buffer and were incubated with the antibody mix for 
30 minutes at 4°C. If a secondary antibody conjugation was required (marked with * in 
table), cells were then incubated with the secondary antibody after intracellular 
staining, following which they were washed twice in FACs buffer and re-suspended in 
100μl of FACs buffer ready to run on the flow cytometer. Cells were read on either a 








Table 3. Antibodies used for flow cytometry experiments. *denotes a secondary antibody conjugation 
 
 Electrophysiology 
2.9.1.  Electrophysiology Preparation 
Animals were killed humanely by anaesthetic overdose with inhaled isoflurane and 
intramuscular injection ketamine (≥100 mg kg−1) and xylazine (≥10 mg kg−1) as 
previously described by the group (Driver, Racca et al. 2007). When all reflex (flinch 
reflex, pedal withdrawal reflex) disappeared animals were transcardially perfused with 
at least 25mls of sucrose rich artificial cerebral-spinal fluid (SaCSF) - composed of (mM) 
252 sucrose, 3.0 KCl, 1.25 NaH2PO4, 24 NaHCO3, 2.0 MgSO4, 2.0 CaCl2 and 10 glucose. 
The brain was removed and sliced to 450um horizontal slices with a Leica VT1000S 
vibratome in ice cold SaCSF.  
 
Antigen  Fluorophore  Vendor  Dilution  
Live/Dead  BV241  Life Technologies  1/100  
FXR  AF594* Thermofisher Scientific 1/50  
CD45  BV510  Biolegend  1/50  
CD11b  PerCP-Cy5.5  Biolegend  1/500  
Sca1  APC Biolegend  1/50  
ARG1  PE  R&D  1/50  
INOS  PE-Cy7  eBioscience  1/50  
Ly6G  BV780 eBioscience 1/50 
F4/80 FITC eBioscience 1/50 
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Slices were trimmed to the hippocampal region and moved into a holding chamber at 
RT for 1 hour before being transferred to the recording chamber and maintained at 32-
34°C at an air liquid interface between normal aCSF (sucrose replaced with 126 mM 
NaCl) and humidified 95% O2/5% CO2. Oscillations were evoked with 10μM cholinergic 
agonist Carbachol, to activate transmission through acetylcholine receptors. The 
chemical composition of SaCSF and aCSF are outlined in table 4.  
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Table 4. Chemicals required to make 1 Litre of artificial cerebral spinal fluid. 
Chemical Name Formula Vendor Amount in 
aCSF Solution 
(mM) 
Sucrose C12H22O11 Sigma-Aldrich 
(16104) 
252 





NaH2PO4 VWR International 
(307164T) 
1.25 
Sodium bicarbonate NaHCO3 Tocris (3152) 24 
Magnesium sulphate MgSO4 Sigma-Aldrich 
(M7506-M) 
2 
Calcium chloride CaCl2 VWR International 
(275844L) 
2 
Glucose C6H12O6 VWR International 
(101176K) 
10 




2.9.2. Recording and data acquisition 
Extracellular recording electrodes were filled with normal aCSF (resistance 2–5 MΩ), and 
field recordings taken from the border between stratum radiatum and stratum 
lacunosum moleculare in CA3. Recordings were taken with Axoclamp-2B amplifier (Axon 
Instruments Inc., Union City, CA, USA) and extracellular data filtered at 0.001–0.4 kHz 
low-using Bessel filters. Mains noise was deducted with a Humbug (Digitimer, Welwyn 
Garden City, Herts, UK), and data redigitized at 10 kHz using an ITC-16 interface 
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(Digitimer, Welwyn Garden City, UK). Axograph 4.6 software (Axon Instruments Inc., 
Union City, CA, USA) was used for data acquisition and analysis. 
 
2.9.3. Data analysis 
To generate power spectra Axograph used Fourier analysis using 60 seconds per 10-
minute recording. This was used to calculate peak frequency and area power (area 
under the peak). Mouse gamma frequency oscillation was measured at frequencies 
between 15 and 49 Hz. Oscillations were categorized as stable when area power 
measured within ±10% for three consecutive 10 min recording intervals. Rhythmicity 
was measured using the first side peak amplitude of the auto-correlations performed 
over 1 s traces, and was shown on the rhythmicity index on a scale between 0-1. 
Multiple slices were gained from each animal, and as such data reported in this 
publication is shown as N to represent the animal number and n for slice number. 
 Neurotoxic Effects of Cholestatic Serum In Vitro 
2.10.1. Growth and Differentiation of 97 Cell Line 
Cells were derived from foetal forebrain by Peter Hanson and Chris Morris. The 
differentiation protocol is adapted from (Kurzawa-Akanbi, Hanson et al. 2012), which 
uses the same cells.  The cells were passaged using trypsin-EDTA solution and were 
seeded into a geltrex coated 48 well cell culture plate at a density 5,000 cells per well 
with 250µl of proliferation media. They were allowed to proliferate for 2 days before 
the proliferation media was withdrawn and replaced with differentiation media. Growth 
medium was replaced with differentiating medium containing Dulbecco’s modified 
Eagle’s medium /F12 supplemented with 10% heat-inactivated Foetal Bovine Serum 
(Sigma), N-1, B27 and N-2  for 2 weeks before beginning experimental procedure. For 
chamber slides cells were plated at a density of 10,000 cells/chamber. 
 
2.10.2. Neurotoxic Effect of Serum from Cholestatic Mice 
Blood was extracted via right ventricular cardiac puncture at harvest from mice that 
underwent either sham or BDL surgery (10 days). These were left at RT for at least 30 
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minutes to allow clotting and spun at 8,000rpm for 10 minutes before collecting the 
clear serum layer and discarding the red blood cell pellet. Serum samples were stored 
at -80oC. 
 
On the day of the experiment serum samples were thawed on ice, vortexed and heat 
inactivated for 30 minutes at 60oC. They were diluted in media to the desired 
concentration and added to the plate for 72 hours. 
 
2.10.3. Neurotoxic effects of PBC patient serum 
Human serum was obtained from the UK-PBC bioresource of samples from well 
characterised PBC patients experiencing cognitive symptoms as defined by the UK-PBC 
cohort questionnaire. Serum samples were stored long term at -80oC. Serum samples 
were thawed on ice, vortexed and heat inactivated for 30 minutes at 60oC. Samples were 
diluted in media to desired concentration added to the plate for 72 hours. 
 
2.10.4. Alamar Blue Cell Viability Assay 
To determine the effect of treatment with cholestatic serum on cell viability, the Alamar 
blue reduction assay was used. Sterile filtered alamar blue (1mg/ml) was added to fresh 
media to a final concentration of 5% alamar blue. The media was removed from all wells 
and replaced with 250µl alamar blue solution per well and plate returned to incubator 
for around 1 hour until a colour change can be observed in the control wells.  
 
Alamar blue solution (100µl) was removed from each well and added to a 96 well plate, 
allowing for two technical replicates. The cell viability was determined using a TECAN 
Nano M+ fluorescent plate reader at 530nm excitation and 590nm emission. Done for 
day 0 (background reading) and media was then replaced with serum dosed media, after 
72hours cell viability measurement was repeated. This assay was performed before and 
after each cell dosing experiment.  
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In order to assess cell viability, alamar blue readings at day 0 and 3 were averaged from 
2x technical replicate and 3x measured wells (biological replicate) and calculated as a 
percentage change over time. 
 
2.10.5. Β-galactosidase Senescence Assay 
This assay was performed using kit ab228562 purchased from abcam. The kit was 
reconstituted according to the manufacturer’s instructions. Cells were washed briefly 
with PBS and fixed for 10 minutes in formaldehyde prior to assay. ß-galactosidase 
solution was added to wells (250μl for 48 well plate, 400μl for chamber slides) and 
incubated in a sealed bag at 37 oC for 3 hours. Cells were washed 3x with sterile PBS 
before being stored at 4 oC in 70% glycerol. Cells were imaged on a Zeiss axioimager 
microscope. To get an average senescence score per condition, 4 areas were analysed 
per well, and three well repeats per condition were averaged. 
 
2.10.6. Immunocytochemistry (ICC) 
Cells were fixed for 10 minutes with 4% PFA before being washed 3x with ice cold PBS 
to remove residue. Permeabilisation step was performed using 0.2% Triton-X100 in PBS 
for 10 minutes and cells were then washed in PBS and blocked in 5% of the 
corresponding serum block with 0.1% Triton-X100 in PBS for 1 hour. Primary antibodies 
were applied overnight at 4oC at a concentration of 1:1000 in the block buffer of 1%BSA, 
0.1% Triton-X100 in PBS. Cell were placed in a humidified chamber on a rocker.  
 
The next day cells were washed 3x in PBS and secondary antibody was applied at 1:1000 
for 1 hour at room temperature. Secondary antibody was diluted in the same buffer as 
the primary antibody. Cells were washed 3x again with PBS and incubated for 10 minutes 
with DAPI in the buffer solution at 4oC. Slides were mounted immediately using 
Vectorshield prolong gold antifade mounting media and glass coverslips. Images were 
taken on Zeiss Axioimager 2 at Bioimaging unit Newcastle university. ROI feature on 
ImageJ was used in order to measure expression per cell and per nucleus. 10 Cells per 
image were analysed to get an average and 4 images taken per treatment. 
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2.10.7. LiCor Fluorescent Western Blot  
Wet nitrocellulose membrane for 2 minutes in 1X PBS. Then wet for 1 minute in 
methanol 100% and rinse with ultrapure water. Membrane blocked in Intercept blocking 
buffer (li-Cor 927-60000) for 1 hour at RT on a rocker, ensuring enough block to cover 
the membrane. Primary antibody diluted 1/2000 in 0.2% Tween 20 + PBS (TBST). FXR 
antibody used is Thermofisher Scientific (PA5-40755), TGR5 antibody is R&D systems 
MAB4286. Primary antibody is incubated with the blot overnight at 4 °C on rocker. 
 
Pour off antibody solution and rinse membrane 3 times in 1X TBST (0.1% tween 20). 
Secondary antibody was then added (IRDye 680RD used) at a concentration of 1:15,000 
in 0.2% Tween20 in Intercept Blocking buffer for 1 hour at RT on rocker. Membrane was 
rinsed with 1X TBST (01% Tween20) 3 times. Membrane was scanned on the Odyssey 
Imaging System. 
 
 Statistical Analysis 
Data are always presented as mean ± standard error of the mean (SEM), where *, **, 
*** and **** equals P values of <0.05, <0.01, <0.001 and <0.0001 respectively. P values 
were calculated using GraphPad prism using an ANOVA with Tukey Post-hoc test, or 
unpaired T-Test. For non-parametric analysis, Kruskal Wallis test was used for groups +2, 




























3. Chapter Three - Cognitive deficits 
and underlying brain pathology occur 
during BDL-induced Cholestasis 
 
 Introduction 
As previously discussed, the pathology behind cognitive deficit is of yet largely unknown. 
In order to begin characterising these deficits molecularly, cellularly and functionally 
first an animal model must be chosen that recapitulates these deficits as widely as 
possible.  
 
3.1.1.  Bile Duct Ligation as a Model for Cholestatic Liver 
Disease 
 
The bile duct ligation (BDL) model provides a robust and largely replicable murine 
surgical model of cholestatic liver disease. The model recapitulates many of the major 
hepatic complications of cholestatic autoimmune liver disease. Including biliary 
obstruction, portal and peri-portal fibrosis (A), collagen deposition (Fiorucci, Antonelli 
et al. 2004, Abshagen, König et al. 2015), jaundice, ductular reaction (DR) (B), immune 
cell infiltration and peri-ductular senescence (C). Example rodent BDL histology can be 




Figure 11. Example histology showing (A) periportal fibrosis, (B) ductular reaction, (C), senescence. 
 
3.1.2. Evidence for Memory Impairments in BDL 
Crucially, limited evidence in rodents shows BDL also recapitulates central spatial 
memory deficits seen in PBC patients. Several studies have reported by 21 days post-
surgery (but not 7 or 14) rats were found to possess significant learning and motor 
impairment when assessed using the Morris Water Maze (Montes, Alcaraz-Zubeldia et 
al. 2001, Huang, Hsieh et al. 2004, Hosseini, Alaei et al. 2014). Spatial memory deficits 
are also seen in mice at 21 days post BDL when subjected to T maze testing (Magen, 
Avraham et al. 2009) (comparable to Y maze). This study also reports locomotor activity 
deficits in Open Field tests.  
 
3.1.3. Changes in Circulating Inflammatory Cytokines 
 
Previous studies using BDL or BDR animals have shown that by day 5, peripheral 
monocytes are recruited to the brain via CCR2 (Kerfoot, D'Mello et al. 2006), and can 
activate resident microglia(D'Mello, Le et al. 2009). These monocytes attach to the 
endothelial wall through P- selectin (D’Mello, Riazi et al. 2013) and cause monocyte 
mediated microglial activation through TNF-α. Brain infiltrating monocytes were found 
at higher concentration in key brain areas such as the motor cortex, hippocampus and 
basal ganglia. 
 
The hippocampus is an important brain region, controlling highly intricate and diverse 
functionality. The hippocampus is susceptible to BBB breakdown and indeed recent 
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studies in humans have shown that BBB breakdown at the hippocampus leaves the brain 
vulnerable to cognitive impairment (Nation, Sweeney et al. 2019). Therefore, it seems 
significant that monocytes were found at high concentrations in this key region. 
 
These circulating inflammatory factors are likely to affect both the BBB and the normal 
homeostatic function of the brain. As ‘changes in neurotransmission that give rise to 
behavioural alterations in such diseases occur before the development of overt 
pathological CNS tissue damage, but after cerebral immune cell infiltration has occurred’ 
(Pollak, Ovadia et al. 2003). Thus, by day 10 when moderate disease has developed, 
changes will likely occur to the BBB and susceptible brain areas experience 
neuroinflammation. 
 
3.1.4. Evidence for Blood-Brain Barrier Dysfunction in BDL 
 
The blood brain barrier ordinarily provides a physical and metabolic barrier from 
between the bodily circulation and the brain. The semi permeable barrier comprises of 
brain microvascular endothelial cells (BMECs) with specialised tight junction properties, 
alongside pericytes and astrocytes exerting synergistic functions. In our studies we have 
focussed mainly on astrocyte attachment at the vessel as these provide the key cell to 
cell signalling between the BBB and functional changes in neurons. Endothelial cells, 
astrocyte and neuron grouping is known as the neurovascular unit, along with pericytes 
or secondary cells such as interneurons, myocytes and components of the extracellular 
matrix (ECM) (shown below). The neurovascular unit (NVU) provides a primary 
mechanism of brain communication and homeostasis, enabling dynamic 
vasoconstriction and vasodilation first described by Harder in 2002 (Harder, Zhang et al. 
2002). 
 
To date, there is little concrete in vivo evidence of changes in the blood brain barrier 
occurring in rodent models of cholestasis. Studies so far have been mainly focussed 
around hepatic encephalopathy (HE); a state characterised by cirrhosis. Though not 
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directly relevant to my PhD studies, these rodent papers provide an insight into the BBB 
alterations that can occur as a result of bile acid and other secondary molecules such as 
ammonia. Several papers have found alterations in BBB as a result of HE, such as 
cerebral oedema, which indicates changes to BBB function (Mouri, Mourabit et al. 2017) 
 
 Early studies by Jaqueline Wahler and Mark Swain in rats showed ANIT and BDL induced 
cholestasis led to a decrease in blood to brain transfer constant (Ki) compared to Sham 
controls, both in the drug induced ANIT model by day 7 and BDR by day 5. This data is 
indicative of changes to BBB function and macrostructure (Wahler, Swain et al. 1993), 
in early cholestatic disease. 
 
 We hypothesised that by 10 days post BDL significant changes to the liver including 
significant myofibroblast activation, and collagen deposition as has been well described 
in the literature (Abshagen, König et al. 2015). We also hypothesised that the changes 
structure of the BBB, as well as neuroinflammatory cell types such as microglia and 
astrocytes will occur, and these cell types will be activated into an M1 phenotype.  
 
 Study Rationale 
 
Our initial studies were run up to 10 days and liver fibrosis, DR, circulating inflammation, 
cognition, microvascular changes at the blood brain barrier, changes to brain resident 
cell populations, senescence in the liver and brain and electrophysiological gamma wave 
oscillations were assessed. A smaller study of animals was harvested at day 6 to 
investigate early changes to circulating inflammatory markers, the blood brain barrier, 
fatigue score, and neuronal/glial cell populations.  
 
Previous studies in the field have reported changes to the BBB by day 5 post BDL 
(Wahler, Swain et al. 1993). However behavioural changes have not been identified until 
day 21 (in rats and mice) (Magen, Avraham et al. 2009). Therefore, we expect to see an 
immune response by day 6 - including changes in circulating inflammatory markers and 
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neuroinflammation. Behavioural deficits may not occur until day 10 (if at all in this 
timeframe). It is likely that we will begin to see changes in neuronal network excitability 
and oscillation capacity by day 10, alongside resulting in memory deficit.  
 
As BDL provides a severe cholestatic model (indeed in many labs is unable to be run as 
long as 21 days), we aim to look at earlier time points in the disease course to assess 
subtle changes to the brain architecture and resulting cognitive decline.  By day 10, these 
animals experience significant fibrosis and inflammation, however they are pre-
cirrhotic. This allows us to look at changes that occur early in the cholestatic process, 
before reaching a point of cirrhosis where such hepatic and neurological changes may 
be irreversible. Studying a cholestatic animal model at these time points allows us to 
pick apart a mechanism not of late stage Hepatic Encephalopathy (HE) (where treatment 
is likely to have little effect), or minimal HE which is also defined as occurring during 
cirrhosis, but earlier still in the disease spectrum. 
 
Circulating and brain infiltrating macrophages in the brain (and their activation 
phenotype) were assessed via fluorescence activated cell sorting (FACs). This method 
was also used to assess endothelial cells of the BBB. Electron microscopy was used to 
assess nanoscopic changes to BBB integrity and to assess astrocytic end-feet attachment 
at the vessel. Astrocytes themselves were assessed for proliferation using 
immunofluorescent marker GFAP. 
 
Other cell types were also assessed for changes using immunofluorescence; neurons 
(NeuN), microglia (Iba1), fast spiking interneurons (Parvalbumin), and progenitors 
(SOX2). All data showing brain tissue is rodent brain isolated or imaged from the 
hippocampus, mainly CA3 and Dentate gyrus, as these are the areas most significantly 
associated with spatial memory deficits. 
 
Telomere associated foci (TAF) and P21 RNA-ish were used to calculate the number of 
neurons that were senescent. Together these form a confirmatory battery of tests. TAFs 
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assess DNA damage co-localised at the shortened ends of telomeres, and p21 forms part 
of the senescence associated pathways.  
 
The standardised behavioural tests used were open field for activity and Y maze for 
spatial memory and were initially designed and performed by Dr. Claire Richardson 
(behavioural expert) and repeated by Dr Ben Millar and myself. Behavioural tests were 
selected by agreed discussion between clinicians at Newcastle upon Tyne hospital trust 
and academic researchers specialising in animal behaviour (Dr. Claire Richardson) at 
Newcastle University. In line with 3Rs animal welfare guidelines behavioural tests were 
never done on the same day as this is known to affect naturalistic behaviours  and causes 









Figure 12. Workflow for behavioural testing experiments 
 68 
 Aims 
The main aims of the research comprising Chapter three are as follows: 
• Assess fatigue and visual spatial memory deficits present in BDL mice at 5- and 
9-days post-surgery when compared to sham operated animals. 
 
• Assess liver function enzymatically (AST and ALP) and assess histologically (PSR, 
α-SMA, CK19, p21) damage to the liver by day 10 of BDL. 
 
• Employ techniques to assess BBB of sham and BDL animals at day 6 and 10 post-
surgery, in order to investigate early loss of BBB function during cholestasis (EM, 
MRI, FACs, Super Resolution imaging). 
 
• Assess changes to neuronal (neurons, neural progenitor) and inflammatory 
(astrocytes, microglia) cell types within the hippocampus which may contribute 
to overall disease phenotype. 
 
• Assess immune cell activation phenotype in the liver, circulation and brain. 
 








3.4.1. Some Pathological Changes Occur by Day 6 
3.4.1.1. Bile duct ligated mice show no fatigue by day 6 post-
surgery 
 
At 5 days post-surgery in our murine model, there were no statistical differences in 
results from open field testing between sham (n=5) and day 5 BDL mice (n=7). Distance 
travelled (FIG 13A), number of steps taken (FIG 13B) and speed of movement (FIG 13C) 
all show a similar trend of a small reduction between the sham and BDL groups. This is 
likely to indicate the beginnings of subtle fatigue like symptoms, with a minor reduction 
in activity in the BDL group, though this doesn’t reach significance.  
 
Figure 13. Open field outputs for the duration of the 5 minute trial (A) distance covered in mm (B) steps taken (C) 







3.4.1.2. BDL mice show subtle changes at the BBB by Day 6 
 
Astrocytes are key to the function of the BBB, and without them brain microvascular 
endothelial cells are unable to form a working barrier (Rubin, Hall et al. 1991). As the 
astrocyte end-feet are in close contact with the vessels themselves, these are known to 
act as ‘injury sensors’ to noxious molecules such as circulating inflammatory cytokines  
(in addition perhaps In this case to bile acids themselves) (Robel, Berninger et al. 2011). 
In response to injury become activated, move away from the vessel and proliferate in 
order to ‘plug the gaps’ in the BBB.   
 
At day 6, electron microscopy nanoscopic analysis revealed reduced astrocyte coverage 
at the vessel (FIG 14E). This is indicative of early changes to the normal ultrastructure of 
the BBB within the hippocampus, and likely resultant changes to ionic permeability.  This 
is likely to be in the early process as astrocyte number isn’t changed between the sham 
and day 6 BDL animals. The number of pericytes (FIG 14D), and their observed 
phenotype looks to still be conserved at this stage in the disease process. The structure 
of the vessels themselves also looks to be conserved; there are no significant changes in 









Figure 14. transmission electron microscopy study day 6 bile duct ligation. (A) Endothelial wall thickness 
(B) vessel circumference in microns (C) astrocyte count (D) pericyte count are similar between sham and 
BDL animals. (E) percentage astrocyte coverage was significantly reduced in BDL animals. (F) sham image 
showing full coverage of astrocyte end-feet (G) BDL day 6 image showing reduced astrocyte end-feet 
coverage. Endfeet are denoted by blue arrows, RBC denotes red blood cell and ETW denotes endothelial 
wall.  Scale = 2microns. N=4 sham N= 4 BDL day 6 animals. 10 vessels imaged per animal and averaged to 




Figure 15. Immunofluorescent stainingof cell populations in the dentate gyrus (A,B,C) Neurons (D, E, F) calretinin interneurons 
(G, H, I) SOX2+ progenitor cells (J, K , L) iba1+ microglia (M,N, O) GFAP+ astrocytes. all similar between sham and day 6 BDL 
mice. N=6 sham N= 10 day 6 BDL. Scale = 50 µm. Data represented as mean +/- SEM, statistics T.TEST. Images are shown with 
DAPI overlay, counts taken within granule cell boundary of the dentate gyrus and represented as a % of DAPI. 
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3.4.1.1. BDL mice show no changes in brain resident cell types 
by day 6 
 
By day 6 BDL mice show little change in the numbers of key brain resident cell types 
within the hippocampus such as neurons (FIG 15A, B, C), calretinin+ interneuron (FIG 
15D, E, F) progenitors (FIG 15G, H, I), microglia (FIG 15J, K, L), and GFAP= astrocytes 
(FIG15 M, N, O). This data indicates that by this early stage in disease there is little 
progression of the neuronal disease process. Astrocytes usually provide the first 
response to injury, and are possibly beginning to show a proliferative phenotype in 
the dentate gyrus increasing from mean value of 1.5% astrocytes to 2% astrocyte 
population of total cells. 
 
3.4.2. Pathological Changes by Day 10 BDL 
3.4.2.1. Changes to the Liver Biochemistry by Day 10 BDL  
 
By day 10 after bile duct ligation mice show significant changes to liver enzymes. 
Aspartate transaminase (AST) (FIG 16A) was more than doubled in the serum of BDL 
mice when compared with sham operated animals. This is indicative of large amounts 
of liver damage. An even more significant increase in alkaline phosphatase (ALP) (FIG 
16B) indicates damage to the ductular cells and gall bladder of the level that is expected 




Figure 16. Liver Biochemistry measurements. BDL day 10 animals had significantly raised Aspartate 
transaminase (AST) (A) and alkaline phosphatase (ALP) (B). N= 6 Sham N= 7 BDL day 10. Data represented 
as mean +/- SEM, statistics T.TEST. These tests were performed by staff scientists at Royal Victoria 
Infirmary Hospital labs, Newcastel upon Tyne. 
 
3.4.2.2. Histological Changes to the Liver by Day 10 BDL 
 
Mice show significant pro fibrotic features by day 10 post BDL surgery. There was a 
significant increase in activated myofibroblasts, (α-SMA), (FIG 17A, B, C), collagen 
deposition as seen in Picrosirius red (PSR) stain (FIG 17D, E, F), a common and well 
characterised phenotype of fibrosis  that is likely to contribute to raised liver enzymes 
seen in Figure 15 and altogether indicates a pro-inflammatory environment. 
 
 DR occurred by day 10 as seen in the cytokeratin 19 (CK19) histology (FIG 17G, H, I). DR, 
known pathologically as biliary hyperplasia is a common and robust feature of 
cholestatic disease, where the bile ducts undergo proliferation of the biliary epithelial 
cells and subsequent remodelling in response to injury (Roskams, Theise et al. 2004). In 
the case of BDL a large portion of this occurs at the large ducts (Alpini, Glaser et al. 1998). 
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Figure 17. Liver histology day 10 BDL animals. BDL animals had significantly increased activated 
myofibroblasts (A) example images of sham (B) and BDL (C), significantly increased collagen deposition 
(D), example images of sham (E) and BDL (F). Ductular proliferation was significantly increased in day 10 
BDL livers (G), example histology for sham (H) and BDL (I). Scale = 50 µm. N= 6 Sham N= 7 BDL day 10 
animals. Data represented as mean +/- SEM, statistics T.TEST. 
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3.4.2.3. Bile duct Ligated mice show Hepatic Senescence and 
DNA damage by day 10 
 
As previously discussed, liver senescence is a well characterised symptom in patients 
with PBC.  Ductular senescence was assessed here and cells sorted into parenchymal 
(mainly hepatocytes as labelled here) and non-parenchymal cell types (comprising of 
cell types such as BECs/cholangiocytes, sinusoidal endothelial cells, stellate cells, Kupffer 
cells, and intrahepatic lymphocytes) based on cell size criteria. These cells make up 60% 
and 40% of liver mass respectively. Hepatocytes are usually thought of as the ‘functional’ 
cells of the liver, however non parenchymal cells have important roles in hepatotoxicity 
and regeneration. Both parenchymal and non-parenchymal cells are sensitive to P21 
mediated senescence. In the BDL model by day 10 an average of 16% of hepatocytes are 
senescent whereas less than 1% of hepatocytes exhibit senescence in Sham animals (FIG 
18B, E, F). Senescence was also induced in non-parenchymal cells (FIG 18A), to a lesser 
extent than in hepatocytes, likely because hepatocytes are sensitive to oxidative 
damage. 
 
Hepatocytes also showed DNA damage as measured by γ-H2AX (FIG 18D), in similar 
levels to non-parenchymal cells, indicative of a global hepatic DDR. DNA damage is 




Figure 18. Senescence (p21+)  and DNA damage were assessed in the Liver of sham and day 10 BDL 
animals. (A) non parenchymal cells and (B) hepatocytes showed more senescence in BDL animals. DNA 
damage was also higher in the non parenchymal (C) and hepatocytes (D) in BDL animals. Histology images 
showing (E) sham and (F) BDL day 10 liver. Scale = 100micron. Data generated by collaborators Thomas 
Bird and Christos Kiourtis at Beatson Institute Glasgow, using HALO software. N=7 Sham animals N= 5 BDL 
day 10 animals. Data represented as mean +/- SEM, statistics T.TEST. 
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3.4.2.4. Circulating inflammatory Factors are raised in BDL 
mice 
 
Mesoscale discovery (MSD) inflammatory panel was run on serum from the day 10 BDL 
cohort (FIG 19). MSD readout revealed significant increase in inflammatory cytokines 
interferon gamma, IL10, IL-1B, IL-2, IL-4, IL-5, and TNFa. The only inflammatory output 
that was not significantly increased was KC gro (CXCL1) which is implicated in neutrophil 
recruitment. IL-6, a member of the senescence associated secretory phenotype (SASP) 
in hepatocytes was hugely inflated in the BDL animals. 
 
 
Figure 19. Mesoscale discovery data showing the serum concentrations of key cytokines between sham 







3.4.2.5. BDL Mice show Fatigue by Day 10 Post-Surgery  
 
Bile duct ligated mice (n= 6) showed significant reduction in both the distance moved 
(FIG 20A) and number of steps taken (FIG 20B) in open field testing by day 9 post-surgery 
when compared to sham (n= 6). In addition, the BDL group also showed a reduction in 
speed of movement by day 9 (FIG 20C), indicative of central fatigue. This data is 
indicative of fatigue symptoms in rodents appearing much earlier than previously 
reported, as Hosseini et al found no motor impairment at day 7 or 14 in rats. Our study 
shows significant locomotor activity deficit occurs as early at 9 days post-surgery. 
 
Figure 20. Open field data indicates significant reductions in distance travelled (A), step taken (B), and 
speed of travel in BDL mice by day 9. . N=6 Sham animals N=6 BDL day 9 animals. Data represented as 
mean +/- SEM, statistics T.TEST. 
3.4.2.6. Bile duct ligated mice show spatial memory deficit by 
day 10 post-surgery  
 
BDL animals shows a significant reduction in spatial memory by day 10 (n=9) compared 
to sham (n=8) animals when using hippocampal dependent task, the Y maze, and 
proportional time spent in novel arm as the primary output. Sham animals exhibit 
naturalistic exploratory behaviour when in the Y maze, and spent the majority of their 
time exploring the novel space as seen in the heatmaps as has been long recorded 
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natural test behaviour (Dember and Fowler 1959). In the example heatmaps shown 
where A1 is the novel arm (FIG 21A) sham animals spent average of 80% of trial time in 
the novel arm, On the other hand, BDL animals spend an average of 39% of the trial time 
in the novel arm (FIG 21B, C)  a number only marginally above statistical probability. The 
heatmaps (FIG 21A and B) indicate example movement pattern of each group when A2 
is the start arm, and A1 is the novel arm. 
 
Though latency to entering novel arm (FIG 21E) showed greater variation in the BDL 
groups, there is a trend towards these animals taking longer to enter the novel space. 
This is likely to be due to animals with impaired memory not recognising the space as 
novel, despite spatial memory cues at the end of each arm (FIG 21D).  This may also be 
indicative of decreased motivation in the BDL animals (Wright and Conrad 2005) 
perhaps due to fatigue symptoms. 
 
Figure 21. Y maze data indicates a visual-spatial memory impairment in BDL animals by day 10. Heatmaps 
showing (A) sham and (B) BDL movement in the Y-maze. (C) BDL mice show reduced time spent in the novel 
arm (D) diagram showing schematics present at the end of each arm of the maze. (E) BDL animals showed 
longer latency to entering the novel arm (P=0.07). N= 8 sham N=8 BDL. Data represented as mean +/- SEM, 
statistics T.TEST. 
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3.4.2.7. Bile duct ligated mice show aberrant astrocyte 
interactions at the blood brain barrier 
 
In order to look at specific changes at the vessel, a step wise protocol of techniques was 
employed (FIG 22C) from a microscopic (confocal microscopy) through to looking at 
specific cell-cell interactions at a nanoscopic scale (electron microscopy). 
 
Hippocampal astrocytes, the primary modulatory glial cell of the BBB significantly 
proliferated in BDL mice by day 10 when investigated by histology (FIG 22A). This 
suggests a loss of integrity at the barrier, leading to astrocyte activation and proliferation 
(astrogliosis). Super resolution imaging of astrocyte specific behaviour at the vessels (FIG 
22A), stained again by GFAP (green) and vessels by RecA (red) indicates a change in 
morphology to an activated state, and a reduction in coverage at the vessel itself. 
Activation of astrocytes is most easily characterised by swelling of the soma and 
processes and increased expression of intermediate filament proteins such as Glial acidic 
Fibrillary protein labelled here (Pekny and Nilsson 2005). It represents the universal 
response of an astrocyte to noxious stimuli, such as infiltrating inflammatory cytokines 
or damage at the vessel. 
 
Flow cytometry enabled a cell specific assessment of microvascular endothelial cells that 
make up the BBB. When labelled using Sca1, microvascular endothelial cell numbers 
were significantly reduced in BDL animals at day 10 (FIG 22D),  indicative of BBB damage 
and adding to the mounting evidence of BBB dysfunction in this model.  
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Figure 22. Immunohistologcial and flow cytometry assessment of BBB. (A) Super Resolution image of blood vessels in 
the DG of Sham and BDL animals. BDL animals show proliferative and poorly attached GFAP+ astrocytes in green. 
ReCA stained vessel in red. (C) a workflow diagram of the BBB work (D) Flow cytometry data showing a reduction in 
Sca1+ endothelial cells in BDL amimals. N=3 Sham animals N=4 BDL. Scale 20µm. Data represented as mean +/- SEM 
and statistics are T.TEST. The image in (A) was taken during my masters. 
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3.4.2.8.  Bile duct ligated mice have reduced astrocyte 
coverage at the blood brain barrier 
 
Electron microscopy (EM) revealed reduced astrocyte coverage at the blood vessels (FIG 
23E), and showed gaps between astrocytes and the vessel, likely caused by astrogliosis 
and scars forming between the vessel surface and astrocyte. Astrocyte coverage at the 
vessel was reduced from 83% to 55%, a large reduction. 
 
 This is supported by histological analysis indicating astrocyte proliferation (FIG 25A), 
and evidence from EM data shown here. Morphological changes can be seen in the EM 
cross sectional images, where sham (A) shows astrocytes (white arrows) tightly 
associated with the vessel with thin end feet enveloping the diameter of the vessel. 
Conversely, in the BDL image (B) astrocytes are more in number, swollen, and detached 
from the vessel in a manner seen in other EM studies (Haley and Lawrence 2016). This 
data indicates that there is a loss of astrocyte coverage; ergo increased permeability at 
the BBB in the BDL model. 
 
Endothelial wall thickness was also assessed using EM in the BDL model. There were no 
significant differences in either circumference (FIG 23D), or pericyte number (FIG 23F).  
However, the decrease in endothelial wall thickness (FIG 23C), may be related to the loss 
of MFI in hippocampal endothelial cells observed in flow cytometry data. A lack of 
differences in the circumference at vessels confirms that the vessels sampled were of 
comparable size, and so the effects seen in the astrocyte population (for example the 




Figure 23. Transmission electron microscopy data for sham and BDL day 10 mice. Histology shows 
astrocyte endfeet surrounding (A) sham and (B) BDL day 10 animals. (C) endothelial wall thickness was 
significantly reduced in BDL day 10 animals. (D) vessel circumference and (F) average number of pericytes 
was comparable between sham and BDL day 19 animals. (E) percentage astrocyte coverage was 
significantly reduced in day 10 BDL mice. . Endfeet are denoted by blue arrows, RBC denotes red blood cell, 
ETW denotes endothelial wall, P denotes pericyte.  N=4 sham and N=4 day 10 BDL animals. Scale = 2 
microns. Data represented as mean +/- SEM, statistics T.TEST. This data was presented as a part of my 
masters thesis. 
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3.4.2.9. Magnetic Resonance imaging assessment of Blood-
Brain Barrier breakdown in BDL  
 
BDL animals showed an increased contrast in the hippocampal region after gadolinium 
injection (FIG 24A, C). This indicates a higher amount of gadolinium contrast agent is 
able to enter the brain in the BDL animals, and thus that the BBB is leaky in the 
hippocampus of the BDL group.  Despite only having 3 animals per group, there seems 
to be an increase in contrast in the BDL animal group, though this does not reach 
significance. This data was generated with help from Andrew Blaimire and Saimir Luli.  
 
Figure 24. (A) Gadolinium enhanced T1 weighted MRI indicate a leaky blood-brain barrier in BDL animals. 
(B) Pre and post gadolinium injection shows little contrast change in sham animals. (C) Contrast change 
can be seen in BDL day 10 animals. N= 3 sham and N=3 BDL day 10 animals. This data was generated with 
help from Andrew Blaimire and Saimir Luli. 
3.4.2.10. BDL mice show some neuroinflammation by day 
10 
 
Hippocampal cell type changes were assessed in the BDL cohort harvested at day 10. In 
the dentate gyrus, an area where we have found BBB breakdown (FIG 23, 24)  
histological analysis indicates a significant proliferation of astrocytes, indicative of 
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neuroinflammatory response in this area (FIG 25A). As well as proliferating, astrocyte 
adopt a ‘reactive’ phenotype (FIG 25C) characterised by enlarged cell body and 
increased thickness of processes with fewer sweeping processes (Wilhelmsson, Bushong 
et al. 2006) instead of the inactivated astrocytes seen in sham animals (FIG 25B).  
 
Astrocytes do not have a proliferative nature, and in response to insult ordinarily 
increase in number around 2-3-fold. Here astrocytes are seen to proliferate 1.5x as an 
average, corroborating the literature, and also indicative of early (pre peak) 
neuroinflammatory response. 
 
Astrocytes activate in response to noxious stimuli or cytokines such as TNF-α. Often 
astrocytes and microglia activate in tandem, and can influence the activation status and 
phenotype of one another in a cytokine dependent manner (Liddelow, Guttenplan et al. 
2017). Microglia are also proliferating and activating in BDL by day 10, and show a trend 
towards significance (p=0.09) (FIG 25D). In the BDL animals’ microglia look by eye to 
show an ameboid phenotype and ramification (densifying and contracting of processes) 
(FIG 23F) when compared to the sham surgery group (FIG 25E), however this needs 
quantification. 
 
In order to investigate the specific activation phenotype of the microglia, FACs was 
employed. FACs analysis showed the total number of macrophages in the hippocampus 
was hugely increased (FIG 25G). Cells were sorted according to F4/80 positivity 
(macrophage marker) and phenotyped according to iNOS (M1) and Arg1 (M2) 
expression. M1 phenotype microglia were significantly increased in BDL animals, as 
expected (FIG 25I). However, these was also a significant increase in Arg1+ microglia, 
indicative of a restorative M2 macrophage phenotype (FIG 25J). When calculated as a 
percentage of all macrophages, the BDL animals had a total of 54% M1 activated 
macrophages and 46% M2 activated macrophages, in comparison to sham animals who 
had 58% M1 macrophages. This data indicates a diverse activation phenotype in the 
microglia, both inflammatory and resolutory.  
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Figure 25. Immunofluorescent and fluorescence associated cell sorting for inflammatory cell types. (A) 
astrocyte number were significantly increased between (B) sham and (C) BDL day 10 mice. (D) there was 
no increase in microglia between (E) sham and (F) BDL day 10 mice. (G) inflitrating macrphage number 
was significantly increased in BDL mice. Both (H) M1 and (I) M2 macrophage phenotype number were 
increased. Histology N=5 sham N=6 BDL. FACs N=4 sham and N=4 BDL. Scale = 50 microns. Data 
represented as mean +/- SEM, statistics T.TEST.  
3.4.2.11. BDL mice show damage to neuronal populations 
by day 10 
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Different neuronal and interneuron populations were assessed histologically for loss of 
positivity. Neurons within the granule cell layer (FIG 26A, B) were found to be 
significantly less NeuN+ in the BDL animals than in sham animals. NeuN expression can 
be modulated by a number of processes, usually NeuN is described as a pan neuronal 
marker, meaning all healthy neurons express it. A loss of neurons specifically within the 
granule cell layer has been shown to result in spatial memory deficit (Colicos and Dash 
1996), indicating a mechanism for behavioural deficit in this model. 
 
NeuN loss in the BDL animals often showed a similar pattern of staining loss in the inner 
granule cell layer and dentate gyrus crest (FIG 26C, G). The inner granule cell layer is 
where adult neurogenesis occurs, however we didn’t see a reduction in SOX2 (immature 
neuron) expression here (FIG 26D, E, F). This may have been skewed by the SOX2 stain 









Figure 26. Immunofluoescent staining of Neuronal populations within the dentate gyrus. (A) Neun+ 
neurons were significantly reduced in Day 10 BDL animals. (B) sham animals showed intact staining, 
whereas (C) BDL showed areas of missing NeuN neurons. (D) Neural progenitors were increased in BDL 
group, this did not reach significance. (E) sham and (F) BDL staining SOX2+ progenitors looked similar. (G) 
diagram outlining subregions of the dentate gyrus. N=4 sham N= 6 BDL day 10 animals (one exlcuded in 
the Sox2 stain group). Scale = 50µm. Data represented as mean +/- SEM, statistics T.TEST. 
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3.4.2.12. BDL animals show neuronal senescence by day 
10 
 
Senescence is a process of cell cycle arrest, preventing the normal cellular function. 
When neurons become dysfunctional in response to cellular stressors such as oxidative 
stress DNA damage or SASP they enter a senescent state, losing ordinary function. 
Neuronal senescence was investigated in several ways in order to unpick phenotypic 
changes. Expression of checkpoint protein P21 RNA (how many neurons were producing 
P21 RNA and how much of it) was measured alongside Telomere Associated Foci (TAF) 
staining. An integrative approach taking into account both DNA damage via γ-H2AX and 
uncapping of telomeres, two intricately linked processes that occur in tandem (Hewitt, 
Jurk et al. 2012).  
 
In BDL animals both the number of P21+ neurons, and the number of foci per neuron in 
the DG (FIG 27B and C) and CA3 (FIG 27E and F) were significantly increased, indicating 
a strong senescence phenotype in both regions. While the percentage increases of P21 
expression in both regions were similar between sham and BDL, there were area 
differences between the DG and CA3 in the baseline level of senescence in the sham 
group. The average percentage of P21 RNA + neurons in the DG is 14% whereas in the 
CA3, this is 34%.  
 
Neuronal populations in the CA3 have a high proportion of pyramidal cells. There are 
publications suggesting pyramidal cells in the CA3 are susceptible to oxidative stress 
(Cruz-Sánchez, Gironès et al. 2010), as well as further recent studies indicating that fast 
spiking basket cells in the CA3 are very sensitive to oxidative stress (Morishita, Cabungcal 
et al. 2015). Stress responses and resultant DDR in the CA3 may account for the higher 
levels of P21 RNA. TAFs show higher levels of DNA damage in BDL animals, and a higher 
percentage of TAF+ neurons (FIG 27G), and more than double the number of co-
localising TAFs per neuron (FIG 27I).  
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Figure 27. Neuronal senescence staining. (A) sham dentate gyrus showed less P21 RNA than (B) BDL. (C)Percentage of P21+ neurons and (D) AVG P21 foci were 
incereased in BDL animal dentate gyrus. (E) sham CA3 showed less P21 RNA than (F) BDL. (G) Percentage of P21+ neurons and (H) AVG P21 foci per neuron 
were increased in BDL. (I) Percentage of Telomere associated foci (TAF) was also increased in CA3 of  (L)BDL animal compared to (J) sham. (K) AVG TAFs per 
CA3 neuron was also increased in BDL day 10 animals. Scale P21 = 50 microns. Scale TAF =1.5µm (Sham), 1.2µm (BDL). Data represented as mean +/- SEM, 
statistics T.TEST. Staining oerformed by Diana Jurk, analysis performed by me 
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 A Summary of Key Findings from Chapter 3 
 
• BDL causes deficits in visual – spatial memory (Y maze) and fatigue (Open Field) by 
day 10 when compared to Sham operated animals. 
 
• There are key changes to BBB morphology (EM, STED imaging) and permeability 
(MRI) by day 10 BDL, which together are highly indicative of loss of BBB function 
in the BDL mice leaving the brain permeable to toxins produced during cholestasis. 
 
• There are key changes to cell types within the brain by day 10. NeuN positivity is 
lost, and a significant portion of neurons within the CA3 and DG have a senescent 
phenotype, an outcome which may contribute to the cognitive deficit. 
 
• Inflammatory cell types microglia and astrocytes are upregulated in the 
hippocampus in BDL animals by day 10, indicative of neuroinflammation. 
 
  Conclusions 
 
Results from this chapter clearly show cholestasis causes cognitive impairment as well as 
hepatic damage in the BDL model.  The liver phenotype seen in the mice has been well 
characterised by other groups (Abshagen, König et al. 2015) and is recapitulated in this 
experimental data set. Myofibroblast activation and proliferation (FIG 17A), collagen 
deposition (FIG 17D), DR (FIG 17G), and senescence of hepatocytes and non-parenchymal 
cells (FIG 18A, B) all occur by day 10. This model is severe, with quickly progressing 
cholestasis. This is also indicated by fibrosis and DNA damage (FIG 18C, D) by day 10, and 
also the increased presence of liver enyzmes such as AST (FIG 16A), which is released from 
stressed hepatocytes. There is also a significant increase in ALP (FIG 16B), another enzyme 
released upon damage to the ducts and increases step wise in relation to ductular 
damage, allowing tracking of the disease progression in these BDL animals. Though BDL 
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represents a severe cholestatic model, by day 10 mice haven’t yet developed cirrhosis 
(Tag, Sauer-Lehnen et al. 2015). Utilizing this earlier end-point in our study allowed us to 
assess pre-cirrhotic changes to cognitive function. 
 
The presence of a phenotype of senescence is corroborative with human data  showing 
that cholestatic liver diseases such as PBC induce a phenotype of senescence in the 
ductular cells (which we see in our studies as non-parenchymal cell fraction), and in peri-
ductular hepatocytes (hepatocyte fraction) (Sasaki, Ikeda et al. 2005). These senescent 
cells in patients are found to undergo both telomere shortening and DNA damage (Sasaki, 
Ikeda et al. 2008). In our model we have found evidence of DNA damage around the ducts 
(FIG 18C), again in keeping with reported changes in the cholestatic liver in humans.  
 
Behavioural deficits are yet to occur by day 6 (FIG 13), but are prominent by day 10 (FIG 
20, FIG 21), with both activity and spatial memory domains affected. This correlates with 
fatigue seen commonly in PBC patients (Newton, Bhala et al. 2006) and also with visual 
spatial deficit seen in patients (Newton, Hollingsworth et al. 2008). Therefore, the BDL 
model goes some way to recapitulating cholestasis induced cognitive decline, and its 
associated phenotype of fatigue. Cognitive phenotype has been associated with physical 
changes in the hippocampus in patients (Mosher, Swain et al. 2018). Changes in cognitive 
function in cholestatic mice using hippocampal dependent tasks allows a measurement 
more comparable to the human phenotype. 
 
Results from this chapter indicate a powerful circulating inflammatory phenotype, both 
from inflammatory cytokines (FIG 19) and macrophage activation (FIG 25). There is an 
increase in activated macrophages within the brain itself (FIG 25). Previous publications 
show monocyte recruitment to the brain leads to signaling to and activation of resident 
microglia (Kerfoot, D'Mello et al. 2006) or that circulating monocytes themselves can 
infiltrate the brain through a compromised barrier (D'Mello, Le et al. 2009). Evidence from 
our data of BBB dysfunction lends itself to the idea of circulating immune infiltration. 
 
By day 10 astrocytes possess an abhorrent phenotype at the barrier (EM fig, STEM at BBB), 
and are activated leading to proliferation (FIG 25A) when counted both at the barrier and 
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generally within the dentate gyrus of the hippocampus. Microglia become activated and 
change phenotype, attracting more astrocytes via the inflammatory feedforward loop, 
modulated chiefly by TNF-α (D'Mello, Le et al. 2009). In our models we saw a significant 
increase of the pro-inflammatory cytokine’s TNF-α alongside other inflammatory 
cytokines such as IL-6 (FIG 19). In turn the neuroinflammatory processes induce 
dysfunction and leakiness at the barrier. The hippocampus has been found to be more 
susceptible to BBB damage, both in normal age and pathological conditions such as 
traumatic brain injury (Montagne, Barnes et al. 2015). This may explain why breakdown 
in the hippocampus is affected in diseases such as cholestatic disease caused by a 
circulating inflammatory phenotype. 
 
By day 10, NeuN expression appeared to be lost in some granule cells in the crest of the 
dentate gyrus (FIG 26A). Despite NeuN expression being lost, the cells remained DAPI 
positive, pointing towards a loss of function rather than cell death. This has been reported 
in disease states due to apoptosis, and can lead directly to a cognitive deficit (Colicos and 
Dash 1996). When we investigated the senescence phenotypes of the granule cells, we 
found large increase in both the expression of p21 RNA (FIG 27 C, D, G, H), and the 
presence of DNA damage foci at uncapped telomere ends, named Telomere associated 
foci (TAFs) (FIG 27I, K). In BDL mice P21 RNA was present in more neurons in the DG (35% 
neurons) and CA3 (50% neurons) areas key in spatial memory (FIG 27C, G). In addition, 
there were more RNA copies in these regions in BDL mice than in Sham operated animals 
(FIG 27D, H). This senescence phenotype is a candidate to be the underlying cause of the 
behavioural deficits experienced by BDL mice.  
 
Currently there are no studies published linking senescence of peripheral organs with 
induced senescence within post mitotic neurons in the brain. In ageing, multiple organ 
senescence occurs, primarily due to pro inflammatory cytokine secretion, termed 
‘inflammaging’ (Franceschi, Bonafè et al. 2000). In our data we have shown that BDL 
animals show increased senescence in the hippocampus of the brain as well as within the 
liver. We also see huge increases in circulating inflammatory cytokines, detected by MSD 
using serum samples. Particularly cytokines such as IL-6, which are known to be secreted 
from senescent hepatocytes (Irvine, Skoien et al. 2014) and forms a part of the SASP.  
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We have also demonstrated the presence of breakdown of the normal function of the 
blood brain barrier. A non-functional or leaky barrier allows inflammatory cytokines 
infiltration and to exertion of effects in the brain, infiltrating key regions such as the 
hippocampus, and leading to the induction of senescence within the neurons there. In 
tandem, the induced activation of brain resident immune cells such as microglia and 
astrocytes, causes neuroinflammatory cascade, a damaging process mediated by M1 
microglia. Due to intricate coupling at the neurovascular unit, astrocytes that are 
activated into an A1 phenotype induced by microglia have damaging effects at the 
neuron, reducing synaptogenesis, neuronal health and can even induce neuronal death 
(Liddelow, Guttenplan et al. 2017).  Here, by unknown mechanisms- neuroinflammatory, 
activated astrocytes have induced a senescent phenotype in hippocampal neurons, 












4. Chapter Four – The effects of 
Primary Biliary Cholangitis drug 
treatments on cognitive symptoms 




Thus far, the search for effective therapeutics for cognitive symptoms in PBC has been 
fruitless. In fact, as currently used no treatment – both drug or liver transplantation - 
improves the cognitive symptom set at all (Pells, Mells et al. 2013). As transplantation 
improves other features (liver biochemistry, fibrosis) and effectively ‘resets’ the disease 
course (recurrence rates are 1 in 3), it seems likely then that cognitive symptoms possess 
an intrinsically linked but distinct pathological mechanism. Symptoms are likely triggered 
by the liver pathology but once kick started can self-aggravate and continue despite 
resolution of hepatic insult. Therefore, the failure of current therapy may be related to a 
lack of direct action on the pathological processes within the brain.  
 
There are only two drug therapies currently approved for the treatment of PBC. The first 
is the first line therapy Ursodeoxycholic acid (UDCA) which has a high proportion of none 
responders and second-line therapy Obeticholic Acid (OCA) a more recently FDA approved 
(2016).  
 
4.1.1. Ursodeoxycholic Acid (UDCA) 
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UDCA is a naturally occurring bile acid, first approved for use in 1997. It works by 
increasing bile flow, thereby diluting the bile acids present in the body and reducing 
natural production of bile acids from the bile ducts via negative feedback, as well as weak 
anti-oxidant properties. The use of UDCA is associated with improved liver biochemistry, 
increased survival and reduction in liver transplants. 
 
 Although it does not provide a cure, UDCA improves transplant free survival at time 
points of both 10 and 35 years (Poupon, Bonnand et al. 1999, Floreani, Caroli et al. 2011). 
UDCA is the currently recommended first treatment option for PBC treatment by the 
European Association for the Study of Liver (EASL)  guidelines (13-15 mg/kg/d) (EASL 
2009). Despite improved liver biochemistry (serum AST ALT and ALP), 40-50% are 
classified as unresponsive to UDCA therapy and therefore have little resulting therapeutic 
benefit. To date, there is little understanding of the pathological differences between 
UDCA responders and non-responders. Prognostic outcomes vary hugely between the 
groups, with UDCA non -responders representing an at-risk patient population, with a 
greater likelihood of faster disease progression (Corpechot, Abenavoli et al. 2008, Kuiper, 
Hansen et al. 2009).  
 
4.1.1.1. UDCA Mechanism of Action 
 
UDCA works by three main mechanisms. The presence of UDCA has been found to 
stimulate biliary secretion and therefore reduce bile acid toxicity in both animal models 
(Kitani, Ohta et al. 1985) and patients (Jazrawi, de Caestecker et al. 1994). Therefore, 
many of the beneficial effects seen in those treated with UDCA in part come from 
enhanced elimination of toxic compounds from the liver, in particular hepatocytes. 
 
Though the exact anti-cholestatic mechanisms of UDCA remain unclear, hepatoxic effects 
during cholestasis are counteracted by stimulating mechanisms of biliary excretion. UDCA 
can stimulate the expression of the transporter proteins required for biliary secretion 
through the canicular membrane (Jazrawi, de Caestecker et al. 1994) in humans, it is 
known to encourage insertion of transporters in the canicular membrane such as Mrp2 
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and Bsep in rodents, thereby stimulating excretion and removal of toxic compounds from 
the liver (Beuers, Bilzer et al. 2001, Dombrowski, Stieger et al. 2006).  
 
Other postulated effects include reducing the toxic effects of bile acids on the 
phospholipid bilayer by increasing the hydrophobic bile acid load in the system (UDCA is 
the most hydrophilic bile acid) and thereby reducing cell death and expelling hydrophobic 
damaging bile acids such as lithocholic acid in vivo (Takano, Ito et al. 1994).  
 
Several in vitro experiments have also indicated a likely anti-apoptotic role for UDCA, 
through preventing mitochondrial depolarization and reducing the production of the 
resulting ROS in hepatocytes (Rodrigues, Fan et al. 1998). UDCA has also been found to 
stimulate pro-survival signals in injured hepatocytes through cyclic adenosine 
monophosphate (CAMP) (Webster and Anwer 1998) or nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) mediated mechanisms.  
 
4.1.2. Obeticholic Acid (OCA) 
 
The Farnesoid X Receptor (FXR) agonist OCA was FDA approved in 2016 following the 
reported ALT improvements in the large scale POISE study (Nevens, Andreone et al. 2016), 
becoming the first drug approved for use in the treatment of PBC in nearly 20 years. The 
largest reported adverse outcome of the trial was pruritis, which continues to be the most 
commonly reported side effect and reason for drug discontinuation. Currently the 
prescription guidelines of OCA state usage only in conjunction with UDCA in cases of non-
response (after 1 year follow up on UDCA) or alone in rare cases of UDCA intolerance 
(Hirschfield, Dyson et al. 2018). 
 
4.1.2.1. OCA Mechanism of Action 
 
A series of conducive mechanisms have been reported for OCA pharmacology. It has 
reported anti cholestatic, anti-inflammatory and anti-fibrotic effects in a variety of 
diseases (Mudaliar, Henry et al. 2013, Hirschfield, Mason et al. 2015), and is currently 
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undergoing the FDA approval process to be the first drug treatment available for the 
fibrosis induced during non-alcoholic steatohepatitis (NASH), following positive results 
from the REGENERATE study (Younossi, Ratziu et al. 2019).  
 
OCA is a semi-synthetic 6-ethyl derivative of natural chenodeoxycholic acid (Pellicciari, 
Fiorucci et al. 2002) and  potent FXR-receptor agonist, binding with an affinity 100x 
stronger than the natural ligand CDCA (De Magalhaes Filho, Downes et al. 2016). The FXR 
receptor provides a powerful therapeutic target against PBC due to its regulation of bile 
flow (discussed in chapter One). Therefore, FXR can act within the liver stimulating biliary 
excretion of toxic bile acid compositions through mechanisms similar to UDCA. It can also 
work directly through stimulation of FGF-19 (human) or FGF-15 (mouse) release in the 
gut. 
 
FXR activation of SHP (its downstream target) has been shown to have anti-fibrotic effects 
in vivo and in vitro (Fiorucci, Antonelli et al. 2004), with FXR agonists  such as OCA 
preventing the onset of fibrosis directly through inhibiting collagen gene expression in 
HSCs. It also influences inflammatory processes within the liver. FXR KO mice have been 
shown to aberrant cellular processes, triggering inflammation and the development of 
tumours (Yang, Huang et al. 2007). Follow-up research implicates a direct modulatory 
effect via NF-κB agonism, implicating FXR as a master hepatic regulator of inflammation 
(Wang, Chen et al. 2008). The identification of a role for FXR key immunomodulatory 
implicates FXR and its agonists as key therapeutic targets in a number of diseases.  
 
4.1.3. Bezafibrates (BZ) 
 
Bezafibrate is one of the fibrate family of peroxisome proliferator-activated receptor-α 
(PPARα) agonists (though studies indicate secondary effects on both PPARγ and PPARδ) 
that are currently being investigated for use in PBC. The fibrate drug class have been 
approved for medical use since 1978 but are not currently approved for use in PBC.  
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Patients trials combining UDCA and Bezafibrate treatment have shown promising 
improvements in key prognostic indicators such as liver biochemistry (AST/ALT/ALP) 
(Corpechot, Chazouillères et al. 2018, Agrawal, Majeed et al. 2019), and need for 
transplantation (Corpechot, Chazouillères et al. 2019) when compared to UDCA 
monotherapy.  This makes Bezafibrate the most likely drug candidate to be next approved 
for use in PBC. 
4.1.3.1. Bezafibrate Mechanism of Action 
 
Bezafibrate works on PPARs, a nuclear receptor family that are abundant in the liver. It 
exerts many of its pharmacological effects on PPAR-α, which is highly expressed in 
hepatocytes. However, as previously mentioned, effects are also propagated secondarily 
through PPAR-δ and PPAR-γ. PPAR-δ is equally distributed through various liver resident 
cell types, such as hepatocytes, cholangiocytes, Kupffer cells, and stellate cells whilst 
PPAR-γ exists largely in Kupffer cells. 
 
PPARs are classically known as lipid lowering drugs and are used for treatment in 
conditions such as atherosclerosis. Fibrates are able to increase fatty acid oxidation, 
leading to a reduction in low-density lipoprotein (LDL) in plasma and triggering a reduction 
in LDL-cholesterol levels (Staels, Dallongeville et al. 1998).  
 
In the context of cholestatic disease, fibrate action through PPAR-α downregulates 
processes of BA synthesis by inhibiting key BA synthesising enzymes cytochrome P450 
cholesterol 7A1-hydroxylase (CYP7A1) and cytochrome sterol 27-hydroxylase (CYP27A1) 
(Post, Duez et al. 2001). Agonism at this receptor can repress CYP7A1 activity by 60%, 
reducing hepatocyte BA production.  
 
Fibrates also have anti-inflammatory effects. Historically, this was thought to be through 
PPAR-α, which has long been shown to inhibit IL-6 production through repression of NF-
κB (Delerive, De Bosscher et al. 1999). It now seems likely that this is only part of the story. 
More recent studies show promising anti-inflammatory effects and resulting reduction in 
cholangitis using drugs that effect PPARγ (Nozaki, Harada et al. 2013) and PPARδ 
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(Haczeyni, Wang et al. 2017). The latter of these induced a multi-centre clinical trial for 
the agent Seladelpar (Jones, Boudes et al. 2017).  
 Study Rationale 
 
As currently used, no PBC treatment has any effect on cognitive symptoms, including 
transplantation. The following studies were designed to evaluate the benefit of early 
therapeutic intervention with drug candidates that are either approved for use in PBC 
(UDCA, OCA), or are being currently investigated in trial (Bezafibrate). There were 
assessed individually for efficacy and potential for cognitive benefit in a controlled and 
replicable animal model of cholestasis, that recapitulates the cognitive symptoms seen in 
humans.  
 
Primary studies (highlighted as such) investigating UDCA and OCA efficacy used a 
prophylactic and therapeutic dosing schedule in order to assess time dependent effects 
on behavioural and histological changes. Clearly, in a patient prophylactic dosing is 
impossible. However, this allows us begin to pick apart the mechanism of cholestasis-
induced cognitive decline, especially in the brain where it is not known clearly whether 
damage is cause via primary cascades within the brain (independent pro inflammatory 
signalling cascades triggered within the brain) or by secondary mechanisms (pro 
inflammatory signalling from the liver).  
 
In later studies (bezafibrate studies and later OCA studies), drug dosing treatments were 
started on the day of surgery after prophylactic and therapeutic dosing schedules showed 
little discrepancy. The testing parameters of the studies were the same as the animal 
studies in chapter one liver histology, behavioural testing using Open Field and Y maze, 
hippocampal cell type histology, FACs, senescence staining, were all assessed. 
 
UDCA and OCA were used in this study as they represent the current 1st and 2nd line 
therapies approved for use in patients. No drug treatments as currently used improves 
cognitive symptoms in patients, however models such as BDL provide a unique 
opportunity to explore mechanisms of cognitive decline and the ability (or inability) of 
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conventional, approved, drug treatments to impact disease course if used early in the 
disease process.  
 
PPAR agonists are currently being explored for approval in patients and are an attractive 
therapeutic option for patients, in part due to itch experienced with other anti-cholestatic 
agents such as OCA. The experiments outlined in this chapter allowed a direct comparison 
between novel treatments such as Bezafibrate and current treatment options (FIG 29). 
This allowed in depth investigation into the effect of Bezafibrate with focus on cognitive 
symptoms, an avenue which has been little explored in previous animal models. 
  
 
Figure 29 Experimental timelines for drug intervention studies (A) Prophylactic and therapeutic dosing 




 Aims of the Chapter 
 
• To compare the therapeutic effects of administering either the first or second line 
PBC drug therapies UDCA and OCA in the BDL animal model of cholestatic liver 
disease. 
 
• In addition, compare the therapeutic benefit of Bezafibrate, an experimental PPAR 
agonist to currently used therapies. 
 
The therapeutic effects to be assessed are: 
 
• Liver damage and histology (fibrosis, activated myofibroblasts, ductular 
proliferation) 
 
• Cognitive function and memory (Y maze), fatigue (Open Field). 
 
• Histology of neuronal and inflammatory (astrocytes, microglia) cell types. 
 
• Neuronal Senescence within the hippocampus. 
 
Additional experiments for treatments with positive therapeutic benefit: 
 




 Ursodeoxycholic acid Study 
 
4.4.1. UDCA shows little therapeutic benefit in liver 
histology outputs 
 
This study replicates histological increase in collagens, activated myofibroblasts and DR 
previously reported in result chapter one. Treatment with 0.5% (500mg/kg) UDCA both 
prophylactically and therapeutically had little impact on liver histology in the BDL model. 
Activated myofibroblasts (α-SMA, FIG 30A) were still upregulated during BDL compared 
to sham, accompanied by an increase in collagen deposition (Picrosirius red) (FIG 30E). 
Both the parameters remained upregulated despite the UDCA treatment. Ductular 
reaction (CK19) was also still upregulated (FIG 30I), mirroring results from the previous 
study (Chapter Three FIG 17). UDCA prophylactic intervention did not improve the DR 
phenotype and may have marginally exacerbated the phenotype, possibly due to increase 
bile flow in the days prior to surgery. Therapeutic dosing of UDCA made no change to DR. 
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Figure 30.Liver histology from the UDCA dosing study. (A) percentage cover of activated myofibroblasts were 
similar between (B) BDL day 10, (C) prophylactic UDCA and (D) Therapeutic UDCA dosing. (E) fibrosis was 
similar been (F) BDL, (G) prophylactic UDCA and (H) therapeutic UDCA. (I) ductular proliferation was similar 
between (J) BDL (K) prophylactic UDCA and (L) therapeutic UDCA. Scale = 100µm. N=7 BDL, N= 8 pro UDCA 
N= 7 Ther UDCA. Data represented as mean +/- SEM. Statistics ANOVA.  
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4.4.2. UDCA Treatment did Not Affect Senescence in the 
Liver 
Senescence staining in the liver showed no differences in p21 positivity in either non 
parenchymal cells (FIG 31A) or hepatocytes (FIG 31B) in the liver between BDL and either 
UDCA treated group. The non-parenchymal group showed a small trend towards decease 
with prophylactic UDCA treatment. 
 
Figure 31. P21 stain from the liver of BDL untreated mice, or treated prophylactically or therapeutically with 
UDCA. (A) There were no differences in percentage of p21+ parenchymal cells in the liver (B) There were no 
differences in the percentage of p21+ hepatocytes between any group. N=7 BDL N= 8 prophylactic UDCA 
N=6 Therapeutic UDCA. Data represented as mean +/- SEM statistics ANOVA. Data analysed using HALO 
system with thanks to collaborators Thomas Bird and Christos Kiourtis. 
4.4.3. UDCA Treatment had No Effects on Behaviour 
Neither prophylactic nor therapeutic dosing with UDCA showed improvement in 
behavioural testing. Open Field steps taken were similar between all three groups (FIG 
32A), though the data set is variable. This data illustrates the animal may still be 
experiencing fatigue, and therefore have no prevention or alleviation of cognitive 
symptoms with treatment. 
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Y maze output time spent in the novel arm was also similar between the three groups (FIG 
32C), indicating there is no improvement in the visual-spatial memory impairment in the 
treated group. Figure 32B, D and E depicts heatmaps from all three treatment arms where 
the start arm is A2 and the novel arm A3. The animals in all three groups exhibited no 
preference for the novel arm. 
 
Figure 32. Behavioural testing for UDCA study. (A) UDCA treated and BDL untreated mice took similar 
number of steps in the Open Field. (C) animals spent similar time in the novel arm in the Y maze, (B) example 
heatmap of BDL mice, (D) prophylactically treated UDCA mice, and (E) therapeutically UDCA treated mice. 
N=7 BDL N= 7 pro UDCA mice N=6 Ther UDCA mice. 1 BDL and 1 pro UDCA mice excluded from the Y-maze 




4.4.4. UDCA treatment induced no Changes in Cell Type 
Expression within the Dentate Gyrus of the 
Hippocampus 
 
Treatment with UDCA had no effect on any of the cell types stained within the dentate 
gyrus. NeuN expression in neurons was similar between all three of the treatment groups 
(FIG 33A, B, C, D).  The percentage of NeuN positive neurons within the dentate gyrus is 
sustained between this study and the studies in Chapter one, showing that this is likely to 
be a true effect in the BDL group, as are the inflammatory cell populations the microglia 
(FIG 33E) and astrocytes (FIG 33F). Thus, there are no anti-inflammatory effects of UDCA 
drug treatment (prophylactically or therapeutically) within the brain. 
 
Parvalbumin interneuron numbers were marginally reduced in UDCA animals (FIG 33G), 
however there are highlighted outliers in the BDL group, showing any difference is likely 
due to variation within the groups. 
 110 
 
Figure 33. Hippocampal immunofluorescent stain of UDCA study mice. (A) Each group had similar NeuN+ 
neuron numbers, example image from (B) BDL (C) prophylactic UDCA (D) Therapeutic UDCA mice. UDCA 
treated mice also had similar numbers of (E) iba1+ microglia (F) GFAP+ astrocytes (G) Parvalbumin + 
interneurons. Scale = 50 µm. N= 4 BDL N= 8 pro UDCA N= 6 Ther UDCA mice. Data represented as mean +/- 
SEM statistics ANOVA. Data generated by RuoXie Law UG student under supervision.  
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4.4.5. UDCA Does not Improve Neuronal Senescence when 
Compared to BDL control 
 
UDCA treated animals showed no difference from BDL using either the prophylactic or the 
therapeutic dosing schedule. P21+ RNA ISH shows a similar amount of P21 RNA between 
BDL control and UDCA treatment groups in both the DG (FIG 34A-C) and CA3 (FIG 34D-F) 
regions of the hippocampus. P21+ foci per neuron remained similar in both regions 
between treated and untreated groups (FIG 34G, I), as did the percentage of P21+ neurons 
present in both the DG (FIG 34H) and CA3 (FIG 34J). 
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Figure 34. P21 RNA-ISH histology for UDCA dosing study. (A) BDL and UDCA treated animals had similar P21+ 
foci per neuron and (B) percentage of P21+ neurons in the dentate gyrus. (C) BDL and UDCA treated groups 
had similar (C) P21+ foci per neuron and (D) percentage of P21+ neurons in the CA3. Example histology 
showing dentate gyrus P21+ RNA-ISH in (E) BDL (F) Prophylactic UDCA (G) therapeutic UDCA. Example 
histology showing CA3 P21+ RNA-ISH in (H) BDL (I) Prophylactic UDCA (J) therapeutic UDCA. Scale = 50µm. 
N= 5 BDL N=7 Pro UDCA N=6 Ther UDCA (one DG broke). Data represented as mean +/- SEM statistics 
ANOVA. Stain performed by Diana Jurk analysed by me. 
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 Obeticholic Acid (OCA) Study 
4.5.1. Obeticholic Acid Treatment Reduces Fibrosis and DR 
in the Liver in BDL Mice 
Day 10 BDL animals showed comparable levels of activated myofibroblasts ( FIG 35A, B, 
C), fibrosis ( FIG 35D, E, F), and DR (FIG 35G, H, I)) to previous studies. Treatment with 
Obeticholic acid from day of surgery until harvest on day 10 significantly reduced fibrosis, 




Figure 35. Liver histology for OCA study. (A) OCA treated animals had significantly less activated 
myofibroblasts. Example α- SMA histology for (B) BDL and (C) OCA treated mice. (D) OCA treated animals 
had less fibrosis. Example PSR histology for (E) BDL and (F) OCA treated mice. (G) Ductular proliferation is 
significantly reduced in OCA treated animals. Example PSR histology for (H) BDL and (I) OCA treated mice. 




4.5.2. Obeticholic Acid Reduces Liver Senescence in the BDL 
Model 
 
Chapter three established a liver senescence phenotype in BDL mice by day 10, present in 
both hepatocytes and non-parenchymal cell types. There is also an established DNA 
damage phenotype by day 10 in the BDL animals, likely to contribute to the senescent 
phenotype. P21 positivity is reduced in animals treated with OCA in both non-
parenchymal (FIG 36A) and hepatocyte (FIG 36B) cell populations. DNA damage is also 
reduced in OCA treated animals, to significance in non-parenchymal populations (FIG 36C) 




Figure 36. Senescence staining in the liver. (A) percentage of P21+ non parenchymal cells were reduced in 
OCA treated mice. (B) percentage of P21+ hepatocytes in the liver were reduced in OCA treated mice. (C) 
percentage of DNA damaged non parenchymal cells in the liver were reduced in OCA treated mice. (D) 
percentage of DNA damaged hepatocytes in the liver were reduced in OCA treated animals. Histology of P21 
in the liver of (E) BDL and (F) OCA treated animals. Scale = 100µm. N=5 BDL N= 11 OCA. Data represented as 
mean +/- SEM statistics T.TEST. Data analysed using HALO system with thanks to collaborators Thomas Bird 
and Christos Kiourtis. 
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4.5.3. OCA Restores BBB damage Associated with BDL  
Endothelial wall thickness and vessel circumference remain similar between sham and 
BDL as reported in the previous study. Treatment with OCA from day 0 led to no significant 
changes in vessel thickness or circumference between drug treated and either BDL or 
sham animals (FIG 37B, C). Interestingly loss of astrocyte end-feet coverage at the vessel 
with BDL was maintained in this repeat study, and OCA treatment led to improved 
astrocyte coverage at the vessel (FIG 37A). The difference is marginal by day 6 and shows 
no significant change, however by day 10 the OCA treated animals showed significantly 
more astrocyte coverage at the vessel (FIG 37E, F, G, H, I), indicative of a more intact BBB.   
 
Pericyte numbers were also reduced in the BDL animals by day 6, when compared to sham 
though this does not reach significance. Pericyte were increased in both BDL control and 
OCA treated animals by day 10 with OCA treated animals showing on average significantly 
more pericytes present within the vessel (FIG 37D). This data could be indicative of more 
severe BBB breakdown by day 6, accompanied by loss of both astrocyte and pericyte 
coverage at the vessel. 
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Figure 37. Transmission electron microscopy of hippocampal blood vessels. (A) percentage astrocyte 
coverage was significantly reduced in day 6 BDL, day 6 OCA treated and day 10 BDL animals when compared 
to sham animals. Astrocyte coverage is significantly increased between BDL day 10 and OCA day 10 treated 
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animals. No significant differences in (B) endothelial wall thickness and (C) circumference between groups. 
(D) number of pericytes around the vessel was significantly increased between day 6 and day 10 OCA treated 
animals. Images for (E) sham (F) BDL day 6 (G) OCA day 6 (H) BDL day 10 (I) OCA day 10. N= 4 sham N=3 BDL 
day 6 N=4 day 6 OCA N=4 BDL day 10 N=4 day 10 OCA. Data represented as mean +/- SEM statistics ANOVA. 
Blue arrows denote astrocyte endfeet. 
 
4.5.4. OCA treated animals show improved behavioural 
phenotype  
BDL animals treated with OCA showed no changes in Open field testing (FIG 38A XB), 
however these mice spent more time in the novel arm in the Y maze (FIG 38C). Spatial 
memory deficits but not fatigue appeared ameliorated in animals treated with OCA either 
prophylactically or therapeutically when compared with untreated BDL animals. This data 
indicate that OCA may have positive effect on deficits of cognitive domain but not fatigue 
symptoms.  Heatmaps indicate example for each group of time spent in novel arm when 


















Figure 38. Behavioural testing for OCA drug dosing study. (A) Number of steps taken was significantly reduced between 
day 5 and day 10 BDL. (B) open field speed of travel was reduced between day 5 and day 9 BDL. (C) Time spent in the 
novel arm in the Y maze was significantly increased in OCA animals treated with prophylactically or therapeutically on 
day 10. Y maze heatmaps for (D) BDL and (E) prophylactically OCA where A1 is the start arm and A2 is the novel arm. 
N= 20 D5 BDL N=20 D5 pro-OCA N= 10 Ther-OCA N= 16 BDL day 9 N=15 pro-OCA N=9 Ther-OCA. Data represented as 
mean +/-SEM statistics ANOVA. 
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Figure 39 Immunofluorescent stains in the dentate gyrus of mice from BDL OCA study. (A) NeuN+ neurons 
were similar between BDL and BDL OCA animals. (C) Astrocytes were significantly more in (B) BDL animals 
compared to (D) OCA. (E) Iba1+ microglia were similar between BDL and BDL OCA groups. (F) SOX2+ 
progenitors were similar between BDL and BDL OCA animals. Scale = 50 µm. N=5 BDL N= 7 BDL OCA. Data 
represented as mean +/- SEM Statistics T.TEST. 
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4.5.1. Obeticholic Acid treatment affects astrocyte 
activation 
 
There was no significant difference in neuron number between the BDL control and BDL 
OCA treated groups (FIG 39A). Animals treated with OCA maintained the reduced NeuN 
expression found in the BDL animals. However, OCA treatment did have an effect on the 
astrocyte numbers present in the hippocampus during BDL. OCA treated animals had 
significantly less astrocytes recruited to the hippocampus than comparative BDL control 
animals (FIG 39C, D), this is likely to indicate lower levels of neuroinflammation in the 
hippocampus in these mice. Interestingly microglia did not show the same reduction (FIG 
39E). Neural progenitors were slightly increased in the OCA treated animals, though not 
to significant levels (FIG 39F). Overall the brain resident cells show minor changes with 
OCA treatment when compared to BDL. 
 
4.5.2. OCA Treatment Reduces Neuronal Senescence in BDL 
Mice 
 
Neuronal senescence was assessed in BDL untreated animals at day 10 post BDL and 
compared with OCA treated day 10 BDL animals. In the CA3, both the P21 foci per neuron 
(FIG 40G) and  percentage of P21+ neurons (FIG 40H) were significantly reduced in OCA 
treated animals. In the dentate gyrus there is also some reduction in the 21+ foci per 
neuron (FIG 40C), and percentage of P21+ neurons (FIG 40D), but it doesn’t each 
significance in this region. Part of the reason for this is likely to be that the senescence 
phenotype isn’t as severe in this region, with the percentage of P21+ neurons in the BDL 
in the DG only reaching 27%, whereas in the CA3 this is nearly double at 55%.  
 
Telomere associated foci in the CA3 are significantly reduced in the OCA treated animals 
when compared to the BDL controls. percentage of TAF positive neurons (FIG 40I) and TAF 
per neuron (FIG 40K) were both halved on average in OCA treated animals (FIG 40L). 
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Figure 40. Senescence data for hippocampal neurons in the OCA study. (C) P21 RNA ish showed partially reduced average P21+ foci per neuron in dentate gyrus between 
(A) BDL and (B) BDL OCA mice. (D) OCA treated mice also had partially reduced percentage of P21+ neurons in the dentate gyrus. (G) There significantly more P21+ foci in 
the CA3 of (E) BDL mice than (F) BDL OCA mice. (I) percentage of telomere associated foci (TAF)+ neurons in the CA3 were reduced in OCA treated mice. (K) TAF per neuron 
was also reduced in the OCA treated mice. (J) Example TAF image from BDL mouse showing co-localisation of DNA damage (green) and telomere fish probe (red). (L) 
example TAF image from OCA. Scale for P21 RNA ish = 50 µm. BDL TAF image = 0.8 µm OCA TAF image 1.2 µm. P21 N= 5 BDL, N=5 OCA. TAF N= 4 BDL N=6 OCA. Data 
represented as mean +/- SEM statistics T.TEST. Stain performed by Diana Jurk and analysed by me. Pink arrows denote P21+ RNA stain, blue indicate negative cell 
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Figure 41. FXR expression profile at the BBB and in hippocampal neurons. (A) gating for endothelial cells as SCa1+ (B) Histogram for sham BDL and OCA animals. (C) BDL 
animals had significantly less FXR expression than sham animals. (D) FXR expression was also significantly reduced in the dentate gyrus in BDL animals. Histology from 
(E) sham (F) BDL and (G) BDL OCA mice. FACs N=4 Sham N=4 BDL day 10 N=4 OCA day 10. Histology N=13 sham, N=12 BDL N=8 OCA. Scale = 50 µm. Data represented 
as mean +/- SEM statistics ANOVA. 
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4.5.3. Assessment of FXR expression within the BBB and 
Brain 
 
In order to explore the mechanistic basis of therapeutic benefit of OCA within the brain, 
flow cytometry was undertaken to assess FXR expression in brain microvascular 
endothelial cells (BMEC) of the BBB. FXR was expressed in the BMECs from sham BDL and 
BDL OCA animals (FIG 41), and expression was depressed in BDL, suggesting the action of 
FXR on the barrier could be through direct mechanisms. When FXR expression was 
quantified in the dentate gyrus it was also found to be expressed in granule cells. The 
expression pattern in the DG with BDL showed reduced FXR in the BDL group (FIG 41D, 
41F), mirroring what is seen at the BBB. OCA treatment led to increased FXR expression 
in the DG (FIG 41G), to near Sham levels (FIG 41E). 
 
 Bezafibrate Study  
4.6.1. Bezafibrate treatment improves liver pathology in 
BDL 
 
Treatment with Bezafibrates reduced both activated myofibroblasts (α-SMA) (FIG 42A, B, 
C), and fibrosis (PSR) (FIG 42D, E, F) by day 10 when compared to BDL animals. This 
indicates bezafibrate has antifibrotic properties. However, ductular reaction as measured 
by CK19 (FIG 42G, H, I) was comparable between both BDL control and Bezafibrate treated 
groups. This data highlights the success of Bezafibrate treatment when comparing 
Bezafibrate and the other drugs on anti-fibrotic action. Bezafibrate performed as well as 




Figure 42. Liver histology images from the Bezafibrate study. (A) activated myofibroblasts (αSMA) were reduced in Bezafibrates 
(C) compared to BDL (B). (D) fibrosis (PSR) was reduced in (F) bezafibrate compared to (E) BDL. (G) ductular reaction was 
similar between (H) BDL and (I) Bezafibrate treated mice. N= 5 BDL N=7 Bezafibrate. Scale= 50µm. Data represented as mean 
+/- SEM statistics T.TEST. 
 127 
4.6.2. Bezafibrate treatment exacerbates senescence in the 
liver 
Senescence as measured by P21+ count in the liver was significantly increased in the liver 
of BDL mice treated with bezafibrate  (FIG 43C) when compared to BDL control mice (FIG 
43A, B). This data indicates that in the context of liver damage Bezafibrate treatment 
appears to be pro-senescent. 
 
Figure 43. P21+ senescence counts in the liver of BDL and Bezafibrate treated mice. (A) P21+ count in the 
liver is significantly increased in the (C) Bezafibrate compared to (B) BDL day 10 animals. Scale =50µm. N= 7 







4.6.3. Bezafibrate Treatment Does not Improve Behavioural 
Phenotype in BDL mice 
 
BDL mice treated with Bezafibrate showed similar fatigue to BDL control mice, and travel 
a similar distance in the open field (FIG 44A), as well as comparable rears (FIG 44B). They 
also showed comparable time in the novel arm in the Y maze to BDL animals (FIG 44C), 
indicating there was no reduction in memory impairment or fatigue behaviour in 
Bezafibrate treated mice. 
 
Figure 44. Behavioural testing results from the Bezafibrate study. (A) Open field distance travelled is comparable between 
groups, as is (B) rear number. (C) Similar time was spent in the novel arm by BDL day 10 and Bezafibrate treated mice. 
(D) heatmap indicate little time is spent in the novel arm for BDL animals or for (E) Bezafibrate treated animals. Novel 
arm = A2, start arm = A3. N= 7 BDL mice N= 7 Bezafibrate mice. 1 mouse from Bezafibrate study excluded due to 
insufficient movement. Data represented as mean +/- SEM statistics T.TEST. 
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4.6.4. Bezafibrate shows no significant effects on cell types 
in the Brain 
 
Drug treatment with Bezafibrate showed no significant differences in cell type histology 
when compared to BDL control animals. Neurons (stained by NeuN) remained reduced in 
the BDL control animals as reported in chapter 3. Treatment with Bezafibrate had no 
effect on DG neuronal number (FIG 45A). Similarly, GABAergic Parvalbumin+ interneurons 
showed no differences between BDL control and Bezafibrate treated animals by day 10 
(FIG 45C). Inflammatory cell types microglia (FIG 43B), and astrocytes (FIG 45D, E,F) counts 
indicate similar levels of neuroinflammation between BDL control (FIG 45E) and  
bezafibrate treated animals (FIG 45F).  
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Figure 45. Immunofluorescent histology from the dentate gyrus of BDL mice in the Bezafibrate study. (A) Neuron number 
was comparable between groups (B) Iba1+ Microglia numbers were comparable between groups. (C) Parvalbumin + 
interneuron number was comparable between groups (D) Astrocyte numbers were similar between (E) BDL day 10 and (F) 
Bezafibrate treated mice. N= 7 BDL N=4 Bezafibrate mice. Scale = 50µm.  Data represented as mean +/- SEM statistics 
T.TEST. 
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4.6.5. Bezafibrate Treatment Exacerbates Hippocampal 
Neuronal Senescence 
P21 RNA ish was used to assess the presence of P21 RNA in neurons in the dentate gyrus 
and CA3 regions of the hippocampus, as previously described in chapter 3. The P21 RNA 
ish in the hippocampus seems to reflect what is seen in the liver (FIG 43), in that the 
Bezafibrate shows largely inflated P21 counts when compared to BDL. When compared 
to BDL on both P21+ foci per neuron (FIG 46A, E) and percentage of P21+ neurons (FIG 
46B, F) Bezafibrate treated animals showed major increase in both DG (FIG 46G, H) and 
CA3 (FIG 46C, D) regions of the hippocampus. In the CA3 percentage of increased by 15% 



















Figure 46. P21+ RNA ish in the hippocampus of mice from the Bezafibrate study. (A) P21 foci per neuron in the CA3 was significantly increased in the (D) Bezafibrate group compared to (C) BDL 
mice. (B) Average percentage of P21+ neurons in the CA3 was also increased in the Bezafibrate treated mice. (E) P21+ foci per neuron in the dentate gyrus was also significantly increased in the 
(H) Bezafibrate group compared to (G) BDL group. (F) Average percentage of P21+ neurons were also increased in the Bezafibrate group. Scale = 50µm. N= 7 BDL N=7 Bezafibrate mice. 
Data represented as mean +/- SEM statistics T.TEST. Stain performed by Diana Jurk analysed by me.
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 Summary of Findings from Chapter Four 
 
• When used in the BDL model UDCA does not protect against fibrosis, 
myofibroblast activation, cellular senescence, or ductular proliferation.  
 
• UDCA provides no protection against cholestasis induced cognitive decline as 
measured by Y maze behavioural testing. 
 
• UDCA does not improve neuroinflammation or neuronal loss induced by BDL, and 
shows no improvement in neuronal senescence. 
 
• Bezafibrate improves liver histology in the BDL model, with particular reductions 
in fibrosis (PSR) and activated myofibroblasts (α-SMA) but not in ductular reaction 
(CK19). 
 
• Bezafibrate treatment does not result in any improvement in spatial memory (Y 
maze) or fatigue (Open Field) and does not reduce the neuronal loss or 
neuroinflammation caused by BDL. 
 
• Bezafibrate exacerbates senescence in the BDL model, in neurons within the 
hippocampus of the brain as evidenced by P21+ RNA ish.  
 
• OCA produces comparable reduction to Bezafibrate in liver damage related 
histology stains for fibrosis and activated myofibroblasts, and provided additional 
reduction in ductular reaction.  
 
• OCA treatment either prophylactically or therapeutically improves spatial memory 
(Y maze), but not fatigue scores when compared to BDL controls. 
 
 134 
• OCA treatment reduces astrocyte neuroinflammation but BDL related neuronal 
loss remains comparable. 
 
• OCA reduces senescence in both the liver as measured by P21 histology counts, 
and within neurons in the hippocampus of the brain, both in CA3 and DG regions 
and as counted by P21 RNA ish and telomere associated foci (TAF) counting. 
 
• OCA impacts morphological changes at the BBB as measured by TEM, Super 
resolution imaging and MRI scanning. This data indicates that OCA has a positive 
impact on BBB breakdown caused by BDL surgery. 
 
• FXR is expressed at the BBB and in the hippocampus, meaning these effects could 




In our studies, BDL mice treated with UDCA on either a prophylactic or therapeutic dosing 
schedule showed no significant improvement in any studied parameter. Principally, 
previous study of the use of UDCA in BDL (both mice and rats) found it to be largely 
ineffective in treating the liver damage (Zimmermann and Reichen 1992, He, Mennone et 
al. 2011) caused by the BDL model. One study even found it to aggravate bile infarcts and 
trigger further necrosis (Fickert, Zollner et al. 2002). Conversely, very few studies find 
beneficial effects in this model (Poo, Feldmann et al. 1992).  
 
Indeed, even patient studies show inconsistent results regarding symptom improvement 
following UDCA treatment. Many studies show little histological improvement. One 
clinical trial showed improved portal and lobular inflammation as well as ductular reaction 
(Poupon, Balkau et al. 1991) and few have seen beneficial histological effects beneath the 
level of significance (Leuschner, Fischer et al. 1989, Turner, Myszor et al. 1994, Eriksson, 
Olsson et al. 1997). Though it is important to note differing clinical criteria of some clinical 
trials (earlier vs late disease etc) it is clear that UDCA is not a reliable therapeutic approach 
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for a patient population that can show disparate disease. Given that up to 40% of patients 
fall into category of UDCA non response, it is clear that better patient disease stratification 
is needed as are robust biomarkers of UDCA non-response. Currently guidelines require 
minimum one year’s therapy with UDCA to assess non-response (EASL 2017). However, 
some studies suggest this can be assessed after only 6 months (Zhang, Shi et al. 2013). 
This would allow earlier intervention with OCA, which could be key for patient outcome. 
 
In our studies, UDCA treatment had no impact on cognition in BDL animals. Spatial 
memory impairment (Y maze FIG 32) and fatigue (Open field FIG 32) remain prevalent in 
animals regardless of dosing schedule. These animals also experience similar levels of 
neuroinflammation to the BDL animals as measured by GFAP+ astrocytes (FIG 33F). 
NeuN+ neuron loss (FIG 33A) and senescence (FIG 34) in the hippocampus remain similar 
to BDL, indicating no improvement to neuronal health. 
 
There is currently little literature on the effects of UDCA on cognitive symptoms in BDL or 
in patients. Large scale Cochrane review of clinical trials shows no beneficial effects on 
fatigue, but do not specifically mention cognition (Rudic, Poropat et al. 2012), though the 
prevalence of advanced stage cognitive conditions such as HE were not reduced by UDCA 
treatment. More recent functional studies in PBC patients indicate that changes in the 
hippocampus occur regardless of UDCA therapy (Mosher, Swain et al. 2017, Mosher, 
Swain et al. 2018) suggesting it has little effect on cognitive pathology. 
 
Fibrates such as bezafibrate are from the drug class peroxisome proliferator–activated 
receptors (PPAR) agonists, and are currently being investigated for use in PBC. Our studies 
show that although bezafibrate treatment in BDL mice improves many liver outcomes 
such as reduced activated myofibroblasts (FIG 42A) and fibrosis (FIG 42D), it does not 
provide any reductions in ductular reaction (FIG 42G) or liver senescence, and in fact 
exacerbates senescence in this model (FIG 41). These results may mirror selected previous 
studies using fibrates in the BDL model, that also found reduction in fibrosis and 
inflammation, however reported an increase in bile duct proliferation (Cindoruk, Kerem 
et al. 2007). In this study, authors did not look at senescence. Patient trials using 
Bezafibrate have found promising biochemical improvement (Corpechot, Chazouillères et 
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al. 2018, Agrawal, Majeed et al. 2019), but no studies so far have published histological 
changes. 
 
Our studies also show that bezafibrate treatment has no beneficial effects on cognition, 
when assessed using Y maze (FIG 44C) and animals remain fatigued (FIG 44A). Bezafibrate 
treatment also had no effect on NeuN+ neuron count (FIG 45A, GFAP+ astrocytes (FIG 
45D) and Iba1+ microglia (FIG 45C) in the DG. Interestingly, the increased senescence 
discovered in the liver, is mirrored in the brain, with Bezafibrate treated animals showing 
a marked increase in P21 RNA when compared to BDL control animals. 
 
Senescence has been highlighted as a key pathogenic driver in cholestatic disease in both 
animal models (Sasaki, Ikeda et al. 2005) and human biopsy studies (Tabibian, O'Hara et 
al. 2014).  In this study, we see that both liver and neuronal senescence are increased 
beyond disease levels in bezafibrate animals (FIG 43, FIG 46), which raises interesting 
questions about the possibility of cross organ senescence as a mechanism of disease 
pathology in PBC. 
 
Neuronal senescence has been shown to be key in a number of neurodegenerative 
diseases including Alzheimer’s disease where it has been discovered to be pathologically 
relevant in both astrocytes and neurons (Bhat, Crowe et al. 2012, He, Jin et al. 2013). In 
the context of many age-related diseases, clearance of accumulated senescent cells can 
lead to delay in onset or progression of disease (Baker, Wijshake et al. 2011). Due to the 
relevance of senescence in the liver pathology of PBC (it is associated with progressive 
disease), the presence of senescence within the brain is striking, and provides an 
interesting multi-organ mechanism of disease. 
 
On the other hand, use of OCA in our studies led to significant improvement in many of 
the studied parameters. Activated myofibroblasts (FIG 35A), liver fibrosis (FIG 35D), and 
ductular reaction (FIG 35D) were reduced in BDL animals treated with OCA. This mirrors 
similar reductions in fibrosis observed in other rodent studies (Zhou, Huang et al. 2019) 
and in recent long term human trials (Bowlus, Pockros et al. 2020), providing positive 
indications of efficacy. 
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The OCA treated animals also show improvement in cognitive outputs, making this the 
first evidence that OCA treatment can benefit cholestasis induced cognitive impairment. 
Visual spatial memory score in the Y maze was consistently improved across repeated 
trials and with different observers (FIG 38 C). Fatigue scores were not improved (FIG 38A, 
B), suggesting this is a specific CNS effect and highlighting the mechanistic separation 
between cognitive and fatigue symptoms. Astrocyte activation is reduced, as visualised 
by GFAP (FIG 39C), illustrating reduction in neuroinflammation, although there is no 
mirrored reduction in Iba+ microglia which represent a relatively low portion of the cell 
population. Although NeuN+ neuron count isn’t increased with OCA treatment (FIG 39A), 
there is a marked decrease in neuronal senescence as measured by both P21 RNA-ish, and 
by telomere associated foci (TAF) (FIG 40) in the CA3 and to near significance in the DG.  
 
FXR, the receptor for OCA has been found to be ubiquitously expressed in the central 
nervous system. In our studies we assessed its expression on the endothelial cells of the 
BBB (FIG 41A-C) and in granule cell neurons in the hippocampus (FIG 41D-F), and in both 
found its expression to be repressed by BDL, and increased upon treatment with OCA 
showing it be a working receptor. While the functional importance of FXR in the brain 
remains unclear, there are proven consequences of its knockout.  Both the expression of 
neurotransmitters (GABA, NA, 5HT) and behaviour are affected by FXR knockout in mice, 
including impaired cognitive function and motor coordination (Huang, Wang et al. 2015).  
 
There is also evidence in our data that OCA may directly protect the function integrity of 
the BBB in vivo. BDL mice treated with OCA have fuller astrocyte and pericyte coverage at 
the vessel (FIG 37A, D) both of which are required for normal barrier function (Iadecola 
and Nedergaard 2007, Armulik, Genové et al. 2010). The astrocytes present in the OCA 
animals are also morphologically ‘non-reactive’ when compared to BDL (FIG 39B-D). In our 
data we found Sca1+ BMECs at the BBB to express FXR, in sham BDL and OCA treated mice 
(FIG 41A-C).  
 
Treatment with OCA has been previously found to reduce permeability and inflammation 
at the intestinal barrier in a variety of animal models (Verbeke, Farre et al. 2015, 
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Ceulemans, Verbeke et al. 2017), implicating FXR in intestinal barrier functionality. 
Though direct evidence of FXR signalling at the BBB is scant these studies provide a 
physiologically relevant insight into the possible functions of FXR in the BBB. In an EAE 
Multiple sclerosis mouse model, FXR KO increased disease severity and conversely OCA 
treatment found to have anti-inflammatory effects at the barrier, alleviating disease (Ho 
and Steinman 2016). These published studies and the studies presented in this thesis 
implicate an as yet undiscovered role of FXR in modulation of permeability at the BBB.  
 
The data presented in this chapter indicates that early intervention with Obeticholic acid 
may be beneficial to PBC patients. The current standard treatment plan of PBC involves 
UDCA therapy as a 1st line (often for up to 18 months), and then combined OCA/UDCA 
therapy in cases of UDCA non-response. This is a lengthy process, and for patients with 
cognitive deficit OCA intervention within this timescale may prove too little too late. 
Evidence shows OCA as currently used has no cognitive benefit, however our evidence 
shows that in BDL mice when introduced early in the disease process ( +3 days), as well at 
or before disease onset (-3, 0 days) OCA can preserve cognition, and reduce BDL 
associated neuronal senescence - likely through a combination of indirect (through 



























5. Chapter Five – Changes to 
electrophysiological properties within 
the hippocampus in BDL mice  
 Introduction 
5.1.1. The hippocampus 
 
The importance and functions of the human hippocampus were only understood after 
reports of a patient named HM, who had a bilateral removal of his hippocampi, which 
lead to an inability to form new memories (Scoville and Milner 1957). This discovery 
launched an entire field of research, and over the next 20 years several important 
discoveries were made, for example the discovery of place cells (neurons that respond to 
specific locations) and their role in spatial memory within the hippocampus (O'Keefe and 
Dostrovsky 1971) and the discovery of episodic and sequential memory (Suzuki and 
Eichenbaum 2000). 
 
The hippocampus exists as a bilateral structure in the temporal lobe, and is named so due 
to its resemblance of the seahorse (in Greek hippo for horse and kampus for sea monster). 
The hippocampus is comprised of several regions; the dentate gyrus (DG), and the cornu 
ammonis (CA) regions 3, 2 and 1. Axons from the entorhinal cortex (the major 
hippocampal input)  travel through either the perforant pathway (forming synapses with 
the CA1), or via the indirect pathway of the trisynaptic circuit (FIG 47), where signaling 
from the EC first reaches granule cells in the dentate gyrus as a part of the first synapse, 
then through to the mossy fibers of the CA3 for the second synapse, and finally the 




Figure 47. directional flow through the rodent hippocampus (the trisynaptic circuit). The entorhinal 
cortex provides input to the hippocampus via feedforward to the DG into the trisynaptic loop through 
CA3 and CA1 via the perforant pathway. 
Within the CA regions, there are two major neuronal cell types. Pyramidal cells are the 
primary excitatory cell of the circuit, providing the major excitatory current. GABAergic 
basket cells within the CA3 receive excitatory input from pyramidal cells and exert 
inhibitory outputs, allowing inhibitory feedback loops which can dampen hippocampal 
excitatory responses.  
 
5.1.2. Pyramidal Cells 
Pyramidal cells are so called because of their triangle shaped soma. Pyramidal cells 
possess apical and basal dendrites – the basal dendrites extend through stratum 
pyramidales through to the stratum oriens and the apical dendrites extend through the 
stratum radiatum to stratum lacunosum moleculare (FIG 48). 
 142 
 
Figure 48. The molecular cell layers of the hippocampus. Stratum Oriens (SO) can be seen distal to the 
hippocampus, followed by stratum pyramidales (SP, or pyramidal cell layer), then stratum lucunos (SL), 
through stratum radiatum (SR) and the stratum lacunosum moleculare (SLM). 
5.1.3. GABAergic interneurons in the Hippocampus 
Interneurons within the hippocampus make up around 11% of cells, and can be largely 
categorised based on expression of key calcium binding proteins, parvalbumin, calbindin 
and calretinin. These markers provide an easy way to differentiate the different types of 
GABAergic interneurons (Kepecs and Fishell 2014). 
 
5.1.3.1. Parvalbumin+ Interneurons 
Parvalbumin is only expressed within two subpopulations of interneurons, the basket cells 
and chandelier (axo-axonic or AAC) cells and bi-stratified. Basket cells make up most of 
the interneuron population within the CA3, and their cell bodies are located near the 
stratum pyramidales (over 50%), some in the stratum oriens (30-40%) and a smaller 
number in the stratum radiatum (Kosaka, Katsumaru et al. 1987). One basket cell has the 
ability to innervate the soma of up to 2500 pyramidal cells, giving them control of 




The vast majority of parvalbumin+ (PV+) interneurons are fast spiking, meaning they have 
a high frequency of firing, caused by expression of Kv3.1 potassium channels. The high 
firing rate of PV+ interneurons means they have an extremely fast turnover of GABA 
(Kosaka, Katsumaru et al. 1987). This makes these cells extremely demanding of energy 
(Kann, Papageorgiou et al. 2014). 
 
PV+ interneurons have been implicated in many of the functions of the hippocampus and 
are largely responsible for co-ordinating the responses of other neurons in processes such 
as memory consolidation (Ognjanovski, Schaeffer et al. 2017), pattern recognition which 
allows separation of synaptic inputs (Guzman, Schlögl et al. 2016), and generation of 
gamma frequency oscillations (Whittington, Traub et al. 1995). 
 
5.1.4. Oscillatory networks within the Hippocampus 
Neuronal networks generate different frequencies of oscillation for various sleep-wake 
states. Depending on the frequency, hippocampal oscillations have diverse biological 
functions. Oscillations encode region specific outputs, which in the hippocampus and 
prefrontal cortex is associated with memory formation and processing (Navawongse and 
Eichenbaum 2013). The synchronous activity of these neuronal networks is responsible 
for the cognitive processing and storage of information, and produce detectable 
fluctuations in electric field of the group of neurons (termed local field potential) which 
can be picked up by electrophysiological recordings in ex vivo brain slices. The association 
of oscillation wavelength with cognitive tasks has been performed largely in rodents, and 











Table 5. the different oscillation wavelengths and their associated functions. 
Name Frequency  Associated function 
Delta 0.5 – 4 Hz Slow wave sleep (Dang-Vu, Schabus et al. 2008) 
Theta 4 – 12 Hz Explorative behaviour (Buzsáki 2005) and REM sleep 
(Grosmark, Mizuseki et al. 2012) 
Alpha 8 – 10 Hz Relaxed wakefulness (resting with eyes closed) 
(Niedermeyer 1997) 
Beta I; 15 – 20 Hz 
II; 20 – 30 Hz 
Resting with open eyes (Niedermeyer 1997), motor 





20 – 50 Hz Navigation and visual spatial memory, cognitive 




 50-80 Hz Sensory information processing (Colgin, Denninger et al. 
2009), spatial memory (object-place pairing) (Zheng, 
Bieri et al. 2016) 
 
The mechanisms that generate gamma frequency oscillations were initially unclear. 
Pyramidal cells in the hippocampus (thought to be the cells to encode information with 
their firing), fire at a frequency of only 3 Hz. In 1995 GABAergic interneurons 
(aforementioned basket and AAC cells in the hippocampus) were first implicated in the 
generation of gamma frequency oscillations. Under the antagonism of NMDA, AMPA and 
kainate, agonism of GABAergic interneurons via a metabotropic glutamate stimulation 
was able to produce gamma activity in a slice (Whittington, Traub et al. 1995). This 
showed for the first time that interneurons were responsible for the production of gamma 
frequency oscillation. 
 
This work gave rise to the interneuron network gamma model (ING model) of attentional 
gamma oscillations (Whittington, Traub et al. 1995). The ING model suggests that gamma 
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oscillations are generated solely by interneuron activity in the local networks. However, 
this raised questions over the mechanism of gamma propagation over larger distances 
within the brain outside of the hippocampus. Therefore, a more integrative model the 
pyramidal-cell interneuron network gamma model (PING model) was proposed (Börgers, 
Epstein et al. 2005). The PING model implicates excitatory firing by the pyramidal cells 
into reciprocally connected networks of excitatory and inhibitory input. In this model, 
pyramidal cells fire earlier and interneurons provide necessary inhibitory feedback, 
producing IPSPs that are sufficient to end firing. 
 
In vitro brain slice models were first published in 1966 (Yamamoto and McIlwain 1966). 
Since their introduction these models have facilitated investigation into the mechanisms 
underlying network activity. This has allowed unique insight into not just how networks 
oscillations are generated, but how network activity can alter during neuropathology. 
With many in vitro models gamma frequency oscillation is found to occur spontaneously, 
without drug intervention (Pietersen, Patel et al. 2009). 
 
5.1.5. Slow VS Fast Gamma in Memory 
 
In the literature, slow (20-50Hz) and fast gamma (50-80 Hz) events have been associated 
with different memory integration and processing events. There are several studies 
implicating slow gamma frequency oscillations with memory recall events. Slow gamma 
is paired with increase gamma synchronicity between CA3 and CA1, which is proposed to 
be coupled with memory recall (Montgomery and Buzsáki 2007). Therefore, this 
associative slow gamma band activity likely promotes the CA3-CA1 synchronicity that 
allows memory retrieval (Carr, Karlsson et al. 2012) 
 
However, fast gamma activity was found to synchronise with the entorhinal cortex 
(Colgin, Denninger et al. 2009). The entorhinal cortex primarily processes sensory 
information, therefore, a role for fast gamma oscillations has been proposed in the 
integration of sensory information during the encoding of new memories. Fast gamma 
activity in the hippocampus also becomes the primary gamma frequency oscillation when 
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novel object and place environments were explored (Zheng, Bieri et al. 2016), and when 
navigating towards a goal (Cabral, Vinck et al. 2014).  
 
5.1.6. The Role of Gamma frequency Oscillation in Memory 
Encoding 
 
High frequency gamma oscillations allow the fast transfer of information across the brain. 
They have thus far been implicated in learning and working memory, spatial navigation 
(alongside theta activity), and executive function and processing, in humans (Fell, Klaver 
et al. 2001, Sederberg, Schulze-Bonhage et al. 2007) and rodents (Montgomery and 
Buzsáki 2007, Zheng, Bieri et al. 2016). Because of this breadth of function, gamma 
frequency oscillations have been at the centre of scientific investigation of some years. 
 
In human studies into memory, gamma frequency oscillations have been implicated. 
When human EEG was recorded intracranially and subjects were asked to remember a list 
of words, an increase in gamma power during encoding was correlated with an increased 
likelihood of recall (Sederberg, Schulze-Bonhage et al. 2007). In a similar study, a higher 
level of gamma synchronization was associated with words that were remembered in 
comparison to those which were later forgotten (Fell, Klaver et al. 2001). In non-human 
primates, a similar phenomenon has been described – a higher level of synchronisation 
between LFPs and spiking were seen in the hippocampus when presented with stimuli 
that were later remembered, as opposed to those which were forgotten (Jutras, Fries et 
al. 2009).  
 
In rodents, novel object, and novel location testing, has allowed for intricate untangling 
of the role of gamma activity. In studies where rats were presented with a novel object in 
a new location (as opposed to a familiar object or familiar location), it was found that fast 
gamma and CA3-CA1 gamma frequency synchrony were increased (Montgomery and 
Buzsáki 2007). It is already known that neuron spiking occurs in response to 
environmental stimuli. In this experiment, place cell spiking was found to increase in 
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power in conjunction with fast gamma, heavily implicating gamma frequency oscillations 
in the encoding of novel object-place associations (Zheng, Bieri et al. 2016). 
 
The fast spiking inhibition arising from PV+ interneurons is essential for the generation of 
gamma frequency activity. When GABAergic interneurons fire, they provide inhibitory 
input into the pyramidal cell, causing an inhibitory post synaptic potential in the cell, and 
controlling the timing of the pyramidal firing. When multiple pyramidal cells are 
stimulated to fire in temporal proximity this spike-timing process generates long-term 
potentiation in hippocampal neurons thereby encoding memory  (Bi and Poo 1998).  
 
In mice, it has been shown that the optogenetic control of PV+ GABAergic interneurons is 
sufficient to suppress or drive gamma frequency oscillation in vivo (Sohal, Zhang et al. 
2009). This implicates PV+ interneurons (in in CA3 largely basket cells) as master 
regulators of network oscillations. Other in vivo studies show that gamma oscillations can 
only be generated in areas such as the CA3 region of the hippocampus, the amygdala, and 
the neocortex which have a local excitatory network between regions (e.g. in CA3 the 
Schaffer’s collaterals project to the CA1) (Bragin, Jandó et al. 1995). Rodent studies in ex 
vivo hippocampal slices also indicate that CA3 gamma frequency oscillations are 
dependent on PV+ fast spiking interneurons (Traub, Bibbig et al. 2000, Fuchs, Zivkovic et 
al. 2007).  
 
5.1.7. The Role of Gamma frequency Oscillation in Memory 
Recall 
 
Gamma frequency oscillations have been linked to memory recall processes. Rats 
performing a spatial cue alternation task (that required previous learnt trial knowledge) 
showed higher gamma synchronicity in LFP between CA3 and CA1, when information was 
being recalled in order to make the correct choice of arm to traverse (Montgomery and 
Buzsáki 2007). This indicates that gamma frequency oscillations facilitated transfer of 
stored memories from CA3 to CA1 for recall. 
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It is well known that in the rodent hippocampus place cell ‘maps’ represent visuo-spatial 
maps of the animal’s  environment (Johnson and Redish 2007). When an animal pauses 
to consider a route, place cells are activated in tandem with increased power of gamma 
oscillations. Primarily, slow gamma activity is generated; oscillations at 30-60 Hz increased 
in the CA3 upon learned association tasks (Tort, Komorowski et al. 2009).  
 
5.1.8. Neurodegenerative and Psychiatric Disease 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease, characterised by 
distinctive pathology of amyloid-ß in plaque deposits in the brain, alongside tau 
neurofibrillary tangles accumulating in and around neurons (Soto 2003). The 
hippocampus and associated entorhinal cortex are particularly susceptible to amyloid 
pathology. The earliest cognitive symptoms associated with AD are episodic and spatial 
memory impairment.  
 
Recent landmark data suggests that patients may preserve the ability to encode memories 
but not to retrieve them (Roy, Arons et al. 2016). This is in keeping with reports from 
rodent models of AD, showing disrupted slow wave gamma power in CA1 region of the 
hippocampus (Mably, Gereke et al. 2017). In addition, the coordination of slow wave 
gamma with CA1 place cell firing was reduced (Mably, Gereke et al. 2017). APOE4 knock-
in mice have demonstrated that alleviation of slow gamma impairment rescued the 
learning deficits, specifically implicating slow wave frequency gamma (Gillespie, Jones et 
al. 2016). The study went one step further, showing that specifically deleting APOE4 only 
from GABAergic interneurons diminished slow wave gamma disturbance, highlighting the 
important role of GABAergic interneuron firing. These results were mirrored in a similar 
study, demonstrating improved slow gamma firing rescued deficit in 5xFAD mouse model 
(Iaccarino, Singer et al. 2016). It is important to note that slow gamma activity deficits 




Changes to network oscillations have long been of interest in psychiatric diseases such as 
schizophrenia. Post-mortem studies have shown a reduction in GABA synthesizing 
enzyme GAD , driving a reduction in GABA synthesis in the PV+ interneuron population 
(Addington, Gornick et al. 2005). This leaves PV+ interneurons unable to fire, or misfiring, 
in turn causing disruption to gamma frequency oscillations and their associated memory 
forming mechanisms.  
 
5.1.9. Could Oscillation be impaired in Liver Disease related 
Cognitive Deficit? 
There is currently no evidence of changes to hippocampal gamma frequency oscillations 
in chronic liver disease during an early disease stage. However, changes to various 
neurotransmitter systems have been implicated in the pathogenesis of cognitive decline 
in cholestatic liver disease (Cauli, Mansouri et al. 2009, Dhanda and Sandhir 2015). 
Research to-date has been around late stage liver disease and hepatic encephalopathy 
(HE). Using models of hyperammonia, GABA has been shown to be significantly increased 
in the cerebellum of hyperammonic mice which are cognitively impaired. In this model, 
behaviour is normalised by treatment with bicuculline, a competitive GABAA antagonist  
(Cauli, Mansouri et al. 2009). Other commonly used models of HE such as 4 week BDL 
have implicated additional neurotransmitter systems, such as the serotonergic system in 
cognitive decline and dopaminergic system in motor dysfunction (Dhanda and Sandhir 
2015).  
 
Even in late stage liver disease models, such as 4-week BDL, very limited evidence is 
available around changes to network oscillations. Of the evidence that is available, patch 
clamp electrophysiology was used to assess the electrophysiological properties of single 
cells in the cerebellum (Aghaei, Hajali et al. 2016), and CA1 (Tahamtan, Aghaei et al. 2017), 
but not the oscillation patterns of the network. These studies have shown profound 
differences to the electrophysiological properties of neurons 4 weeks post BDL. The 
patched Purkinje neurons in the cerebellum were found to be hyperexcitable, with 
increased firing rates  (Aghaei, Hajali et al. 2016), whereas in the CA1 neurons were found 
to be less excitable with a decreased firing rate (Tahamtan, Aghaei et al. 2017). 
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Contradictions such as these make it difficult to predict the network firing changes that 
might occur in the CA3, as the data suggests area specific changes to individual neuron 
properties. In addition, our cholestatic liver disease model is less severe, choosing only to 
run the BDL to day 10 to investigate early changes to cognition in cholestatic liver disease, 
in a pre-cirrhotic state (Chapter 3 and 4). 
 
 Study Rationale  
 
Electrophysiological recordings were undertaken in the CA3 region of the hippocampus in 
BDL animals and compared to sham control animals (experimental timeline outlined in 
figure 49). BDL surgery was performed as outlined in Methods section (chapter 2) and 
animals were maintained for a maximum of 11 days after surgery. Local field potentials 
(LFP) were recorded from between the stratum radiatum and stratum lacunosum 
moleculare regions of the CA3. Behavioural testing was performed as in previous studies 
on days 9 and 10 where possible. Where this was not possible, open field testing was 
undertaken on day 8 and Y maze on day 9.  
 
In order to produce a consistent and sustained oscillation, methods to induce 
hippocampal gamma-frequency oscillations pharmacologically are used. The most 
commonly used drugs are the cholinergic agonist carbachol (CCH), which activates 
muscarinic and nicotinic acetylcholine receptors (described in (Fisahn, Pike et al. 1998)) 
and kainate (KA) which activates ionotropic glutamatergic kainate receptors. To produce 
comparable results, carbachol was used in each study. 
 
This study was undertaken to provide in depth mechanistic analysis of the effect of pre-
cirrhotic liver disease on the generation of gamma frequency oscillations in CA3. Evidence 
outlined above illustrates that the CA3-generated gamma frequency oscillations are 
essential for visual spatial memory encoding (Fell, Klaver et al. 2001, Sederberg, Schulze-
Bonhage et al. 2007) and retrieval (Montgomery and Buzsáki 2007). PV+ interneurons 
which are required for the proper maintenance of network oscillations, were also 
quantified using optical density. 
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Electrophysiological studies were undertaken on sham (n=8), BDL (n=8), and Obeticholic 
acid treated animals (0.03% OCA from day 0) (n=7), in order to gain a picture of not just 
of the effects of cholestatic liver disease on network oscillation, but also the impact (if 
any) of OCA drug treatment when compared to untreated BDL animals.  
 
 























The aims of these studies were as follows: 
 
• Quantify any possible differences in the ability of the CA3 neuronal networks to 
generate and maintain gamma frequency oscillations in hippocampal slices from 
sham or BDL animals.  
 
• Investigate the differences in the properties (area power, amplitude, and 
frequency) of gamma frequency oscillations generated from hippocampal slices 
from sham or BDL animals.  
 
• Investigate the changes to gamma frequency oscillations in BDL animals when 
treated with OCA from surgery date. 
 
• Investigate changes in oscillation propagation proximal and distal to CA3. 
 
• Assess the rhythmicity of stable network oscillations produced by sham, BDL 
untreated and BDL animals treated with OCA, to investigate changes in stable 
oscillation phenotype. 
 
• IHC quantification of PV+ interneurons in sham BDL and BDL-OCA, as these are 







5.4.1. BDL animals show significant abnormalities in 
hippocampal gamma frequency oscillations 
Once slices were trimmed and placed in the chamber with aCSF flow, electrodes were 
placed in the CA3 region. Slices were bathed in the cholinergic agonist carbachol which 
was applied through the aCSF flow. Carbachol induces oscillations that generally grow in 
power to a ‘stable area power measurement by 3 hours post application (Lu, Wang et al. 
2012).  In cognitively normal animals’ oscillations largely follow this so-called ‘stable’ 
pattern (FIG 50E). Rarely, a slice will show a ‘fluctuating’ pattern, where the oscillation 
doesn’t produce stable oscillations within 3 hours and instead the area power constantly 
increases and decreases (FIG 50F). Slices may also produce a ‘growing’ oscillation, where 
the area power continually increases over 3 hours and never stabilises (FIG 50G), or very 
rarely the slice will show no oscillation (FIG 50H). In this study I found that in sham mice, 
89% of slices produced a stable oscillation phenotype (FIG 50A). Example traces can be 
seen in Figure 50D. 
 
In contrast, Cholestatic mice showed significant instability in the patterns of carbachol-
evoked neuronal network. BDL animals were generally unable to produce stable gamma 
frequency oscillation within 3 hours recording. Only 18% of BDL mice produced a stable 
oscillatory pattern (FIG 50B), compared to nearly 90% of sham animals. In contrast, the 
most frequent pattern of oscillation seen in slices from the BDL was a fluctuating 
oscillation (FIG 50F). This oscillation pattern is indicative of unstable neuronal network 
activity. Equal numbers of BDL hippocampal slices produced growing oscillation and no 
oscillation (FIG 50G, H).  
 
I then assessed the proportions of different oscillation patterns in BDL mice treated with 
OCA (FIG 50C). The most frequent gamma frequency oscillation pattern in OCA-treated 
mice was a stable pattern (62%), which may be representative of the improved network 
health of the neurons. A proportion of slices from OCA treated mice were of unstable 
oscillatory patterns, for example, fluctuating oscillations represented 26.7%. However, 
the distribution of oscillation patterns aligns more closely to that seen in sham mice. 
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Figure 50. Types of oscillation pattern within gamma frequency. A. the ratio of each oscillation pattern 
in Sham animals B. the ratio of each oscillation pattern in BDL animals C. the ratio of each oscillation 
pattern in OCA treated animals. D. Example traces for each group. Outline of oscillation patterns E. 
stable oscillation F. Fluctuating oscillation pattern G. Growing oscillation pattern H. No oscillation. N = 
animal number n = slice number N = 8 n=22 BDL N=8 n=27 OCA N= 7 n =17 
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5.4.2. Changes to Oscillations Over Time 
 
Figure 51. Longitudinal plot showing change to average area power (A), amplitude (C), and Frequency over time. 
N = 8 n=22 BDL N=8 n=27 OCA N= 7 n =17. Area power (B), amplitude (D), and frequency (F) of stable slices were 
compared between groups n= 19 sham, 5 BDL, n=10 OCA. N = animal number n = slice number. 
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When comparing all animals per group over time, generally in the first 90 minutes 
following carbachol administration area power increased steadily, after which power 
began to plateau. By 140 minutes post Cb application slices from BDL  mice had a larger 
average area power than sham, to near significance (FIG 51A). However, as all animals 
were included this may be an artefact, due to BDL animals exhibiting a larger number of 
‘growing’ oscillations. Therefore, the area power, frequency and amplitude were then 
compared in only the stable slices from each group. Stable oscillation area power showed 
that BDL animals on average had a larger area power of the oscillation than either sham 
or OCA treated animals, though this did not reach statistical significance.  
 
However, stable oscillation amplitude (FIG 51B), and amplitude over time (FIG 51A) in OCA 
mice appeared to have a larger average amplitude than BDL. When comparing area and 
amplitude, OCA animals have a smaller area power but larger amplitude than BDL animals, 
possibly indicating that BDL oscillations have a less defined peak in the power spectrum 
(example seen figure 50D). 
 
In contrast to area power and amplitude, oscillation frequency was initially variable but 
once oscillations are established the frequency remained constant (FIG 51A). There is a 
minor increase in the frequency of stable oscillations in BDL animals, on average 34 Hz, 
compared to 27 Hz for OCA and 28 Hz for sham animals (FIG 51B) though this is not 
significant. The above compares stable slices from each group n= 19 sham, n=5 BDL, n=10 
OCA. 
 
5.4.3. Propagation of oscillations differs Between Sham and 
BDL Animals  
 
Hippocampal oscillations propagate through the hippocampal structure from CA3 to CA1. 
Ordinarily oscillations propagate to CA1 via the Schaffer’s collaterals generating an 
oscillation in the CA1 region. This process is important for the encoding and retrieval of 
spatial memory (Montgomery and Buzsáki 2007) In this experiment once oscillations had 
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stabilised, one electrode was placed in the stratum radiatum region of the CA3, and the 
other placed initially in a near (proximal) location (FIG 52A), and recorded 3 times for 5 
minutes to obtained an average measure.  The second electrode was then moved to a 
more distal location near the CA1 region (FIG 52D), where three X five-minute recordings 
were again taken. Results were calculated as a percentage difference between the CA3 
electrode and the other (proximal or distal) electrode. 
 
Slices from Sham animals on average retained half of their area power and amplitude, 
with slightly less efficient propagation distally (around 40%). They were able to retain the 
power of the oscillation even when measured further away in the CA1. In these 
experiments slices taken from BDL mice appear worse in all measurements when 
compared to Sham. Stable BDL slice oscillations propagate on average half as well 
proximally with sham showing mean 60% area power, BDL mean 27% areas power when 
compared to the ME1 electrode (FIG 52B). Distal area power was almost completely lost 
in BDL animals, dropping to just 6% of the oscillation area power propagated to CA1, 
compared to 45% in sham animals (FIG 52E). 
 
The percentage propagation of the oscillation amplitude was also reduced in the BDL 
animals. Both proximal (FIG 52C) and distal (FIG 52F) propagations of amplitude were 
reduced by just under a half in the BDL animals when compared to sham (proximal sham 
mean of 52%, BDL 28%, distal sham mean of 56%, BDL 3%.
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Figure 52. CA3-CA1 propagation was c ompared between sham and BDL groups. Slices were assessed for proximal (near) propagation (A), and distal propagation (D). Area 
power showed large reduction both proximally (B), and even larger distally (E) in the BDL group. Amplitude also showed reduction proximal (C) and distal (F) though to a lesser 
extent. N= 5 for sham and N= 3 for BDL. 
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5.4.4. Changes to Rhythmicity Occur with Bile Duct Ligation 
 
Rhythmicity index (RI) is a way to measure synchronicity of oscillations and sham animals 
show the highest rhythmicity index with a score of 0.7 +/- (FIG 53A, D). BDL animals produce 
significantly less rhythmic oscillations, and were very variable (FIG 53B, D). OCA treated 
animals had more rhythmic oscillations than BDL untreated animals, however this did not 
reach significance (FIG 53C, D).  
 
 
Figure 53. Autocorrelation of traces was performed on a 1second trace to assess oscillation rhythmicity 
index (RI). An example trace for Sham (A), BDL (B), and OCA treated animals (C). An example of traces 
from each group (D), rhythmicity index calculations per group (E) n=12 N=6 sham  n=12 N=6 BDL, n=14 
N=7 OCA. Data presented as mean +/- SEM statistics ANOVA. 
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5.4.5. Parvalbumin interneurons are partially lost with BDL  
 
Histological assessment of PV+ fast spiking interneurons within the CA3 revealed a significant 
reduction in both soma number (FIG 54A) and optical density of dendritic spines (FIG 54B) in 
BDL mice by day 10 (10.08 vs 12.69 in Sham). Optical density is indicative of parvalbumin 
expression within the entirety of the interneuron, axons and dendrites (neuropil) in addition 
to the cell body.  
 
Treatment with OCA (FIG 54E) salvaged the PV+ loss, bringing the cell counts back up to near 
sham level (sham 10.67 OCA 9.66, BDL 4.23 Average counts) (FIG 54A, E). However, OCA 
treatment did not significantly increase the optical density measurements (11.08) (FIG 54B), 
suggesting although cell counts remain similar to sham, the total levels of PV+ expression may 
be reduced.  
 
 
Figure 54. Parvalbumin+ GABAergic interneuron counts (A), and optical density (B) measurements in 
the CA3. Representative images from sham (C), BDL (D), OCA treated animals (E). These stains were 
performed on a separate cohort not undergoing electrophysiology. N= 6 sham, N= 12 BDL, N= 6 OCA. 
Data represented as mean +/- SEM statistics ANOVA. Scale= 100µM 
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 Summary of findings of Chapter 5 
 
In chapter 5 I aimed to assess changes to circuit functionality in animals undergoing BDL 
surgery, when compared to sham and OCA treated BDL mice. The key findings from the 
chapter are as follows: 
• Gamma frequency oscillation are impaired as measured in the CA3 stratum radiatum 
region in BDL animals. Only 18% of BDL produced stable oscillations by 3 hours post 
carbachol administration, compared to 89% of sham animals. 
 
• This phenotype is partially improved with OCA treatment from day of surgery. 62% of 
slices from OCA treated animals produced stable oscillations within 3 hours. 
 
• Although there are a few differences in key parameters, such as area power, 
amplitude and frequency longitudinally, of the BDL slices that do stabilize on average 
they have a slightly higher frequency and area power, though these don’t reach 
significance.  
 
• The propagation of gamma oscillations from CA3 to CA1 is also affected in BDL mice - 
propagation was reduced both at proximal and distal locations, and in both area 
power and amplitude, though area power shows a larger reduction to just 6% power 
in distal regions. 
 
• BDL animals also produce less synchronous oscillations than sham, with a significantly 
reduced rhythmicity index. 
 
• Parvalbumin+ interneuron counts revealed a significant loss of interneuron soma in 
the CA3, as well as a reduced staining throughout the neuropil, resulting in reduced 
optical density in BDL animals when compared to sham. OCA treated animals retained 






Previous data from this thesis showed that BDL mice display visual-spatial memory deficit by 
day 10 post-surgery (Chapter 3). The aim of this chapter was to characterise changes 
occurring in the gamma frequency oscillations of the hippocampus, which facilitate short 
term memory process (Montgomery and Buzsáki 2007). We also assessed histologically 
alterations in PV+ interneurons in the CA3, as they directly contribute to the generation of 
gamma oscillations by inhibiting the firing of pyramidal cells(Ognjanovski, Schaeffer et al. 
2017, Antonoudiou, Tan et al. 2020).  
 
I found BDL mice exhibited several changes to hippocampal networks and subsequently to 
gamma frequency oscillation. Hippocampal slices from BDL mice were found to be 70% less 
likely than sham slices to produce stable oscillations by 3 hours post carbachol administration 
(18% stable vs 89%). This loss of network stability could be directly related to the memory 
deficit seen in the previous behavioural testing. Stable gamma frequency oscillations are 
important for the encoding of several types of memory, such as visual spatial memory and 
executive function (Lu, Vreugdenhil et al. 2012) and object-place recognition (Zheng, Bieri et 
al. 2016).  
 
We also assessed the rhythmicity of the gamma frequency oscillation and found BDL animals 
showed significantly less rhythmic oscillations at 180 minutes post-carbachol application (FIG 
53). Synchrony of the neuronal network has been proposed to form neural correlates of 
cognitive information and facilitate memory encoding (Singer 1999). Loss of network 
synchrony can be seen in various pathological conditions including in Alzheimer’s disease, 
Parkinson’s disease, schizophrenia (Uhlhaas and Singer 2006), and to a smaller extent in 
normal ageing. The loss of this network synchrony is a common pathological marker indicating 
reduced network capacity and health.  
 
Gamma frequency oscillations are generated in the CA3 and propagate through to CA1 
(Csicsvari, Jamieson et al. 2003) via the Schaffer collaterals. This process has long been 
implicated in the storage and retrieval of memory (Steffenach, Sloviter et al. 2002), and 
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gamma CA3-CA1 synchrony is seen in tasks such as the Y maze, where retrieval of memories 
from previous trials affects arm choice (Montgomery and Buzsáki 2007). In this study BDL 
mice showed decreased propagation with reduced area power and amplitude of the 
oscillations in the CA1 compared to sham animals, both proximally and distally (FIG 50. 
Therefore, a loss of CA3-CA1 propagation may underpin the short-term memory recall deficit 
seen in BDL mice in the Y-maze.  
 
We also found a significant loss of parvalbumin PV+ interneurons, as both the number of cell 
bodies and the overall optical density in the BDL group was reduced (FIG 54). This loss of 
parvalbumin expression could provide an underpinning mechanism for the circuit dysfunction 
and asynchrony. Fast spiking GABAergic interneurons (basket cells) within the CA3 initiate 
oscillations via the reciprocal firing interactions of pyramidal cell and fast-spiking GABAergic 
interneurons which are PV+ (Gulyás, Szabó et al. 2010, Whittington, Cunningham et al. 2011). 
The synchronous firing of Parvalbumin+ interneurons is linked directly to the encoding of 
short-term and visual spatial memory (Colgin, Denninger et al. 2009).  
 
However, these parvalbumin+ interneurons are highly sensitive to oxidative damage (Kann, 
Papageorgiou et al. 2014), leading to cell loss during old age.  The death or dysfunction of 
Parvalbumin+ interneurons is associated with cognitive decline in both healthy aged 
(Vreugdenhil and Toescu 2005) mice and in rodent models of neurodegenerative conditions 
(Robson, Tweedy et al. 2018).  
 
Oxidative damage can be caused by several biological processes. The dysfunction of 
mitochondria is a common cause of oxidative stress, with impaired mitochondria 
overproducing reactive oxygen species (ROS) and leading to oxygen free radicals, an excess 
of which cause oxidative stress. ROS can damage cells in a number of ways, by oxidising 
proteins and causing DNA damage which can lead to cellular senescence. Though we have not 
assessed mitochondrial function in the BDL model, we do see a senescence phenotype within 
the CA3 in BDL mice (Chapter 3). We also see an increase in DNA damage as measured by 
γH2AX (Chapter 3). There is also an abundance of evidence of oxidative stress and 
mitochondrial dysfunction in the liver during cholestasis (Heidari, Ghanbarinejad et al. 2018). 
Therefore, it is likely that oxidative damage and resulting senescence is causing harm to 
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sensitive PV+ interneurons, and that the senescence seen within the CA3 region is affecting 
the generation and transmission of gamma frequency oscillations.  
 
Even if the senescent neurons are not themselves the PV+ interneurons, the presence of 
senescent cells could damage surrounding neurons. Senescent cells actively release SASP, and 
cytokines such as IL-6 and IL-8 are commonly produced, triggering damage to nearby cells. IL-
6, for example, is associated with cognitive dysfunction in several disease states, including a 
exacerbator role in Alzheimer’s disease (Bauer, Ganter et al. 1992). 
 
Previous data from this thesis has also shown that BDL mice have increased 
neuroinflammation within the hippocampus (Chapter 3). Chronic inflammation has been 
shown to impair LTP  in the Schaffer collaterals (Min, Quan et al. 2009) and, therefore, may 
play a role in disruption of gamma frequency oscillations, particularly in the CA3-CA1 
propagation impairment seen in BDL animals.  
 
From the data shown in this chapter it seems that OCA treated BDL mice have fewer network 
abnormalities than untreated BDL mice. However, there are still clear differences when 
compared to the sham group. Slices from OCA treated animals were less likely to produce 
stable oscillations than sham animals, and had a higher incidence of unstable oscillation 
phenotypes such as fluctuating oscillations than sham animals. 
 
OCA treated mice also had a slight reduction in rhythmicity index score, and showed a rescue 
of the PV+ cell loss seen in BDL, but the optical density was only slightly higher. This mixed 
phenotype may serve as a partial explanation for the circuit abnormalities still occurring in 
the OCA group. Obeticholic acid treatment may prevent the absolute loss of the PV+ 
interneurons, but expression of parvalbumin is still reduced in these interneurons.  
 
To date, there is little mechanistic evidence of neuronal dysfunction in cholestatic models, 
beyond behavioural testing data. Previous papers published on electrophysiology in the BDL 
model find variable results through patch clamping CA1 neurons, which displayed reduced 
excitability  in the CA1 (Tahamtan, Aghaei et al. 2017), and hyperexcitability in the cerebellum  
(Aghaei, Hajali et al. 2016). While other studies have found impaired hippocampal LTP from 
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liver disease using models of hyperammonia, to emulate hepatic encephalopathy (Monfort, 
Muñoz et al. 2005). 
 
These data provide the first evidence of cholestasis related changes to hippocampal gamma 
frequency oscillation properties. They also provide further evidence that OCA treatment, 
when given to cholestatic mice from the day of surgery, can modify disease course and reduce 
the cognitive dysfunction. In this instance, OCA partially improves PV+ interneurons, reducing 
the number of cells lost during cholestasis. OCA also prevented loss of synchrony and network 
stability that is induced by cholestasis in this model. It remains unclear whether senescence 
is the driver of cognitive decline, inducing oxidative damage, senescence or death in the PV+ 
interneuron group. This could directly cause the changes seen in the oscillations, and lead to 
cognitive decline. Alternatively, PV+ interneurons may be damaged or become senescent due 
to secondary effects of circulating inflammatory liver phenotype. Proposed mechanisms 
outlined below (figure 55). 
 
 
Figure 55. Proposed mechanism for the culmination of direct and indirect effects of circulating inflammatory 




6. Chapter Six – In vitro Modelling of 
cholestasis mediated cognitive decline 
 
 Introduction 
In vitro models provide invaluable insight into specific disease pathology that isn’t possible 
with animal models. Though animal models provide a whole system, unless producing a knock 
in or knock out, it becomes extremely difficult to tease apart the complex signalling pathways 
and interlinking cellular function in a whole organism model. Therefore in vitro modelling is 
required to tease apart the specific effects of cholestasis and circulatory toxins on neurons. 
 
6.1.1. A Role for Bile Acid Receptors in the Brain? 
Publications investigating the activity of bile acid receptors in the brain have stipulated 
receptors to be present in several key cell types. TGR5 has been characterised within both 
neurons and astrocytes within the brain, and it’s presence confirmed by different groups 
(Keitel, Görg et al. 2010, McMillin, Frampton et al. 2015). The presence and functionality of 
FXR is less well defined. A study published in 2015 found FXR mRNA absent in the brain 
(Huang, Wang et al. 2015). However, global FXR deletion in mice led to several changes to 
both neurotransmission and behaviour, with reduced anxiety and impaired memory. 
Subsequent studies show FXR at mRNA and protein level in neurons in the mouse and human 
cultured brain. FXR was found to be localised to the nucleus in cultured neurons, but more 
cytoplasmic in vivo (Huang, Wang et al. 2016). However, the functions of brain resident glia 
such as astrocytes and microglia do not seem to be modified by activation through FXR 
(Albrecht, Fleck et al. 2017). 
Other bile acids have also been identified in the brain, cholic acid presence was shown to 
activate liver X Receptor (LXR) present in dopaminergic neurons of the midbrain promoting 
neurogenesis there (Theofilopoulos, Wang et al. 2013). Knockout mouse models for LXR 
suffer motor degeneration and astrocytosis, with impaired motor function (Andersson, 
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Gustafsson et al. 2005). It is clear from these studies that bile acids are able to exert pleotropic 
effects in the brain – and that signalling is required for normal functions. Bile acids are able 
to signal in the brain, several bile acid receptors have been found to be expressed, indicating 
an as yet undiscovered role for bile acids within the brain itself.  
6.1.2. In vitro signalling evidence in liver research  
6.1.2.1. The Blood Brain Barrier 
 
A lot of research in the field supports the idea that blood brain barrier (BBB) breakdown could 
facilitate entry into the brain, where bile acid signalling could cause toxic effects and the 
resultant pathological neurological deficits. Proof of bile acid related BBB breakdown is largely 
limited to in vitro modelling of human cells. There is in vitro evidence that bilirubin exposure 
can affect the function of BMECs and render them apoptotic (Palmela, Cardoso et al. 2011), 
as well as affecting tight junctions (Palmela et al., 2012). The upregulation of IL-6 in these 
studies was postulated to have a role in BBB breakdown, as in other conditions such as stroke 
(Blecharz-Lang, Wagner et al. 2018) and systemic inflammation (Hirohata, Matsueda et al. 
2017).  
 
In these experiments treatment with bilirubin (UCB) led to a bi-phasic response, of which the 
second phase caused the reduction in zonula occludens (ZO)-1 and β-catenin levels, thus 
leading to reduction of tight junctions and cell-to-cell contacts. These changes could 
potentially increase para- cellular permeability and allow bile acid entry into the brain in 
pathogenic conditions. Of the few studies that have been performed in vivo, disruption of 
tight junction proteins occludin and claudin-5 (Quinn et al., 2014) are observed, however 
other aspects of the cellular matrix, including astrocytic and pericytic modulation of the blood 
brain barrier, have not been thoroughly studied bar one paper using an in vitro BMEC 
astrocyte co-culture system (Cardoso, Kittel et al. 2012). 
 
Follow up studies by the same group go on to suggest that certain bile acid properties such 
as hydrophilicity may affect their actions on the BBB (Palmela, Correia et al. 2015). Hydrophilic 
bile acids such as ursodeoxycholic acid (UDCA) and glycoursodeoxycholic acid (GUDCA) were 
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found to have protective effects at the barrier, both reducing apoptotic nuclei. However only 
GUDCA was effective in reducing caspase 3 activity. 
6.1.3. Bile acid Therapies in Neurodegenerative disease 
6.1.3.1. Alzheimer’s disease 
 
The use of bile acid therapies in Alzheimer’s disease (AD) has become a widely researched 
area, first investigated due to their cholesterol modifying properties. Changes to cholesterol 
metabolism have been directly implicated in AD progression (Puglielli, Tanzi et al. 2003). One 
of the major risk factors for Alzheimer’ disease, Apolipoprotein E (APOE) mutation 4, is a 
protein which combines with lipids to form lipoproteins. APOE4 modifies cholesterol 
homeostasis by altering lipoprotein particle formation.  
 
In vitro modelling of AD is often using cultured neurons treated with amyloid-β (Aβ) peptides, 
leading to cytotoxicity in the cells. Pre-treatment of cells with tauro-conjugated UDCA 
(TUDCA) was found to reduce apoptosis in primary cortical rat Aβ cultures through 
phosphatidylinositide 3ʹ-OH kinase (PI3K) signalling (Solá, Castro et al. 2003). Follow up from 
the same group showed UDCA and TUDCA both had anti-apoptotic properties through the 
mineralocorticoid receptor (Solá, Amaral et al. 2006) in neurons,  and through NF-κB 
regulation in microglia (Joo, Won et al. 2004). 
 
The outcomes of these in vitro studies have been so successful that bile acid therapies have 
since been studied in mouse models. Longitudinal 0.4% (wt/wt) TUDCA dosing for six months 
in APP/PS1 mice was found to reduce the number of amyloid plaques and resulting neuron 
damage in the hippocampus and frontal cortex, improving memory (Nunes, Amaral et al. 
2012).  
 
Humans studies investigating bile acid composition changes in AD patients found lithocholic 
acid to be highly increased in the bile acid pool of those with AD. Other implicated bile acids 
include glycine conjugated bile acids glycodeoxycholic acid (GDCA), glycolithocholic acid 
(GLCA), glycochenodeoxycholic acid (GCDCA). Other blood based studies identified different 
glycine conjugated bile acids such as glycoursodeoxycholic acid (GUDCA) as an early 
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predicator of cognitive impairment (Mapstone, Cheema et al. 2014). Studies from as recently 
as 2019 find significant changes to bile acid profile in AD patients, finding increased ratio of 
secondary bile acids strongly associated with progression from mild cognitive impairment to 
AD, implicating change to secondary transformation processes in the gut. Bile acids 
highlighted by these studies such as LCA and GLCA are some of the most hydrophobic. 
Hydrophobicity is known to affect cytotoxic properties of bile acids, reported in the liver to 
cause damage to mitochondria and inhibit normal cell function (Krähenbühl, Talos et al. 
1994). 
 Aims of Chapter Six 
 
Bile acids are a diverse group of neuroactive compounds with wide ranging effects. This 
chapter uses in vitro fetal derived neuronal cells to investigate the effects of patient and 
mouse serum treatments on neurons, and of the effects of specific bile acids treatments.  
 
We also aim to tease apart specific effects of OCA on the development of senescence. In 
mouse models we see a reduction in hippocampal neuronal senescence in OCA treated 
groups. However, as it occurs in parallel with reduced hepatic senescence, it remains unclear 
whether the OCA effect is driven through primary effects on neuronal cells, or through 
secondary signalling from the liver. Therefore, we chose to assess the anti-senescent action 
of OCA when cells are pre-treated for 1 hour before cholestatic serum dosing. This will enable 
us to see the effects of OCA signalling on neurons treated with cholestatic serum. 
 
The aims of this chapter are as follows: 
• Investigate differential effects on neuron death when treated with hydrophobic 
(lithocholic acid) and hydrophilic (taurocholic acid) using concentrations ranging from 
0.5pm to 100µm 
• Investigate the effect on viability of direct neuron exposure to serum from cholestatic 
mice and patients when compared with normal controls 
• Assess influence of anti-cholestatic drug treatments such as OCA on cell viability  
• Investigate the impact of human and mouse cholestatic serums on senescence of cells 
by using B-galactosidase assay  
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• Assess influence of anti-cholestatic treatment OCA on neuronal senescence  
• Investigate bile acid receptor FXR and TGR5expression in 97 neuronal cells to elucidate 
mechanism of OCA effects 
 
 Workflow 
 Results  
6.4.1. Differential Effects of Dosing with Cholestatic Versus 
Normal Serum 
6.4.1.1. Mouse Serum Dosing Dilution Testing 
Initial dosing experiments with mouse serums from sham, BDL and BDL mice treated with 




Figure 56. In vitro experimental workflow for 97 neuronal cells 
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Figure 57. Initial experiment focussed on dosing varying dilutions of serum from sham and BDL mice. H202 
was used as a positive control and viaibility was calculated based on media only wells per plate. N= 3 
animals per group. Statistical analysis using ANOVA. Data represented as mean  +/- SEM 
 
6.4.1.2. BDL Serum Treatments show Mild Effects on Neuron 
Viability 
Using a final concentration of 1:100 for dosing experiment, the experiment was repeated with 
additional outputs. Wells containing Sham, media only and hydrogen peroxide were also 
treated with Obeticholic acid. Each of the wells treated with OCA trended towards increased 
viability, including both sham and BDL treatment groups (FIG 58A). Both sham plus OCA and 
media only plus OCA groups showed a significant increase in viability as measured by the 
alamar blue assay. Wells treated with BDL serum showed a minor decrease in viability when 
compared to media only and sham wells, though this didn’t reach significance.  
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Figure 58. Experiment was repeated at chosen dose of 1:100 serum dilution. Three more sham and BDL 
mouse serums were tested and compared to media only well. N=3 animals per group. Statistical analysis 
using ANOVA. Data represented as mean  +/- SEM 
 
6.4.1.3. BDL serum treatment causes senescence in Neurons 
 
The same neurons underwent Sen-B galactosidase assay in order to assess levels of 
senescence induced by each treatment. Peroxide treatment strongly induced senescence as 
expected (FIG 59). However, 72-hour treatment with serum from BDL mice induced 2x the 
senescence seen in media only wells. Pre-treatment of neurons with OCA significantly 
reduced senescence in the BDL treated wells. Pre-treatment of sham serum wells with OCA 






Figure 59. The combined plates were used for sen B gal senescence assay. BDL serum was found to be 
significantly pro-senescent when compared to media only wells, or those treated with sham serum.  
Pretreatment with OCA was found to significantly reduce the percentage of senescent cells in BDL serum 
wells. OCA pretreatment in sham serum treated wells did not significantly reduce senescence. Data are 
mean +/- sem, N= 6 animals per group.Statistical analysis using ANOVA 
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Figure 60. Neurons treated with serums from PBC patients at concentration of 1:100 showed reduced 
viability when compared to media only wells. Neurons treated with normal human serum did not show 
reduced viability. Normal serum wells pre-treated with OCA had significantly increased viability when 
compared to PBC patient serum wells. Data are mean +/- sem, N= 3 samples per group to date. Statistical 
analysis using ANOVA 
6.4.1.1. Treatment with serum from PBC patients and Healthy 
controls affects neuronal Viability 
 
Similarly, to mice cholestatic serums, serums from PBC patients caused some reduction in cell 
viability, when compared to media only wells (FIG 60). This indicates that some cell death is 
likely occurring as a result of serum dosing to the neurons. Viability increases stepwise with 




6.4.1.2. Treatment with serum from PBC patients and Healthy 
controls Induces Neuronal Senescence  
 
Treatment with serum from cognitively dysfunctional PBC patients produced a similar effect 
to cholestatic mouse serum (FIG 61). Patient serum treatment induced the second highest 
level of senescence after peroxide treatment, and was significantly more pro-senescent than 
normal serum or media only wells. Pre-incubation with OCA significantly reduced senescence 
in neurons treated with patient serums. 
 
 
Figure 61. Sen B gal senescence assay on wells in figure 4 showed significant increase in senescence in 
Patient serum group compared to media only wells, and compared to Normal serum wells +/- OCA. 
Pretreatment of patient serum with OCA significantly reduced senescence. N= 3 samples per group to date. 
Statistical analysis using ANOVA. Data represented as +/- SEM. 
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6.4.2. Effects of Specific Bile acids on Neuronal Health  
6.4.2.1. Lithocholic acid Affects the Health of Neurons 
 
Lithocholic acid appears to have a negative impact on neuronal health as measured by the 
alamar blue assay on days 0, 1, 7 and 14. Treatment at a concentration of 100pm shows the 
greatest impact on viability, with a decreasing trend from day 1 (FIG 62A) that becomes 
significant by days 7 and 14 (FIG 62B, C).  Higher concentrations such as 500nm and above 
reduce cell viability. Interestingly, the highest concentrations of LCA 1µm and 100µm have 
less impact on cell viability than 100pm and 500nm. Change over time measurements show 
a general downward trend in viability from day 1 to 14 for all concentrations of LCA treatment 
(FIG 62D). 
 
6.4.2.2. Taurocholic acid has little effect on the Health of 
Neurons 
 
Opposingly taurocholic acid trends towards an increased viability when compared to media 
only in all concentrations over time (FIG 63D). The three highest concentrations of TCA  
500nm, 1µm and 100µm show significantly increased viability by days 7 (FIG 63B) and 14 (FIG 
63C).  This data suggest that TCA treatment improves neuronal viability and therefore health. 
 
6.4.3. Bile Acid Receptor Expression Profile of Neuronal Cells 
6.4.3.1. Farnesoid X Receptor (FXR) 
FXR is the main signalling receptor for OCA.  FXR was found to be expressed in several protein 
samples, including human brain and liver. Interestingly, in the neuronal cells used for the 
other experiments FXR was relatively highly expressed (FIG 64A). In this sample, FXR can be 
seen to be expressed at five different molecular weights. This could be due to the different 
isoforms of FXR, or due to cleavage of the protein in to different molecular weights. There are 
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reported to be at least four FXR isoforms (Zhang, Kast-Woelbern et al. 2003), which perform 
differing cellular functions (Ramos Pittol, Milona et al. 2020). Another explanation for the 
various molecular weights of FXR may be that the protein is undergoing digestion or 
degradation. Mature neurons were treated with either normal or patient serum (+/- OCA) for 
72 hours and  co-stained with NeuN and FXR, colocalised positive staining was seen. When 
ROI was set for whole cell FXR expression was reduced in patient serum treated neurons 
compared to normal serum treated (FIG  64B, D, E). When ROI was reduced to include only 
nuclear expression of FXR, there was no difference between groups (FIG 64C). 
 
6.4.3.2. Takeda G Protein 5 Receptor (TGR5) 
 
OCA has been shown to evoke secondary activation of TGR5. The expression of this receptor 
was very little in the neuronal cells (highlighted) (FIG 65A). TGR5 did show some expression 
in human liver and brain samples, as well as neuroblastoma cell lines SY5Y. There was also 
some expression of TGR5 in BBB endothelial cells.
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Figure 62. Lithocholic Acid treatment experiments. (A) By day 1 viability was improved in some concentrations. (B) By day 7 some concentrations had reduced 
viaibiltyand some increased. (D) by day 14 100pm concentration showed reduced viability. (D) Change over time shows a trend for reduced viability. Data 
represented as mean +/- SEM statistics ANOVA N=4 per concentration 
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Figure 63 Taurocholic Acid treatment experiments. (A) By day 1 viability remained stable. (B) By day 7 some concentrations had increased viability. (D) by day 
14high concentrations showed increased viaibility. (D) Change over time shows a trend for stableviability. Data represented as mean +/- SEM statistics Kruskal 
Wallis test  N=8 per concentration. 
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Figure 64. FXR expression in various neuronal cells, endothelial cells and human brain and liver homogenates. (A) FXR 
is expressed in several isoforms (B)FXR expression is reduced in whole cell patient serum treated neurons, and neurons 
treated with patient serum +OCA to a smaller extent (C)Nuclear FXR expression shows no differences between normal 
or patient serum treated neurons (D) representative image showing FXR expression in normal serum treated neurons 
with NeuN and DAPI overlay image insetted (E) representative image showing FXR expression in patient serum treated 
neurons with NeuN and DAPI overlay image insetted (F) representative image showing FXR expression in patient serum 
+OCA treated neurons with NeuN and DAPI overlay image insetted. Represented as mean +/- SEM, statistics ANOVA. 




Figure 65. TGR5 expression in various neuronal cells, endothelial cells and human brain and liver 













 Summary of findings from Chapter Six: 
Main conclusions of this chapter are as follows: 
 
• Cholestatic sera (patient or mouse) possess potent pro-senescent properties. 
 
• Non-cholestatic serum have minimal senescence inducing properties, indicating 
different pro-senescent molecules present in cholestatic serums. 
 
• Cholestatic serum do have a small but significant effect on cell viability, indicating 
some cell death occurs as a result of serum dosing. 
 
• Pre-treatment with OCA 1hour prior reduces the effects of cholestatic serums, 
including significantly reducing senescence – suggests a partial direct mechanism of 
action for OCA. 
 
• Dosing with specific bile acids with different hydrophobicity profiles produces 
different effects on cell viability – suggests that the presence of ‘harmful’ hydrophobic 
bile acids such as LCA in serum may exert direct effects on neuronal health. 
Hydrophobic bile acid LCA reduces cell viability in neurons. 
 
• Farnesoid X receptor through which OCA primarily signals is expressed in neurons in 












In Chapter one I established that cholestasis induces leakiness at the BBB. This fits in with 
previous observations in vitro (Quinn, McMillin et al. 2014). Therefore, bile acids and other 
potentially toxic constituents of cholestatic serum such as bilirubin (reviewed in (Hansen 
2001)), or ammonia (reviewed in (Braissant, McLin et al. 2013)) can enter the brain. With this 
in mind, we chose to investigate the direct effects of cholestatic serum on mature neurons in 
vitro.  
 
Previous data (chapters 1 and 2) showed that in vivo in the cholestatic bile duct ligation model 
senescence was induced by cholestasis not just in the liver, but in neurons in the critical CA3 
region of the hippocampus. Results from this chapter show that cholestatic serum both from 
BDL mice, that represent a severe cholestatic model with high levels of circulating bile acids, 
and serum from PBC patients experiencing a high level of cognitive dysfunction induce 
senescence in vitro in the brain. This indicates factors in the circulation entering the brain may 
be directly responsible for the senescence phenotype seen in the brain, as oppose to inducing 
an inflammatory phenotype which might lead indirectly to senescence. This data, along with 
key publications showing a close relationship between senescence PBC progression (Sasaki, 
Sato et al. 2020) indicate that senescence is a key pathological feature of the disease, as serum 
constituents from cholestatic patients induce senescence independently of continued 
circulatory inflammatory factors, or a pathological neuroinflammatory environment. 
 
In these studies, pharmacological intervention was achieved via pre-treatment incubation 
with OCA. Our in vivo data from BDL mice shows OCA to be effective in reducing the cognitive 
deficit in cholestatic mice, and also effective in reducing senescence in the liver and the brain. 
The use of therapy in a whole organism model makes it difficult to tease apart mechanism. In 
this case because the OCA was given from the day of surgery or even prophylactically in some 
experiments, it was impossible to tease apart the mechanism of OCA anti-senescent 
properties. These may simply have been as a consequence of reduction of cholestatic damage 
in the liver in the form of fibrosis, senescence etc (chapter 3, 4). 
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However, the ability of OCA to reduce senescence in an in vitro system in neurons indicates a 
direct mechanism of action on the neurons themselves. This suggests a possible role of FXR 
in regulation of the cell cycle. FXR is an established tumour suppressor (Yang, Huang et al. 
2007) and its downregulation reduces liver regeneration in age (Chen, Wang et al. 2010), and 
after fibrotic injury (Hong, Lewis et al. 2014). OCA has previously been reported to suppress 
p53 activation in models of Non-alcoholic Steatohepatitis (NASH) (Goto, Itoh et al. 2018). P53 
is a master regulator of the genome and its stimulation regulates the activation of a vast gene 
set including apoptosis and cell cycle arrest. It directly regulates P21, a well characterised 
marker of senescence in the small ducts in PBC  (Sasaki, Ikeda et al. 2005, Sasaki, Ikeda et al. 
2010). In neurodegenerative diseases such as AD, FXR signalling has been found to trigger 
neuronal apoptosis in areas of amyloid plaque generation (Chen, Ma et al. 2019), suggesting 
a neuroprotective benefit. These findings implicate FXR as a mediator of cell cycle arrest and 
potential moderator of senescence (FIG 59, 61) . Further experiments are needed in order to 
elucidate the specific pathways through which FXR has its anti-senescent effects in our study.   
 
Interestingly, even Sham or normal serum treated wells show a small increase in senescence, 
showing that exposure of neurons to even small doses of non-cholestatic serum may induce 
a phenotype that the BBB is usually able to protect from. Also, the idea of a direct anti-
senescent effect of OCA is strengthened by the fact that even normal patient serum and 
media only wells treated with OCA showed a minor reduction in senescence in the Sen-ß-
galactosidase assay. This points to a universal role of FXR in cell cycle regulation during normal 
function not just disease pathology.  
 
Despite the clear pro-senescent effects of dosing with serum from cholestatic patients, it 
remains unclear which serum components are responsible for the neurotoxic effects. 
Hydrophobic bile acids such as Lithocholic acid have been linked with senescence (Wu, 
Menon et al. 2016), hepatotoxicity (Song, Zhang et al. 2011) and the development of 
neurodegenerative diseases such as Alzheimer’s (MahmoudianDehkordi, Arnold et al. 2019). 
Conversely hydrophilic bile acids such as taurocholic acid and ursodeoxycholic acid are 
thought to be neuroprotective, with the latter currently being investigated in 
neurodegenerative diseases Alzheimer’s and Parkinson’s (reviewed (Ackerman and Gerhard 
2016)). Therefore, we tested differential effects of hydrophobic bile acid LCA and hydrophilic 
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bile acid TCA over a period of 14 days, with cell viability assay (alamar blue) performed at day 
0, 1, 7 and 14. A wide range of concentrations were tested from 0.5pm to 100µm.  
 
The cells treated with TCA resulted in almost universally increased cell viability when 
compared with media only wells. This reached significance by days 7 and 14 at the higher 
concentrations of 500nm and 100µm. Interestingly, LCA treatment significantly reduced cell 
viability by day 14 at the medium dose of 100pm when compared to media only. This adds 
weight to the hypothesis that specific bile acid composition plays a huge factor in its 
physiological function in the brain. 
 
Despite these results, we are still unable to pull apart the specific contributions of serum 
components. As previously mentioned, other potentially toxic molecules such as bilirubin and 
ammonia are likely to be circulating in the serum, and could influence senescence. From MSD 
data reported in chapter 3, we know that the pro-inflammatory cytokine profile in BDL serum 
is prolific and pro-senescent due to the upregulation of cytokines such as IL-8, IL-6 and TNFα, 
known components of SASP. Studies from patients’ sera show similar upregulation in 
proinflammatory cytokines IL-6, TNFα and IFNγ (Golovanova, Il'chenko et al. 2004). With this 
in mind, more thorough investigation into the componential breakdown of cholestatic serum 
is needed in order to carefully pick apart the mechanism of cholestasis induced neuronal 
senescence. In depth bile acid profiling is required in order to distinguish the ‘toxic’ bile acid 
profile and the specific actions of hydrophobic ‘harmful’ bile acids. 
 
It is important to address and discuss the limitations of the neuronal cells used. It is common 
to use induced pluripotent stem cells for this type of analysis, or alternatively to use 
immortalised neuronal cell lines. I chose to use stem cells isolated from the forebrain of 
human embyros. This raises some problems, both ethically and in the context of neuronal 
phenotype. Ethically the harvest of stem cells from human embryo is complex, though it was 
approved for use in this study (harvested by my supervisor Peter hanson, differentiated by 
me). These cells were harvested 8 years ago and can be frozen. The use of these stem cells is 
advantageous to using IPSC stem cells, due to the fact they are not undergoing a forced de-
differentiation. However, there are pit falls. Due to the heterogeneous nature of the culture, 
I cannot definitively state the identity of the cells in the same way I would be able to from cell 
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lines. This means that though the rest of my data is focussed on the hippocampus, these 
mixed neurons are not similar the hippocampal neural cell types and are not a model for the 
hippocampal environment. The culture also contains subpopulations of both astrocytes and 
oligodendrocytes, which I am unable to separate form neurons for the basis of my analysis. 
Feasibly, this could lead to changes in the results, or discrepancies between experiments, 
































7. Chapter Seven- General Discussion 
and Future Directions 
 
 Overall Discussion 
 
The data presented in this thesis explore the potential mechanism/s underpinning the 
cognitive function experienced by a large proportion of cholestatic liver disease patients, with 
a focus on Primary Biliary Cholangitis. Using the Bile duct ligation mouse model of cholestasis 
to study this symptomology, I have recapitulated the human disease through liver fibrosis, 
ductular proliferation and cholestasis resulting in circulating inflammation. Though the BDL 
model is severe and can lead to cirrhosis after 15 days or more, I chose to study the pre-
cirrhotic phase at days 6 and 10, in order to model early disease and intervention. BDL mice 
showed short-term and spatial memory dysfunction, mirroring the human cognitive symptom 
set. 
 
 identified deficits in key hippocampal functionalities: visual spatial memory deficit and 
fatigue, loss of NeuN+ neuron and PV+ interneuron expression, key markers of senescence 
(DNA damage, telomere associated foci (TAF), and P21 RNA), and loss of associated 
functionality including dysfunction in gamma frequency oscillation. Experiments focussing on 
Blood-Brain Barrier dysfunction indicated astrocyte activation and proliferation at the barrier, 
and loss of crucial astrocyte coverage and pilot studies using gadolinium enhanced T1 
weighted MRI scanning reveal increased permeability at vessels within the hippocampus. In 
vitro experiments using human embryonic derived neurons allowed direct manipulation of 
neuron response to circulating cholestatic stimuli in serum, showing the possibility to directly 
induce senescence without the accompanying neuroinflammation.  
 
Furthermore, we assessed the therapeutic benefits of early intervention drug therapies on 
the aforementioned deficits. This allowed us to both tease apart mechanism by manipulating 
cholestasis-mediated cognitive decline, and to evaluate individual drug efficacy specifically on 
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cognitive related symptoms if used early in the disease-course. The current second line 
therapy Obeticholic Acid showed promising improvement to key pathology including 
astrocyte coverage at the BBB, liver and neuronal senescence and restoration of gamma 
frequency oscillation in the hippocampus. In vitro experiments demonstrated a reduction in 
cholestasis induced senescence in neurons, therefore indicating this effect is likely to be in 
part at least by direct action and not entirely due to a general reduction in cholestasis and 
circulating inflammatory stimuli. Below is an implied event cascade to the causes of cognitive 
deficit through the means assessed during the course of my PhD (FIG 66), and on the right in 
(B) is the changes I have found to occur with OCA intervention from day -3 or 0. 
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7.1.1. Blood-Brain Barrier Breakdown is implicated in 
Cholestatic Liver Disease 
 
BBB breakdown is implicated in the pathogenesis of many chronic diseases such as 
Alzheimer’s disease well as in normal ageing (Montagne, Barnes et al. 2015, Nation, Sweeney 
et al. 2019). It has been previously shown by other groups that molecules associated with 
cholestasis such as bilirubin and bile acids have the ability to permeabilise endothelial cell 
tight junctions in vitro (Palmela, Cardoso et al. 2011, Cardoso, Kittel et al. 2012, Palmela, 
Sasaki et al. 2012). Additionally, it has been reported that some hydrophilic bile acids can to 
an extent prevent this increased permeability (Palmela, Correia et al. 2015). Though many of 
the studies have been limited to in vitro modelling, evidence from human imaging studies is 
beginning to emerge showing brain hypoxia and cerebrovascular changes in the brains of PBC 
patients (Duszynski, Avati et al. 2020).   
 
My studies focus on astrocytes, which are required for the normal function of the BBB and 
regulate permeability at the vessel (Iadecola and Nedergaard 2007) via direct connection 
through the end-feet (Mathiisen, Lehre et al. 2010). I found that disruption occurred early, by 
the 6-day timepoint, prefacing the other neuronal and cognitive changes. Both EM and super 
resolution imaging showing proliferative and activated astrocyte with a rounded phenotype 
surrounding the vessels by day 10, though EM showed few points of contact of the end feet 
with the vessel itself. The proper function and attachment of astrocytes is imperative to BBB 
health, and without it vessels become leaky (Heithoff, George et al. 2021). 
 
However, the results of the MRI data remain inconclusive and have a low power of only 3 per 
group. Because of this I cannot say that BDL definitively induces leakiness. The conclusions 
that I can draw about the permeability of the barrier come via proxy due to the EM and IF 
results, which indicate poor astrocyte attachment.  
 
Interestingly, treatment with the FXR agonist OCA from day of surgery resulted in a phenotype 
closer to sham. This group showed fewer activated astrocytes than cholestatic mice without 
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treatment and appeared to form more end-feet connections at the barrier. Fluorescence 
activated cell sorting showed the presence of the receptor FXR on Sca1+ endothelial cells of 
the BBB within the hippocampus. FXR expression was also found to be significantly increased 
upon treatment with OCA, suggesting a dynamically active receptor function. Could there be 
a direct role for FXR modulation of the permeability of the BBB?  
 
FXR signalling has been previously implicated in altering permeability and bile acid 
translocation at the gut in several pathological conditions (Stojancevic, Stankov et al. 2012), 
and since then FXR agonists such as OCA have been shown to direct modulate permeability 
at the gut epithelial (Verbeke, Farre et al. 2015) and vascular barriers (Mouries, Brescia et al. 
2019). The latter is of particular interest because it reveals OCAs ability to modulate the 
vascular barrier not just preventatively (like in our studies where it is administered from the 
day of surgery) but also therapeutically after the onset of disease. This therefore could be of 
importance when evaluating the patient benefit of OCA.   
 
7.1.2. Involvement of the Hippocampus in Cognitive Decline 
 
The hippocampus represents the epicentre of human memory processing network. Without 
the hippocampus, humans are unable to form new memories or to recall them long term, as 
evidenced by the case study of HM (Scoville and Milner 1957). Previous findings from human 
imaging studies of PBC patients report structural and functional changes to the hippocampus 
relatively early in the disease course, from around 6 months (Grover, Southern et al. 2016, 
Mosher, Swain et al. 2018).  
 
Our work consistently highlights cognitive deficits in hippocampal dependent memory tasks 
such as the Y-maze are a feature of BDL induced cholestasis. BDL mice (despite the expected 
individual variability) showed consistent reduction in the primary outcome of time spent in 
the novel arm across all trials. The Y-maze is widely used experimental procedure for the 
assessment of short term visual spatial memory, requiring the recognition of environmental 
cues.  This is in keeping with clinical observations indicating deficit occurs in domains of visual 
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spatial memory and concentration (Jacoby, Rannard et al. 2005, Newton, Hollingsworth et al. 
2008).   
 
The authors of Mosher et al. postulate that the reduced hippocampal volume observed in 
their study occurred as an outcome of chronic neuroinflammation. Again, this theory is in part 
supported by our work showing neuroinflammation in the hippocampus of BDL mice, and the 
degradation of neurons by day 10, a pre-cirrhotic timepoint comparable to the human disease 
presented in this publication.  
 
LFP electrophysiology in the gamma frequency oscillation generating region the CA3 allowed 
us to investigate changes to hippocampal function directly related to cognitive processes. We 
see large disruption to gamma frequency oscillation by day 10, a process associated with 
memory encoding and retrieval (Lu, Vreugdenhil et al. 2012). In our studies, BDL mice showed 
reduction in the ability to produce oscillations of a stable area power, something 89% of slices 
from sham animals produced within 3 hours, as is consistent with the literature (Lu, Wang et 
al. 2012). BDL mice also showed reduced CA3-CA1 synchrony, crucial for the recall of spatial 
cues in visual and working memory tasks such as the Y-maze (Montgomery and Buzsáki 2007) 
though it is important to note the low n numbers of this analysis. 
 
Crucially, PV+ interneurons were reduced in both number and Parvalbumin expression in the 
CA3. Parvalbumin positive interneurons are vital for gamma frequency oscillation as they 
provide inhibitory input to the firing of pyramidal cells (Sohal, Zhang et al. 2009), contributing 
directly to the generation of gamma (Antonoudiou, Tan et al. 2020). However, parvalbumin 
interneurons are sensitive to oxidative stress and are often lost as a result of pathology, which 
may provide mechanistic basis for disorganised oscillation phenotype seen in the BDLs. 
 
I chose to focus on the hippocampus as the primary region of investigation due to primary 
deficit seen in hippocampal dependent tasks such as the Y maze. Another reason for using 
the hippocampus as our primary area of investigation was that the hippocampus is sensitive 
to degradation and damage at the barrier, as was likely to be occurring in a cholestatic model. 
Additionally, previous studies have highlighted early changes to the hippocampus (as 
described above), and we were aiming to assess the early invention of therapeutics. However, 
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this reductionist experimental design may have caused us to overlook whole brain 
phenomena or the involvement of other key regions. Previous studies have also elucidated 
changes to other regions such as the globus pallidus, thalamus and putamen (Forton, Patel et 
al. 2004, Grover, Southern et al. 2016). It is worth noting that many of these studies have a 
focus largely on fatigue, or on cirrhotic patients which is not what we set out to model. With 
this aside, these areas warrant further investigation into the pathogenesis of cholestasis 
induced cognitive decline, questions which can be assessed in future with further utilization 
of our current experimental design, with a shift in focus. 
 
7.1.3. Does Multi-Organ Senescence play a Role in the 
Cognitive Decline in PBC? 
 
Senescence is a phenomenon first described by Hayflick in 1961 (Hayflick and Moorhead 
1961) and is defined as a cell enters irreversible cell-cycle arrest. This process occurs 
throughout the body and is contributary to both normal ageing and several disease processes. 
Senescence is a well characterised feature of cholestatic disease, occurring in the small ducts 
and periductular hepatocytes in mice models and human patient PBC and PSC (Sasaki, Ikeda 
et al. 2005, Sasaki, Ikeda et al. 2008, Sasaki, Ikeda et al. 2010, Sasaki, Miyakoshi et al. 2010, 
Tabibian, O'Hara et al. 2014). More recently, senescence has also been associated with 
phenotypic presentation of disease. The expression of senescence associated proteins such 
as p16 have been associated with recurrent PBC (Sasaki, Hsu et al. 2015), and occur in higher 
levels in UDCA non-responders (Sasaki, Sato et al. 2020).  
 
In neurodegenerative disease models, senescence is known to occur in glial cell types. In AD 
models the clearance of p16+ cells reduces cognitive decline (Bussian, Aziz et al. 2018). 
However, there is growing evidence of senescent like phenotype in non-mitotic cells such as 
neurons (Jurk, Wang et al. 2012, Wei, Chen et al. 2016). Our data provides the first evidence 
of senescence phenotype occurring in hippocampal neurons during cholestasis, in addition to 
within hepatocytes and non-parenchymal cells in the liver. This is evidenced not only by the 
specific senescence staining we performed in collaboration with Diana Jurk and colleagues at 
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the Mayo Clinic, but by the NeuN expression loss seen in the dentate gyrus, and by the 
induction of senescence in our in vitro model.  
 
This raises interesting questions about the pathological mechanisms of cholestatic liver 
disease. Is the core mechanism one of bile acid induced senescence, within the liver, that can 
provoke multi-organ senescence? Is neuronal senescence able to cause cognitive deficit 
during cholestasis? In studies focussing on neurodegeneration such as Bussian et al, clearance 
of senescent cells can directly improve cognition in disease models, supporting the idea of 
senescence-driven cognitive decline. 
 
While these questions are not directly answered by the thesis, our experiments with neuronal 
cell cultures show that senescence is induced in neurons by cholestatic serum even without 
active liver signalling and independent of neuroinflammatory involvement. The fact that the 
induction of senescence occurs directly from cholestatic serum and not as a consequence of 
continued inflammation from the liver implicates it in disease pathogenesis. Patient serums 
also induced senescence within the neuronal culture, implying that the process may be 
physiologically relevant in the patient disease, and not just the severe cholestasis induced 
from bile duct ligation. 
 
7.1.4. Does this Data support the Case for Early Intervention 
therapy with Obeticholic Acid? 
 
Previous clinical trials into pharmacological improvement with therapies in PBC have thus far 
shown little tangible improvement in cognition with therapeutic intervention. There could be 
several reasons for this; clinical trials are rarely designed to assess in detail cognitive 
symptoms, and cognitively impaired patients generally aren’t selected for in trial. This means 
that any slight improvements may be missed by non-targeted testing. Many of those that do 
assess cognition are looking solely at fatigue-based symptoms, leaving those with cognitive 
deficit largely ignored. Different phenotypic presentations of PBC also make it difficult to 
tease apart the effects on specific sub groups of patients. For example, quick or slow 
progressors, UDCA non-responders or responders, or AMA-positive or negative PBC that 
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possess a different disease phenotype. These diverse patient sets may have unique aspects 
to their pathology, and will respond differently to treatments. 
 
Currently, UDCA is given in the UK as a first line therapy for a minimum of one year in order 
to assess biochemical response in the liver. After this OCA the only licensed and labelled 
second-line therapy. Bezafibrate is currently being explored in phase 3 trials, with reported 
data showing a complete biochemical response in 31% of patients (Corpechot, Chazouillères 
et al. 2018). In keeping with the literature, we found UDCA intervention even prophylactically 
to be of little help in reducing cholestasis induced cognitive decline. UDCA treated mice still 
possessed both cognitive deficits and fatigue, had little improvement to liver pathology such 
as fibrosis, and had no associated reduction in senescence in the liver or brain, or change to 
neuroinflammation. Our results indicate therefore in line with previous observations that 
UDCA treatment has little influence on cognitive symptoms or associated pathology.  
 
However, we see improvement with the therapeutic intervention of OCA in many of the 
studied parameters. We see vast improvement in liver histology including a reduction in 
fibrosis in line with previous publications (Goto, Itoh et al. 2018, Zhou, Huang et al. 2019). We 
also see substantial improvements in key experimental parameters such as in hippocampal 
dependent memory task the Y-maze when compared to BDL, as well as a reduction in BBB 
damage, an effect we propose may be due to the direct signalling of FXR at the endothelium. 
Some of the most striking effects of OCA treatment are within the hippocampus. OCA reduces 
neuroinflammation and PV+ interneuron loss, producing stable gamma frequency 
oscillations.  
 
Most convincing are the clear improvements upon OCA pre-incubation of the neuronal cells, 
before introducing them to cholestatic serum. This data indicates direct therapeutic 
modulation by OCA of neurons in a way that bolsters them against the detrimental effects of 
senescence inducing serum. These results show clearly that there is a direct neuroprotective 
effect of OCA, and its beneficial impact in vivo in the BDL model is not just the indirect results 
of reduced cholestatic signalling at the liver. Therefore, I would hypothesise that early 
intervention therapy with OCA for those patient experiencing cognitive deficit may prove an 
effective therapeutic option. However, whether this is practical for clinical practise, when 
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patients can show few early symptoms and are often not diagnosed or given therapy until 
more advanced stage of disease, remains to be seen. 
 
On the other hand, though Bezafibrate provides improvement to liver pathology, treatment 
shows no improvement for cognitive symptoms. In fact, Bezafibrate treatment appears to 
trigger a pro-senescent phenotype in both the liver and the brain. It is not clear how these 
outcomes are triggered by Bezafibrate, or whether this has any direct impact on cognition. 
However, this is an interesting outcome, and of interest to the liver community to explore in 
more detail. 
 
7.1.5. The use of BDL as a model for PBC 
 
The relevance of the findings displayed in this thesis are of course reliant on the validity of 
the studied animal models. While mouse models can provide an excellent framework to 
explore disease, their use has come under scrutiny both ethically and in their biological 
relevance to human disease. However, it remains crucial for determining whole organism 
response to disease or pathological injury in a way that in vitro modelling cannot recapitulate. 
Mouse models allow recapitulation of cholestasis as a progressive disease, with immune 
activation as a systemic response to injury.  
 
The BDL model provides a useful system with which to study cholestatic liver disease. It 
mirrors many aspects of the patient symptom set such as progressive ductular reaction and 
fibrogenic response. It presents in 3 well defined phases (outlined below in table 6) allowing 
for timepoint histological analysis. In contrast, little has been investigated in the cognition 
and brain histology in mice undergoing BDL surgery, and published studies tend to recreate 
end stage cirrhotic disease, at later timepoints up to 21 days post-surgery (Huang, Hsieh et al. 
2004, Magen, Avraham et al. 2009, Hosseini, Alaei et al. 2014, Dhanda and Sandhir 2015). The 
use of a model with well characterised liver response allowed us to compare our more 
investigational findings in the brain alongside liver pathology well recognised in the field. 
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Table 6. Histological Phases of BDL cholestatic model. 
Phase Days Post-Surgery  Pathological Observations 
1 3-5 Biliary and hepatic injury, inflammatory peak 
2 5-14 Progressive fibrosis, ductular reaction, inflammatory 
cytokine profile 
3 14-21 Advanced fibrosis and development of cirrhosis, ascites 
(Abshagen, König et al. 2015, Tag, Sauer-Lehnen et al. 
2015) 
 
Despite this, BDL fails to capture some of the key features of the patient disease. The fact that 
it is such a severe and quick model, though convenient, means that it doesn’t faithfully 
recapitulate the human disease process. PBC is often a slow progressing disease, with patients 
remaining asymptomatic for several years (Long, Scheuer et al. 1977). The BDL model also 
fails to emulate any of the auto-immune triggers of PBC, an important factor in the 
development of the disease.  
 
Another important consideration is that of animal welfare. Bile duct ligation is a severe 
procedure, and can have a high mortality rate. In our studies, we minimised risk to the animal 
as much as possible. Creating a smaller wound meant less injury to the animal and quicker 
wound healing. After their surgery mice were kept in the heated cabinet at 25oC for the 
duration of the study and administered pain relief and sub-cutaneous fluids. Study numbers 
were carefully considered for all animal studies. 
 
Despite the pitfalls of any animal model system, BDL provides an effective system in which to 
study the process of cholestasis at a whole organism level. Using BDL we are able to 
investigate cross organ interaction between the brain and liver in a way that simply would 
not be possible using in vitro modelling alone. However, the in vitro data we have generated 
compliments the use of animal models and allows deeper mechanistic insight of the specific 
effects of cholestasis at the neuronal cellular level.  
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 Future Directions  
 
One of the most interesting aspects of the work has been the multi-organ senescence 
phenotype that occurs with the BDL model. Currently, it remains impossible to say whether 
the senescence phenotype within the hippocampus is a direct trigger of cognitive deficit. As 
it stands, the anecdotal evidence shows that OCA reduces both senescence and cognitive 
deficit in the BDL animals. In order to assess the causal link between senescence and 
cognition, it would be beneficial to employ a senescence clearance model, or to treat the mice 
with senolytic compounds.  
 
The p16Ink4a-INK ATTAC mouse is a transgenic mouse model that allows for induced 
elimination of  p16Ink4a positive cells within the body (Baker, Wijshake et al. 2011). Treatment 
with the drug AP20187 triggers apoptosis in cells expressing the p16 Ink4a gene (full schematic 
below from Baker et al 2011). The transgene can also be targeted, triggering clearance within 
a specific organ or cell type.  
 
Using this transgenic mouse for the BDL model would allow mechanistic insight into the role 
of senescence in the pathogenesis of cholestasis. If senescent cell clearance within the liver 
reduces the senescence in the brain or the cognitive deficit this would indicate that the brain 
senescence is influenced largely by the liver phenotype and not by a separate pathological 
mechanism. Similarly, clearance of senescent cells only in the brain or in neurons would 
enable us to establish the specific role of senescence in cognition. Previously, senescence cell 
clearance in the brain using this technique has been linked to a slowed cognitive decline in 
neurodegenerative models (Bussian, Aziz et al. 2018). Another exciting experiment would be 
to treat BDL mice with senolytic compounds such as Dasatinib and Quercetin (D+Q). D+Q are 
the most thoroughly studied senolytic drugs, and have been shown to alleviate a number of 
age related conditions with few side effects (Xu, Pirtskhalava et al. 2018). This would be 
valuable and give indication of whether the use of senolytic compounds may be of therapeutic 





Figure 67 Figure from original paper (Baker, Wijshake et al. 2011) showing a schematic of the generation of the 
INK-ATTAC model. 
Further development of the in vitro work would be valuable. Treatment with other therapies 
such as UDCA to assess therapeutic benefit, and if there are any direct impact of UDCA 
treatment on senescence. Treatment of neurons with Bezafibrate would identify whether the 
pro-senescent phenotype persists in vitro, and western blot analysis  of protein expression of 
senescent markers such as P21 and P16 would allow thorough mechanistic evaluation of the 
pro-senescent properties of Bezafibrate treatment.  
 
Furthermore, the collection of lysates from cells dosed with human patient and normal serum 
with treatment groups plus and minus drug would elevate the project. This would provide 
valuable mechanism for the protective effects of OCA within the brain. Western blots can be 
used to assess FXR modulation by the drug and to evaluate if the receptor is active within the 
cells by showing a reduction or increase in expression. Western blots of key cell cycle proteins 
such as p53, p21, and p16 would prove that the effect of OCA is largely anti-senescent (as 
oppose to anti-apoptotic), and show through which senescence pathways OCA exerts its 
function. This would provide key knowledge for future drug development and patient trials 
with OCA or other therapeutic developments. It has not been thoroughly investigated in this 
thesis; however, OCA also agonises TGR5 receptor. Assessment of the presence and 
modulation of both FXR and TGR5 in the neurons is required for development of the most 
efficacious compound. 
 
Finally, a patient clinical trial into the impact of early intervention with OCA is warranted. OCA 
has positive outcomes when used in our pre-cirrhotic model, yet in the clinic it is not routinely 
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prescribed until later in the disease. As OCA is already an FDA approved therapy for PBC, it 
could be an easily implemented therapeutic if it is proven to be beneficial for patients with 






Abshagen, K., M. König, A. Hoppe, I. Müller, M. Ebert, H. Weng, H.-G. Holzhütter, U. M. 
Zanger, J. Bode, B. Vollmar, M. Thomas and S. Dooley (2015). "Pathobiochemical signatures 
of cholestatic liver disease in bile duct ligated mice." BMC Systems Biology 9(1): 83. 
Ackerman, H. D. and G. S. Gerhard (2016). "Bile Acids in Neurodegenerative Disorders." 
Frontiers in aging neuroscience 8: 263-263. 
Acosta, J. C., A. Banito, T. Wuestefeld, A. Georgilis, P. Janich, J. P. Morton, D. Athineos, T.-W. 
Kang, F. Lasitschka, M. Andrulis, G. Pascual, K. J. Morris, S. Khan, H. Jin, G. Dharmalingam, A. 
P. Snijders, T. Carroll, D. Capper, C. Pritchard, G. J. Inman, T. Longerich, O. J. Sansom, S. A. 
Benitah, L. Zender and J. Gil (2013). "A complex secretory program orchestrated by the 
inflammasome controls paracrine senescence." Nature cell biology 15(8): 978-990. 
Acosta, J. C., A. O'Loghlen, A. Banito, M. V. Guijarro, A. Augert, S. Raguz, M. Fumagalli, M. Da 
Costa, C. Brown, N. Popov, Y. Takatsu, J. Melamed, F. d'Adda di Fagagna, D. Bernard, E. 
Hernando and J. Gil (2008). "Chemokine Signaling via the CXCR2 Receptor Reinforces 
Senescence." Cell 133(6): 1006-1018. 
Addington, A., M. Gornick, J. Duckworth, A. Sporn, N. Gogtay, A. Bobb, D. Greenstein, M. 
Lenane, P. Gochman and N. Baker (2005). "GAD1 (2q31. 1), which encodes glutamic acid 
decarboxylase (GAD 67), is associated with childhood-onset schizophrenia and cortical gray 
matter volume loss." Molecular psychiatry 10(6): 581-588. 
Aghaei, I., V. Hajali, A. Dehpour, M. Haghani, V. Sheibani and M. Shabani (2016). "Alterations 
in the intrinsic electrophysiological properties of Purkinje neurons in a rat model of hepatic 
encephalopathy: Relative preventing effect of PPARγ agonist." Brain Research Bulletin 121: 
16-25. 
Agrawal, R., M. Majeed, B. M. Attar, Y. A. Omar, C. Mbachi, Y. Wang, E. Flores, S. Shaqib, Y. 
Wang, V. Udechukwu, M. Demetria and S. Gandhi (2019). "Effectiveness of bezafibrate and 
ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of 
randomized controlled trials." Annals of gastroenterology 32(5): 489-497. 
Albrecht, S., A.-K. Fleck, I. Kirchberg, S. Hucke, M. Liebmann, L. Klotz and T. Kuhlmann 
(2017). "Activation of FXR pathway does not alter glial cell function." Journal of 
Neuroinflammation 14(1): 66. 
Allen, D., J. Lannergren and H. Westerblad (1995). "Muscle cell function during prolonged 
activity: cellular mechanisms of fatigue." Experimental Physiology: Translation and 
Integration 80(4): 497-527. 
Alpini, G., S. S. Glaser, Y. Ueno, L. Pham, P. V. Podila, A. Caligiuri, G. LeSage and N. F. LaRusso 
(1998). "Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct 
ligation." Am J Physiol 274(4): G767-775. 
Alpini, G., S. Roberts, S. M. Kuntz, Y. Ueno, S. Gubba, P. V. Podila, G. LeSage and N. F. 
LaRusso (1996). "Morphological, molecular, and functional heterogeneity of cholangiocytes 
from normal rat liver." Gastroenterology 110(5): 1636-1643. 
Alvaro, D., P. Invernizzi, P. Onori, A. Franchitto, A. De Santis, A. Crosignani, R. Sferra, S. 
Ginanni-Corradini, M. Grazia Mancino, M. Maggioni, A. F. Attili, M. Podda and E. Gaudio 
(2004). "Estrogen receptors in cholangiocytes and the progression of primary biliary 
cirrhosis." Journal of Hepatology 41(6): 905-912. 
 204 
Amano, K., P. S. C. Leung, R. Rieger, C. Quan, X. Wang, J. Marik, Y. F. Suen, M. J. Kurth, M. H. 
Nantz, A. A. Ansari, K. S. Lam, M. Zeniya, E. Matsuura, R. L. Coppel and M. E. Gershwin 
(2005). "Chemical Xenobiotics and Mitochondrial Autoantigens in Primary Biliary Cirrhosis: 
Identification of Antibodies against a Common Environmental, Cosmetic, and Food Additive, 
2-Octynoic Acid." The Journal of Immunology 174(9): 5874. 
Amodio, P., S. Montagnese, A. Gatta and M. Y. Morgan (2004). "Characteristics of minimal 
hepatic encephalopathy." Metab Brain Dis 19(3-4): 253-267. 
Anderson, J. M. and C. M. Van Itallie (1995). "Tight junctions and the molecular basis for 
regulation of paracellular permeability." Am J Physiol 269(4 Pt 1): G467-475. 
Andersson, S., N. Gustafsson, M. Warner and J.-Å. Gustafsson (2005). "Inactivation of liver X 
receptor β leads to adult-onset motor neuron degeneration in male mice." Proceedings of 
the National Academy of Sciences 102(10): 3857-3862. 
Antonoudiou, P., Y. L. Tan, G. Kontou, A. L. Upton and E. O. Mann (2020). "Parvalbumin and 
Somatostatin Interneurons Contribute to the Generation of Hippocampal Gamma 
Oscillations." The Journal of Neuroscience: JN-RM-0261-0220. 
Armulik, A., G. Genové, M. Mäe, M. H. Nisancioglu, E. Wallgard, C. Niaudet, L. He, J. Norlin, 
P. Lindblom and K. Strittmatter (2010). "Pericytes regulate the blood–brain barrier." Nature 
468(7323): 557-561. 
Au - Martin, E., M. Au - El-Behi, B. Au - Fontaine and C. Au - Delarasse (2017). "Analysis of 
Microglia and Monocyte-derived Macrophages from the Central Nervous System by Flow 
Cytometry." JoVE(124): e55781. 
Bajaj, J. S., J. G. O’Leary, P. Tandon, F. Wong, G. Garcia-Tsao, P. S. Kamath, B. Maliakkal, S. 
W. Biggins, P. J. Thuluvath, M. B. Fallon, R. M. Subramanian, H. E. Vargas, J. Lai, L. R. Thacker 
and K. R. Reddy (2017). "Hepatic Encephalopathy Is Associated With Mortality in Patients 
With Cirrhosis Independent of Other Extrahepatic Organ Failures." Clinical Gastroenterology 
and Hepatology 15(4): 565-574.e564. 
Baker, D. J., T. Wijshake, T. Tchkonia, N. K. LeBrasseur, B. G. Childs, B. Van De Sluis, J. L. 
Kirkland and J. M. van Deursen (2011). "Clearance of p16 Ink4a-positive senescent cells 
delays ageing-associated disorders." Nature 479(7372): 232-236. 
Banks, W. A. (2009). "Characteristics of compounds that cross the blood-brain barrier." BMC 
neurology 9 Suppl 1(Suppl 1): S3-S3. 
Barrett, K. E. and W. F. Ganong (2012). Ganong's review of medical physiology. New York; 
London, McGraw-Hill Medical ; McGraw-Hill [distributor]. 
Bauer, J., U. Ganter, S. Strauss, G. Stadtmüller, U. Frommberger, H. Bauer, B. Volk and M. 
Berger (1992). "The participation of interleukin-6 in the pathogenesis of Alzheimer's 
disease." Res Immunol 143(6): 650-657. 
Beuers, U., M. Bilzer, A. Chittattu, G. A. Kullak-Ublick, D. Keppler, G. Paumgartner and F. 
Dombrowski (2001). "Tauroursodeoxycholic acid inserts the apical conjugate export pump, 
Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase 
C-dependent mechanisms in cholestatic rat liver." Hepatology 33(5): 1206-1216. 
Bhat, R., E. P. Crowe, A. Bitto, M. Moh, C. D. Katsetos, F. U. Garcia, F. B. Johnson, J. Q. 
Trojanowski, C. Sell and C. Torres (2012). "Astrocyte senescence as a component of 
Alzheimer's disease." PloS one 7(9): e45069-e45069. 
Bi, G. Q. and M. M. Poo (1998). "Synaptic modifications in cultured hippocampal neurons: 
dependence on spike timing, synaptic strength, and postsynaptic cell type." J Neurosci 
18(24): 10464-10472. 
 205 
Bitto, A., C. Sell, E. Crowe, A. Lorenzini, M. Malaguti, S. Hrelia and C. Torres (2010). "Stress-
induced senescence in human and rodent astrocytes." Experimental Cell Research 316(17): 
2961-2968. 
Blecharz-Lang, K. G., J. Wagner, A. Fries, M. Nieminen-Kelhä, J. Rösner, U. C. Schneider and 
P. Vajkoczy (2018). "Interleukin 6-mediated endothelial barrier disturbances can be 
attenuated by blockade of the IL6 receptor expressed in brain microvascular endothelial 
cells." Translational stroke research 9(6): 631-642. 
Boche, D., V. Perry and J. Nicoll (2013). "Activation patterns of microglia and their 
identification in the human brain." Neuropathology and applied neurobiology 39(1): 3-18. 
Börgers, C., S. Epstein and N. J. Kopell (2005). "Background gamma rhythmicity and 
attention in cortical local circuits: A computational study." Proceedings of the National 
Academy of Sciences of the United States of America 102(19): 7002. 
Bowlus, C. L., P. J. Pockros, A. E. Kremer, A. Parés, L. M. Forman, J. P. H. Drenth, S. D. Ryder, 
L. Terracciano, Y. Jin, A. Liberman, R. Pencek, U. Iloeje, L. MacConell and P. Bedossa (2020). 
"Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With 
Primary Biliary Cholangitis." Clin Gastroenterol Hepatol 18(5): 1170-1178.e1176. 
Boyer, J. L. (1983). "Tight junctions in normal and cholestatic liver: does the paracellular 
pathway have functional significance?" Hepatology 3(4): 614-617. 
Bragin, A., G. Jandó, Z. Nádasdy, J. Hetke, K. Wise and G. Buzsáki (1995). "Gamma (40-100 
Hz) oscillation in the hippocampus of the behaving rat." Journal of Neuroscience 15(1): 47-
60. 
Braissant, O., V. A. McLin and C. Cudalbu (2013). "Ammonia toxicity to the brain." Journal of 
inherited metabolic disease 36(4): 595-612. 
Brown, J. P., W. Wei and J. M. Sedivy (1997). "Bypass of senescence after disruption of 
p21CIP1/WAF1 gene in normal diploid human fibroblasts." Science 277(5327): 831-834. 
Burroughs, A. K., I. J. Rosenstein, O. Epstein, J. M. Hamilton-Miller, W. Brumfitt and S. 
Sherlock (1984). "Bacteriuria and primary biliary cirrhosis." Gut 25(2): 133. 
Bussian, T. J., A. Aziz, C. F. Meyer, B. L. Swenson, J. M. van Deursen and D. J. Baker (2018). 
"Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline." 
Nature 562(7728): 578-582. 
Buzsáki, G. (2005). "Theta rhythm of navigation: link between path integration and 
landmark navigation, episodic and semantic memory." Hippocampus 15(7): 827-840. 
Cabral, H. O., M. Vinck, C. Fouquet, C. M. Pennartz, L. Rondi-Reig and F. P. Battaglia (2014). 
"Oscillatory dynamics and place field maps reflect hippocampal ensemble processing of 
sequence and place memory under NMDA receptor control." Neuron 81(2): 402-415. 
Calado, R. T., J. A. Regal, D. E. Kleiner, D. S. Schrump, N. R. Peterson, V. Pons, S. J. Chanock, 
P. M. Lansdorp and N. S. Young (2009). "A Spectrum of Severe Familial Liver Disorders 
Associate with Telomerase Mutations." PLOS ONE 4(11): e7926. 
Campisi, J. and F. d'Adda di Fagagna (2007). "Cellular senescence: when bad things happen 
to good cells." Nat Rev Mol Cell Biol 8(9): 729-740. 
Carbone, M., S. Bufton, A. Monaco, L. Griffiths, D. E. Jones and J. M. Neuberger (2013). "The 
effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a 
prospective study." Journal of hepatology 59(3): 490-494. 
Carbone, M., G. F. Mells, G. Pells, M. F. Dawwas, J. L. Newton, M. A. Heneghan, J. M. 
Neuberger, D. B. Day, S. J. Ducker, R. N. Sandford, G. J. Alexander and D. E. J. Jones (2013). 
"Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and 
Response to Ursodeoxycholic Acid." Gastroenterology 144(3): 560-569.e567. 
 206 
Cardoso, F. L., A. Kittel, S. Veszelka, I. Palmela, A. Tóth, D. Brites, M. A. Deli and M. A. Brito 
(2012). "Exposure to lipopolysaccharide and/or unconjugated bilirubin impair the integrity 
and function of brain microvascular endothelial cells." PLoS One 7(5): e35919. 
Carr, M. F., M. P. Karlsson and L. M. Frank (2012). "Transient slow gamma synchrony 
underlies hippocampal memory replay." Neuron 75(4): 700-713. 
Cauch-Dudek, K., S. Abbey, D. Stewart and E. Heathcote (1998). "Fatigue in primary biliary 
cirrhosis." Gut 43(5): 705-710. 
Cauli, O., M. T. Mansouri, A. Agusti and V. Felipo (2009). "Hyperammonemia increases 
GABAergic tone in the cerebellum but decreases it in the rat cortex." Gastroenterology 
136(4): 1359-1367, e1351-1352. 
Ceulemans, L. J., L. Verbeke, J.-P. Decuypere, R. Farré, G. De Hertogh, K. Lenaerts, I. 
Jochmans, D. Monbaliu, F. Nevens, J. Tack, W. Laleman and J. Pirenne (2017). "Farnesoid X 
Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats." PLOS ONE 
12(1): e0169331. 
Chen, Q., H. Ma, X. Guo, J. Liu, T. Gui and Z. Gai (2019). "Farnesoid X Receptor (FXR) 
Aggravates Amyloid-β-Triggered Apoptosis by Modulating the cAMP-Response Element-
Binding Protein (CREB)/Brain-Derived Neurotrophic Factor (BDNF) Pathway In Vitro." 
Medical science monitor : international medical journal of experimental and clinical 
research 25: 9335-9345. 
Chen, W.-D., Y.-D. Wang, L. Zhang, S. Shiah, M. Wang, F. Yang, D. Yu, B. M. Forman and W. 
Huang (2010). "Farnesoid X receptor alleviates age-related proliferation defects in 
regenerating mouse livers by activating forkhead box m1b transcription." Hepatology 
(Baltimore, Md.) 51(3): 953-962. 
Chiang, J. Y. (2009). "Bile acids: regulation of synthesis." Journal of lipid research 50(10): 
1955-1966. 
Childs, S., R. L. Yeh, E. Georges and V. Ling (1995). "Identification of a Sister Gene to P-
Glycoprotein." Cancer Research 55(10): 2029. 
Cindoruk, M., M. Kerem, T. Karakan, B. Salman, O. Akin, M. Alper, O. Erdem and S. Ünal 
(2007). "Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic 
damage in rats with obstructive jaundice: an experimental study." BMC Gastroenterology 
7(1): 44. 
Clarke, L. E., S. A. Liddelow, C. Chakraborty, A. E. Münch, M. Heiman and B. A. Barres (2018). 
"Normal aging induces A1-like astrocyte reactivity." Proceedings of the National Academy of 
Sciences 115(8): E1896. 
Cohen, Z., M. Ehret, M. Maitre and E. Hamel (1995). "Ultrastructural analysis of tryptophan 
hydroxylase immunoreactive nerve terminals in the rat cerebral cortex and hippocampus: 
their associations with local blood vessels." Neuroscience 66(3): 555-569. 
Colgin, L. L., T. Denninger, M. Fyhn, T. Hafting, T. Bonnevie, O. Jensen, M. B. Moser and E. I. 
Moser (2009). "Frequency of gamma oscillations routes flow of information in the 
hippocampus." Nature 462(7271): 353-357. 
Colicos, M. A. and P. K. Dash (1996). "Apoptotic morphology of dentate gyrus granule cells 
following experimental cortical impact injury in rats: possible role in spatial memory 
deficits." Brain Research 739(1): 120-131. 
Collado, M., M. A. Blasco and M. Serrano (2007). "Cellular senescence in cancer and aging." 
Cell 130(2): 223-233. 
 207 
Colton, C. A., R. T. Mott, H. Sharpe, Q. Xu, W. E. Van Nostrand and M. P. Vitek (2006). 
"Expression profiles for macrophage alternative activation genes in AD and in mouse models 
of AD." Journal of neuroinflammation 3(1): 27. 
Coluzzi, E., S. Leone and A. Sgura (2019). "Oxidative Stress Induces Telomere Dysfunction 
and Senescence by Replication Fork Arrest." Cells 8(1). 
Cornell-Bell, A. H., S. M. Finkbeiner, M. S. Cooper and S. J. Smith (1990). "Glutamate induces 
calcium waves in cultured astrocytes: long-range glial signaling." Science 247(4941): 470-
473. 
Corpechot, C., L. Abenavoli, N. Rabahi, Y. Chretien, T. Andreani, C. Johanet, O. Chazouilleres 
and R. Poupon (2008). "Biochemical response to ursodeoxycholic acid and long-term 
prognosis in primary biliary cirrhosis." Hepatology 48(3): 871-877. 
Corpechot, C., O. Chazouillères, S. Lemoinne and A. Rousseau (2019). "Letter: reduction in 
projected mortality or need for liver transplantation associated with bezafibrate add-on in 
primary biliary cholangitis with incomplete UDCA response." Aliment Pharmacol Ther 49(2): 
236-238. 
Corpechot, C., O. Chazouillères, A. Rousseau, A. Le Gruyer, F. Habersetzer, P. Mathurin, O. 
Goria, P. Potier, A. Minello, C. Silvain, A. Abergel, M. Debette-Gratien, D. Larrey, O. Roux, J.-
P. Bronowicki, J. Boursier, V. de Ledinghen, A. Heurgue-Berlot, E. Nguyen-Khac, F. Zoulim, I. 
Ollivier-Hourmand, J.-P. Zarski, G. Nkontchou, S. Lemoinne, L. Humbert, D. Rainteau, G. 
Lefèvre, L. de Chaisemartin, S. Chollet-Martin, F. Gaouar, F.-H. Admane, T. Simon and R. 
Poupon (2018). "A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis." 
New England Journal of Medicine 378(23): 2171-2181. 
Crowe, J., E. Christensen, D. Doniach, H. Popper, N. Tygstrup and R. Williams (1985). "Early 
features of primary biliary cirrhosis: an analysis of 85 patients." Am J Gastroenterol 80(6): 
466-468. 
Cruz-Sánchez, F. F., X. Gironès, A. Ortega, F. Alameda and J. V. Lafuente (2010). "Oxidative 
stress in Alzheimer's disease hippocampus: a topographical study." J Neurol Sci 299(1-2): 
163-167. 
Csicsvari, J., B. Jamieson, K. D. Wise and G. Buzsaki (2003). "Mechanisms of gamma 
oscillations in the hippocampus of the behaving rat." Neuron 37(2): 311-322. 
d'Adda di Fagagna, F., P. M. Reaper, L. Clay-Farrace, H. Fiegler, P. Carr, T. Von Zglinicki, G. 
Saretzki, N. P. Carter and S. P. Jackson (2003). "A DNA damage checkpoint response in 
telomere-initiated senescence." Nature 426(6963): 194-198. 
D'Mello, C., T. Le and M. G. Swain (2009). "Cerebral microglia recruit monocytes into the 
brain in response to tumor necrosis factoralpha signaling during peripheral organ 
inflammation." The Journal of neuroscience : the official journal of the Society for 
Neuroscience 29(7): 2089-2102. 
D'Mello, C., T. Le and M. G. Swain (2009). "Cerebral microglia recruit monocytes into the 
brain in response to tumor necrosis factorα signaling during peripheral organ 
inflammation." Journal of Neuroscience 29(7): 2089-2102. 
D’Mello, C., K. Riazi, T. Le, K. M. Stevens, A. Wang, D. M. McKay, Q. J. Pittman and M. G. 
Swain (2013). "P-Selectin-Mediated Monocyte–Cerebral Endothelium Adhesive Interactions 
Link Peripheral Organ Inflammation To Sickness Behaviors." The Journal of Neuroscience 
33(37): 14878. 
Dang-Vu, T. T., M. Schabus, M. Desseilles, G. Albouy, M. Boly, A. Darsaud, S. Gais, G. Rauchs, 
V. Sterpenich, G. Vandewalle, J. Carrier, G. Moonen, E. Balteau, C. Degueldre, A. Luxen, C. 
 208 
Phillips and P. Maquet (2008). "Spontaneous neural activity during human slow wave sleep." 
Proceedings of the National Academy of Sciences 105(39): 15160. 
Datto, M. B., Y. Li, J. F. Panus, D. J. Howe, Y. Xiong and X. F. Wang (1995). "Transforming 
growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-
independent mechanism." Proc Natl Acad Sci U S A 92(12): 5545-5549. 
Davalos, D., J. Grutzendler, G. Yang, J. V. Kim, Y. Zuo, S. Jung, D. R. Littman, M. L. Dustin and 
W.-B. Gan (2005). "ATP mediates rapid microglial response to local brain injury in vivo." 
Nature neuroscience 8(6): 752-758. 
Davson, H. and W. H. Oldendorf (1967). "Symposium on membrane transport. Transport in 
the central nervous system." Proc R Soc Med 60(4): 326-329. 
Dawson, P. A., M. Hubbert, J. Haywood, A. L. Craddock, N. Zerangue, W. V. Christian and N. 
Ballatori (2005). "The heteromeric organic solute transporter α-β, Ostα-Ostβ, is an ileal 
basolateral bile acid transporter." Journal of Biological Chemistry 280(8): 6960-6968. 
de Lange, T. (2005). "Shelterin: the protein complex that shapes and safeguards human 
telomeres." Genes Dev 19(18): 2100-2110. 
De Magalhaes Filho, C. D., M. Downes and R. Evans (2016). "Bile Acid Analog Intercepts Liver 
Fibrosis." Cell 166(4): 789. 
Delerive, P., K. De Bosscher, S. Besnard, W. Vanden Berghe, J. M. Peters, F. J. Gonzalez, J.-C. 
Fruchart, A. Tedgui, G. Haegeman and B. Staels (1999). "Peroxisome Proliferator-activated 
Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative 
Cross-talk with Transcription Factors NF-κB and AP-1." Journal of Biological Chemistry 
274(45): 32048-32054. 
Dember, W. N. and H. Fowler (1959). "Spontaneous alternation after free and forced trials." 
Canadian Journal of Psychology/Revue canadienne de psychologie 13(3): 151-154. 
Dhanda, S. and R. Sandhir (2015). "Role of dopaminergic and serotonergic 
neurotransmitters in behavioral alterations observed in rodent model of hepatic 
encephalopathy." Behavioural Brain Research 286: 222-235. 
Dirac, A. M. and R. Bernards (2003). "Reversal of senescence in mouse fibroblasts through 
lentiviral suppression of p53." J Biol Chem 278(14): 11731-11734. 
Dombrowski, F., B. Stieger and U. Beuers (2006). "Tauroursodeoxycholic acid inserts the bile 
salt export pump into canalicular membranes of cholestatic rat liver." Lab Invest 86(2): 166-
174. 
Driver, J. E., C. Racca, M. O. Cunningham, S. K. Towers, C. H. Davies, M. A. Whittington and F. 
E. N. LeBeau (2007). "Impairment of hippocampal gamma (γ)-frequency oscillations in vitro 
in mice overexpressing human amyloid precursor protein (APP)." European Journal of 
Neuroscience 26(5): 1280-1288. 
Duszynski, C. C., V. Avati, A. P. Lapointe, F. Scholkmann, J. F. Dunn and M. G. Swain (2020). 
"Near-Infrared Spectroscopy Reveals Brain Hypoxia and Cerebrovascular Dysregulation in 
Primary Biliary Cholangitis." Hepatology 71(4): 1408-1420. 
Dyson, J., A. Blain, M. Hudson, S. Rushton and D. Jones (2019). "FRI-015-Environmental 
triggering in primary biliary cholangitis: Disease risk relates to coal mining activity." Journal 
of Hepatology 70(1, Supplement): e390. 
Dyson, J. K., N. Wilkinson, L. Jopson, G. Mells, A. Bathgate, M. A. Heneghan, J. Neuberger, G. 
M. Hirschfield, S. J. Ducker, U. K. P. B. C. C. The, R. Sandford, G. Alexander, D. Stocken and D. 
E. J. Jones (2016). "The inter-relationship of symptom severity and quality of life in 2055 
patients with primary biliary cholangitis." Alimentary Pharmacology & Therapeutics 44(10): 
1039-1050. 
 209 
EASL (2009). EASL Clinical Practice Guidelines: management of cholestatic liver diseases. E. 
A. S. L. (EASL). J Hepatol. 51: 237-267. 
EASL (2017). "EASL Clinical Practice Guidelines: The diagnosis and management of patients 
with primary biliary cholangitis." J Hepatol 67(1): 145-172. 
Eriksson, L. S., R. Olsson, H. Glauman, H. Prytz, R. Befrits, B. O. Rydén, K. Einarsson, S. 
Lindgren, S. Wallerstedt and M. Wedén (1997). "Ursodeoxycholic Acid Treatment in Patients 
with Primary Biliary Cirrhosis: A Swedish Multicentre, Double-Blind, Randomized Controlled 
Study." Scandinavian Journal of Gastroenterology 32(2): 179-186. 
Eroglu, C., N. J. Allen, M. W. Susman, N. A. O'Rourke, C. Y. Park, E. Özkan, C. Chakraborty, S. 
B. Mulinyawe, D. S. Annis and A. D. Huberman (2009). "Gabapentin receptor α2δ-1 is a 
neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis." Cell 
139(2): 380-392. 
Fabris, L. and M. Strazzabosco (2011). Epithelial–mesenchymal interactions in biliary 
diseases. Seminars in liver disease, NIH Public Access. 
Fell, J., P. Klaver, K. Lehnertz, T. Grunwald, C. Schaller, C. E. Elger and G. Fernández (2001). 
"Human memory formation is accompanied by rhinal-hippocampal coupling and 
decoupling." Nat Neurosci 4(12): 1259-1264. 
Ferrebee, C. B., J. Li, J. Haywood, K. Pachura, B. S. Robinson, B. H. Hinrichs, R. M. Jones, A. 
Rao and P. A. Dawson (2018). "Organic Solute Transporter α-β Protects Ileal Enterocytes 
From Bile Acid–Induced Injury." Cellular and Molecular Gastroenterology and Hepatology 
5(4): 499-522. 
Fickert, P., G. Zollner, A. Fuchsbichler, C. Stumptner, A. H. Weiglein, F. Lammert, H. U. 
Marschall, O. Tsybrovskyy, K. Zatloukal, H. Denk and M. Trauner (2002). "Ursodeoxycholic 
acid aggravates bile infarcts in bile duct–ligated and Mdr2 knockout mice via disruption of 
cholangioles." Gastroenterology 123(4): 1238-1251. 
Fielder, E., C. Tweedy, C. Wilson, F. Oakley, F. E. N. LeBeau, J. F. Passos, D. A. Mann, T. von 
Zglinicki and D. Jurk (2020). "Anti-inflammatory treatment rescues memory deficits during 
aging in nfkb1−/− mice." Aging Cell n/a(n/a): e13188. 
Fiorucci, S., E. Antonelli, G. Rizzo, B. Renga, A. Mencarelli, L. Riccardi, S. Orlandi, R. Pellicciari 
and A. Morelli (2004). "The nuclear receptor SHP mediates inhibition of hepatic stellate cells 
by FXR and protects against liver fibrosis." Gastroenterology 127(5): 1497-1512. 
Fisahn, A., F. G. Pike, E. H. Buhl and O. Paulsen (1998). "Cholinergic induction of network 
oscillations at 40 Hz in the hippocampus in vitro." Nature 394(6689): 186-189. 
Floreani, A., D. Caroli, A. Variola, E. R. Rizzotto, S. Antoniazzi, M. Chiaramonte, N. Cazzagon, 
C. Brombin, L. Salmaso and V. Baldo (2011). "A 35-year follow-up of a large cohort of 
patients with primary biliary cirrhosis seen at a single centre." Liver Int 31(3): 361-368. 
Floreani, A., M. Marchiori, S. Bonato, M. Zucchetto, R. Naccarato and M. Chiaramonte 
(1995). "Cognitive Assessment in Primary Biliary Cirrhosis: A Case--Control Study." American 
Journal of Gastroenterology 90(2). 
Forton, D. M., N. Patel, M. Prince, A. Oatridge, G. Hamilton, J. Goldblatt, J. M. Allsop, J. V. 
Hajnal, H. C. Thomas, M. Bassendine, D. E. Jones and S. D. Taylor-Robinson (2004). "Fatigue 
and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio 
measurements with fatigue severity and blood manganese levels." Gut 53(4): 587-592. 
Franceschi, C., M. Bonafè, S. Valensin, F. Olivieri, M. De Luca, E. Ottaviani and G. De 
Benedictis (2000). "Inflamm-aging: an evolutionary perspective on immunosenescence." 
Annals of the new York Academy of Sciences 908(1): 244-254. 
 210 
Fuchs, E. C., A. R. Zivkovic, M. O. Cunningham, S. Middleton, F. E. Lebeau, D. M. Bannerman, 
A. Rozov, M. A. Whittington, R. D. Traub, J. N. Rawlins and H. Monyer (2007). "Recruitment 
of parvalbumin-positive interneurons determines hippocampal function and associated 
behavior." Neuron 53(4): 591-604. 
Gatselis, N. K., K. Zachou, G. L. Norman, S. Gabeta, P. Papamichalis, G. K. Koukoulis and G. N. 
Dalekos (2013). "Clinical significance of the fluctuation of primary biliary cirrhosis-related 
autoantibodies during the course of the disease." Autoimmunity 46(7): 471-479. 
Gershwin, M. E., C. Selmi, H. J. Worman, E. B. Gold, M. Watnik, J. Utts, K. D. Lindor, M. M. 
Kaplan and J. M. Vierling (2005). "Risk factors and comorbidities in primary biliary cirrhosis: 
a controlled interview-based study of 1032 patients." Hepatology 42(5): 1194-1202. 
Gillespie, A. K., E. A. Jones, Y.-H. Lin, M. P. Karlsson, K. Kay, S. Y. Yoon, L. M. Tong, P. Nova, J. 
S. Carr and L. M. Frank (2016). "Apolipoprotein E4 causes age-dependent disruption of slow 
gamma oscillations during hippocampal sharp-wave ripples." Neuron 90(4): 740-751. 
Ginhoux, F., M. Greter, M. Leboeuf, S. Nandi, P. See, S. Gokhan, M. F. Mehler, S. J. Conway, 
L. G. Ng and E. R. Stanley (2010). "Fate mapping analysis reveals that adult microglia derive 
from primitive macrophages." Science 330(6005): 841-845. 
Glaser, S., H. Francis, S. Demorrow, G. Lesage, G. Fava, M. Marzioni, J. Venter and G. Alpini 
(2006). "Heterogeneity of the intrahepatic biliary epithelium." World J Gastroenterol 12(22): 
3523-3536. 
Glaser, S., I. P. Lam, A. Franchitto, E. Gaudio, P. Onori, B. K. Chow, C. Wise, S. Kopriva, J. 
Venter, M. White, Y. Ueno, D. Dostal, G. Carpino, R. Mancinelli, W. Butler, V. Chiasson, S. 
DeMorrow, H. Francis and G. Alpini (2010). "Knockout of secretin receptor reduces large 
cholangiocyte hyperplasia in mice with extrahepatic cholestasis induced by bile duct 
ligation." Hepatology (Baltimore, Md.) 52(1): 204-214. 
Goldblatt, J., O. F. James and D. E. Jones (2001). "Grip strength and subjective fatigue in 
patients with primary biliary cirrhosis." Jama 285(17): 2196-2197. 
Goldblatt, J., P. J. Taylor, T. Lipman, M. I. Prince, A. Baragiotta, M. F. Bassendine, O. F. James 
and D. E. Jones (2002). "The true impact of fatigue in primary biliary cirrhosis: a population 
study." Gastroenterology 122(5): 1235-1241. 
Golgi, C., M. Bentivoglio and L. Swanson (2001). "On the fine structure of the pes 
Hippocampi major (with plates XIII-XXIII). 1886." Brain research bulletin 54(5): 461-483. 
Golovanova, E. V., L. Il'chenko, T. M. Tsaregorodtseva, T. I. Serova and R. B. Gudkova (2004). 
"[Cytokines in primary biliary cirrhosis (diagnostic and prognostic value)]." Ter Arkh 76(2): 8-
11. 
Goodwin, B., S. A. Jones, R. R. Price, M. A. Watson, D. D. McKee, L. B. Moore, C. Galardi, J. G. 
Wilson, M. C. Lewis and M. E. Roth (2000). "A regulatory cascade of the nuclear receptors 
FXR, SHP-1, and LRH-1 represses bile acid biosynthesis." Molecular cell 6(3): 517-526. 
Gordon, G. R., H. B. Choi, R. L. Rungta, G. C. Ellis-Davies and B. A. MacVicar (2008). "Brain 
metabolism dictates the polarity of astrocyte control over arterioles." Nature 456(7223): 
745-749. 
Goto, T., M. Itoh, T. Suganami, S. Kanai, I. Shirakawa, T. Sakai, M. Asakawa, T. Yoneyama, T. 
Kai and Y. Ogawa (2018). "Obeticholic acid protects against hepatocyte death and liver 
fibrosis in a murine model of nonalcoholic steatohepatitis." Scientific Reports 8(1): 8157. 
Gregory, J. L., E. F. Morand, S. J. McKeown, J. A. Ralph, P. Hall, Y. H. Yang, S. R. McColl and 
M. J. Hickey (2006). "Macrophage Migration Inhibitory Factor Induces Macrophage 
Recruitment via CC Chemokine Ligand 2." The Journal of Immunology 177(11): 8072. 
 211 
Grosmark, A. D., K. Mizuseki, E. Pastalkova, K. Diba and G. Buzsáki (2012). "REM sleep 
reorganizes hippocampal excitability." Neuron 75(6): 1001-1007. 
Grover, V. P., L. Southern, J. K. Dyson, J. U. Kim, M. M. Crossey, M. Wylezinska-Arridge, N. 
Patel, J. A. Fitzpatrick, A. Bak-Bol, A. D. Waldman, G. J. Alexander, G. F. Mells, R. W. 
Chapman, D. E. Jones and S. D. Taylor-Robinson (2016). "Early primary biliary cholangitis is 
characterised by brain abnormalities on cerebral magnetic resonance imaging." Aliment 
Pharmacol Ther 44(9): 936-945. 
Gulyás, A. I., G. G. Szabó, I. Ulbert, N. Holderith, H. Monyer, F. Erdélyi, G. Szabó, T. F. Freund 
and N. Hájos (2010). "Parvalbumin-containing fast-spiking basket cells generate the field 
potential oscillations induced by cholinergic receptor activation in the hippocampus." The 
Journal of neuroscience : the official journal of the Society for Neuroscience 30(45): 15134-
15145. 
Guzman, S. J., A. Schlögl, M. Frotscher and P. Jonas (2016). "Synaptic mechanisms of pattern 
completion in the hippocampal CA3 network." Science 353(6304): 1117-1123. 
Haczeyni, F., H. Wang, V. Barn, A. R. Mridha, M. M. Yeh, W. G. Haigh, G. N. Ioannou, Y. J. 
Choi, C. A. McWherter, N. C. Teoh and G. C. Farrell (2017). "The selective peroxisome 
proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic 
steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice." Hepatol 
Commun 1(7): 663-674. 
Hale, M., J. L. Newton and D. E. J. Jones (2012). "Fatigue in primary biliary cirrhosis." BMJ : 
British Medical Journal 345: e7004. 
Haley, M. J. and C. B. Lawrence (2016). "The blood–brain barrier after stroke: Structural 
studies and the role of transcytotic vesicles." Journal of Cerebral Blood Flow & Metabolism 
37(2): 456-470. 
Hansen, T. W. (2001). "Bilirubin brain toxicity." J Perinatol 21 Suppl 1: S48-51; discussion 
S59-62. 
Harder, D. R., C. Zhang and D. Gebremedhin (2002). "Astrocytes Function in Matching Blood 
Flow to Metabolic Activity." Physiology 17(1): 27-31. 
Harley, C. B., A. B. Futcher and C. W. Greider (1990). "Telomeres shorten during ageing of 
human fibroblasts." Nature 345(6274): 458-460. 
Hayflick, L. and P. S. Moorhead (1961). "The serial cultivation of human diploid cell strains." 
Exp Cell Res 25: 585-621. 
Hayflick, L. and P. S. Moorhead (1961). "The serial cultivation of human diploid cell strains." 
Experimental cell research 25(3): 585-621. 
He, H., A. Mennone, J. L. Boyer and S.-Y. Cai (2011). "Combination of retinoic acid and 
ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic 
cells." Hepatology (Baltimore, Md.) 53(2): 548-557. 
He, N., W. Jin, K. Lok, Y. Wang, M. Yin and Z. Wang (2013). "Amyloid-β 1–42 oligomer 
accelerates senescence in adult hippocampal neural stem/progenitor cells via formylpeptide 
receptor 2." Cell death & disease 4(11): e924-e924. 
Heathcote, E. J., K. Cauch-Dudek, V. Walker, R. J. Bailey, L. M. Blendis, C. N. Ghent, P. 
Michieletti, G. Y. Minuk, S. C. Pappas and L. J. Scully (1994). "The Canadian Multicenter 
Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary 
cirrhosis." Hepatology 19(5): 1149-1156. 
Heidari, R., V. Ghanbarinejad, H. Mohammadi, A. Ahmadi, M. M. Ommati, N. Abdoli, F. 
Aghaei, A. Esfandiari, N. Azarpira and H. Niknahad (2018). "Mitochondria protection as a 
 212 
mechanism underlying the hepatoprotective effects of glycine in cholestatic mice." 
Biomedicine & Pharmacotherapy 97: 1086-1095. 
Heithoff, B. P., K. K. George, A. N. Phares, I. A. Zuidhoek, C. Munoz-Ballester and S. Robel 
(2021). "Astrocytes are necessary for blood–brain barrier maintenance in the adult mouse 
brain." Glia 69(2): 436-472. 
Herbig, U., W. A. Jobling, B. P. Chen, D. J. Chen and J. M. Sedivy (2004). "Telomere 
shortening triggers senescence of human cells through a pathway involving ATM, p53, and 
p21(CIP1), but not p16(INK4a)." Mol Cell 14(4): 501-513. 
Herland, A., A. D. van der Meer, E. A. FitzGerald, T.-E. Park, J. J. Sleeboom and D. E. Ingber 
(2016). "Distinct contributions of astrocytes and pericytes to neuroinflammation identified 
in a 3D human blood-brain barrier on a chip." PLoS One 11(3). 
Hernandez-Segura, A., J. Nehme and M. Demaria (2018). "Hallmarks of Cellular Senescence." 
Trends Cell Biol 28(6): 436-453. 
Heuman, D. M., P. B. Hylemon and Z. R. Vlahcevic (1989). "Regulation of bile acid synthesis. 
III. Correlation between biliary bile salt hydrophobicity index and the activities of enzymes 
regulating cholesterol and bile acid synthesis in the rat." J Lipid Res 30(8): 1161-1171. 
Hewitt, G., D. Jurk, F. D. M. Marques, C. Correia-Melo, T. Hardy, A. Gackowska, R. Anderson, 
M. Taschuk, J. Mann and J. F. Passos (2012). "Telomeres are favoured targets of a persistent 
DNA damage response in ageing and stress-induced senescence." Nature Communications 
3(1): 708. 
Hirohata, S., Y. Matsueda, T. Yanagida and T. Yoshio (2017). "FRI0297 Role of serum 
interleukin-6 in blood brain barrier damages in neuropsychiatric systemic lupus 
erythematosus." Annals of the Rheumatic Diseases 76(Suppl 2): 598. 
Hirschfield, G. M. (2011). "Diagnosis of primary biliary cirrhosis." Best Pract Res Clin 
Gastroenterol 25(6): 701-712. 
Hirschfield, G. M., J. K. Dyson, G. J. Alexander, M. H. Chapman, J. Collier, S. Hübscher, I. 
Patanwala, S. P. Pereira, C. Thain and D. Thorburn (2018). "The British Society of 
Gastroenterology/UK-PBC primary biliary cholangitis treatment and management 
guidelines." Gut 67(9): 1568-1594. 
Hirschfield, G. M. and P. Invernizzi (2011). Progress in the genetics of primary biliary 
cirrhosis. Seminars in Liver Disease, © Thieme Medical Publishers. 
Hirschfield, G. M., X. Liu, C. Xu, Y. Lu, G. Xie, Y. Lu, X. Gu, E. J. Walker, K. Jing and B. D. Juran 
(2009). "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants." New 
England Journal of Medicine 360(24): 2544-2555. 
Hirschfield, G. M., A. Mason, V. Luketic, K. Lindor, S. C. Gordon, M. Mayo, K. V. Kowdley, C. 
Vincent, H. C. Bodhenheimer, Jr., A. Parés, M. Trauner, H.-U. Marschall, L. Adorini, C. 
Sciacca, T. Beecher-Jones, E. Castelloe, O. Böhm and D. Shapiro (2015). "Efficacy of 
Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to 
Ursodeoxycholic Acid." Gastroenterology 148(4): 751-761.e758. 
Hiscock, R., L. Bauld, A. Amos and S. Platt (2012). "Smoking and socioeconomic status in 
England: the rise of the never smoker and the disadvantaged smoker." Journal of Public 
Health 34(3): 390-396. 
Ho, P. P. and L. Steinman (2016). "Obeticholic acid, a synthetic bile acid agonist of the 
farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis." 
Proceedings of the National Academy of Sciences 113(6): 1600. 
 213 
Hofmann, A. F., J. Sjövall, G. Kurz, A. Radominska, C. D. Schteingart, G. S. Tint, Z. R. Vlahcevic 
and K. D. Setchell (1992). "A proposed nomenclature for bile acids." Journal of Lipid 
Research 33(4): 599-604. 
Hollingsworth, K. G., J. L. Newton, R. Taylor, C. McDonald, J. M. Palmer, A. M. Blamire and D. 
E. Jones (2008). "Pilot study of peripheral muscle function in primary biliary cirrhosis: 
potential implications for fatigue pathogenesis." Clinical Gastroenterology and Hepatology 
6(9): 1041-1048. 
Hong, I.-H., K. Lewis, P. Iakova, J. Jin, E. Sullivan, N. Jawanmardi, L. Timchenko and N. 
Timchenko (2014). "Age-associated change of C/EBP family proteins causes severe liver 
injury and acceleration of liver proliferation after CCl4 treatments." The Journal of biological 
chemistry 289(2): 1106-1118. 
Hong, S., V. F. Beja-Glasser, B. M. Nfonoyim, A. Frouin, S. Li, S. Ramakrishnan, K. M. Merry, 
Q. Shi, A. Rosenthal, B. A. Barres, C. A. Lemere, D. J. Selkoe and B. Stevens (2016). 
"Complement and microglia mediate early synapse loss in Alzheimer mouse models." 
Science 352(6286): 712. 
Hosseini, N., H. Alaei, M. Nasehi, M. Radahmadi and Z. Mohammad Reza (2014). "Effects of 
cholestasis on learning and locomotor activity in bile duct ligated rats." The Malaysian 
journal of medical sciences : MJMS 21(1): 19-28. 
Huang, C., W. Han, C. Wang, Y. Liu, Y. Chen and Z. Duan (2019). "Early Prognostic Utility of 
Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis." Dis Markers 
2019: 9121207. 
Huang, C., J. Wang, W. Hu, C. Wang, X. Lu, L. Tong, F. Wu and W. Zhang (2016). 
"Identification of functional farnesoid X receptors in brain neurons." FEBS Letters 590(18): 
3233-3242. 
Huang, F., T. Wang, Y. Lan, L. Yang, W. Pan, Y. Zhu, B. Lv, Y. Wei, H. Shi, H. Wu, B. Zhang, J. 
Wang, X. Duan, Z. Hu and X. Wu (2015). "Deletion of mouse FXR gene disturbs multiple 
neurotransmitter systems and alters neurobehavior." Frontiers in behavioral neuroscience 
9: 70-70. 
Huang, L.-T., C.-S. Hsieh, M.-H. Chou, J.-H. Chuang, C.-W. Liou, M.-M. Tiao and M.-C. Lai 
(2004). "Obstructive Jaundice in Rats: Cause of Spatial Memory Deficits with Recovery after 
Biliary Decompression." World Journal of Surgery 28(3): 283-287. 
Huber, R. M., K. Murphy, B. Miao, J. R. Link, M. R. Cunningham, M. J. Rupar, P. L. Gunyuzlu, 
T. F. Haws, A. Kassam, F. Powell, G. F. Hollis, P. R. Young, R. Mukherjee and T. C. Burn (2002). 
"Generation of multiple farnesoid-X-receptor isoforms through the use of alternative 
promoters." Gene 290(1-2): 35-43. 
Hylemon, P. B., H. Zhou, W. M. Pandak, S. Ren, G. Gil and P. Dent (2009). "Bile acids as 
regulatory molecules." J Lipid Res 50(8): 1509-1520. 
Iaccarino, H. F., A. C. Singer, A. J. Martorell, A. Rudenko, F. Gao, T. Z. Gillingham, H. Mathys, 
J. Seo, O. Kritskiy and F. Abdurrob (2016). "Gamma frequency entrainment attenuates 
amyloid load and modifies microglia." Nature 540(7632): 230-235. 
Iadecola, C. and M. Nedergaard (2007). "Glial regulation of the cerebral microvasculature." 
Nature neuroscience 10(11): 1369-1376. 
Inagaki, T., M. Choi, A. Moschetta, L. Peng, C. L. Cummins, J. G. McDonald, G. Luo, S. A. 
Jones, B. Goodwin and J. A. Richardson (2005). "Fibroblast growth factor 15 functions as an 
enterohepatic signal to regulate bile acid homeostasis." Cell metabolism 2(4): 217-225. 
Insull, W., Jr. (2006). "Clinical utility of bile acid sequestrants in the treatment of 
dyslipidemia: a scientific review." South Med J 99(3): 257-273. 
 214 
Invernizzi, P., M. Miozzo, P. M. Battezzati, I. Bianchi, F. R. Grati, G. Simoni, C. Selmi, M. 
Watnik, M. E. Gershwin and M. Podda (2004). "Frequency of monosomy X in women with 
primary biliary cirrhosis." The Lancet 363(9408): 533-535. 
Irvine, K. M., R. Skoien, N. J. Bokil, M. Melino, G. P. Thomas, D. Loo, B. Gabrielli, M. M. Hill, 
M. J. Sweet, A. D. Clouston and E. E. Powell (2014). "Senescent human hepatocytes express 
a unique secretory phenotype and promote macrophage migration." World journal of 
gastroenterology 20(47): 17851-17862. 
Ito, D., Y. Imai, K. Ohsawa, K. Nakajima, Y. Fukuuchi and S. Kohsaka (1998). "Microglia-
specific localisation of a novel calcium binding protein, Iba1." Molecular brain research 
57(1): 1-9. 
Jacoby, A., A. Rannard, D. Buck, N. Bhala, J. L. Newton, O. F. James and D. E. Jones (2005). 
"Development, validation, and evaluation of the PBC-40, a disease specific health related 
quality of life measure for primary biliary cirrhosis." Gut 54(11): 1622-1629. 
Jazrawi, R. P., J. S. de Caestecker, P. M. Goggin, A. J. Britten, A. E. Joseph, J. D. Maxwell and 
T. C. Northfield (1994). "Kinetics of hepatic bile acid handling in cholestatic liver disease: 
effect of ursodeoxycholic acid." Gastroenterology 106(1): 134-142. 
Johnson, A. and A. D. Redish (2007). "Neural ensembles in CA3 transiently encode paths 
forward of the animal at a decision point." J Neurosci 27(45): 12176-12189. 
Jones, D., P. F. Boudes, M. G. Swain, C. L. Bowlus, M. R. Galambos, B. R. Bacon, Y. Doerffel, 
N. Gitlin, S. C. Gordon, J. A. Odin, D. Sheridan, M. A. Worns, V. Clark, L. Corless, H. 
Hartmann, M. E. Jonas, A. E. Kremer, G. F. Mells, P. Buggisch, B. L. Freilich, C. Levy, J. M. 
Vierling, D. E. Bernstein, M. Hartleb, E. Janczewska, F. Rochling, H. Shah, M. L. Shiffman, J. H. 
Smith, Y. J. Choi, A. Steinberg, M. Varga, H. Chera, R. Martin, C. A. McWherter and G. M. 
Hirschfield (2017). "Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with 
primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-
blind, randomised, placebo-controlled, phase 2, proof-of-concept study." Lancet 
Gastroenterol Hepatol 2(10): 716-726. 
Jones, D. E., K. Hollingsworth, G. Fattakhova, G. MacGowan, R. Taylor, A. Blamire and J. L. 
Newton (2010). "Impaired cardiovascular function in primary biliary cirrhosis." American 
Journal of Physiology-Gastrointestinal and Liver Physiology 298(5): G764-G773. 
Joo, S. S., T. J. Won and D. I. Lee (2004). "Potential role of ursodeoxycholic acid in 
suppression of Nuclear factor kappa B in microglial cell line (BV-2)." Archives of Pharmacal 
Research 27(9): 954. 
Jurk, D., C. Wang, S. Miwa, M. Maddick, V. Korolchuk, A. Tsolou, E. S. Gonos, C. 
Thrasivoulou, M. J. Saffrey, K. Cameron and T. von Zglinicki (2012). "Postmitotic neurons 
develop a p21-dependent senescence-like phenotype driven by a DNA damage response." 
Aging cell 11(6): 996-1004. 
Jutras, M. J., P. Fries and E. A. Buffalo (2009). "Gamma-band synchronization in the macaque 
hippocampus and memory formation." J Neurosci 29(40): 12521-12531. 
Kann, O., I. E. Papageorgiou and A. Draguhn (2014). "Highly Energized Inhibitory 
Interneurons are a Central Element for Information Processing in Cortical Networks." 
Journal of Cerebral Blood Flow & Metabolism 34(8): 1270-1282. 
Keitel, V., B. Görg, H. J. Bidmon, I. Zemtsova, L. Spomer, K. Zilles and D. Häussinger (2010). 
"The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain." Glia 58(15): 
1794-1805. 
Kepecs, A. and G. Fishell (2014). "Interneuron cell types are fit to function." Nature 
505(7483): 318-326. 
 215 
Kerfoot, S. M., C. D'Mello, H. Nguyen, M. N. Ajuebor, P. Kubes, T. Le and M. G. Swain (2006). 
"TNF-α–secreting monocytes are recruited into the brain of cholestatic mice." Hepatology 
43(1): 154-162. 
Kerr, T. A., S. Saeki, M. Schneider, K. Schaefer, S. Berdy, T. Redder, B. Shan, D. W. Russell and 
M. Schwarz (2002). "Loss of nuclear receptor SHP impairs but does not eliminate negative 
feedback regulation of bile acid synthesis." Developmental cell 2(6): 713-720. 
Kita , H., Z.-X. Lian , J. Van de Water , X.-S. He , S. Matsumura , M. Kaplan , V. Luketic , R. L. 
Coppel , A. A. Ansari  and M. E. Gershwin (2002). "Identification of HLA-A2–restricted CD8+ 
Cytotoxic T Cell Responses in Primary Biliary Cirrhosis : T Cell Activation Is Augmented by 
Immune Complexes Cross-Presented by Dendritic Cells." Journal of Experimental Medicine 
195(1): 113-123. 
Kita, H., S. Matsumura, X.-S. He, A. A. Ansari, Z.-X. Lian, J. Van de Water, R. L. Coppel, M. M. 
Kaplan and M. E. Gershwin (2002). "Quantitative and functional analysis of PDC-E2–specific 
autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis." The Journal of clinical 
investigation 109(9): 1231-1240. 
Kitani, K., M. Ohta and S. Kanai (1985). "Tauroursodeoxycholate prevents biliary protein 
excretion induced by other bile salts in the rat." American Journal of Physiology-
Gastrointestinal and Liver Physiology 248(4): G407-G417. 
Kobayashi, M., Y. Kakuda, K. Harada, Y. Sato, M. Sasaki, H. Ikeda, M. Terada, M. Mukai, S. 
Kaneko and Y. Nakanuma (2014). "Clinicopathological study of primary biliary cirrhosis with 
interface hepatitis compared to autoimmune hepatitis." World journal of gastroenterology 
20(13): 3597-3608. 
Kornienko, J. S., I. S. Smirnova, N. A. Pugovkina, J. S. Ivanova, M. A. Shilina, T. M. Grinchuk, 
A. N. Shatrova, N. D. Aksenov, V. V. Zenin, N. N. Nikolsky and O. G. Lyublinskaya (2019). 
"High doses of synthetic antioxidants induce premature senescence in cultivated 
mesenchymal stem cells." Sci Rep 9(1): 1296. 
Kosaka, T., H. Katsumaru, K. Hama, J. Y. Wu and C. W. Heizmann (1987). "GABAergic 
neurons containing the Ca2+-binding protein parvalbumin in the rat hippocampus and 
dentate gyrus." Brain Res 419(1-2): 119-130. 
Kraeuter, A.-K., P. C. Guest and Z. Sarnyai (2019). "The Y-Maze for Assessment of Spatial 
Working and Reference Memory in Mice." Methods in molecular biology (Clifton, N.J.) 1916: 
105-111. 
Krähenbühl, S., C. Talos, S. Fischer and J. Reichen (1994). "Toxicity of bile acids on the 
electron transport chain of isolated rat liver mitochondria." Hepatology 19(2): 471-479. 
Krizhanovsky, V., M. Yon, R. A. Dickins, S. Hearn, J. Simon, C. Miething, H. Yee, L. Zender and 
S. W. Lowe (2008). "Senescence of activated stellate cells limits liver fibrosis." Cell 134(4): 
657-667. 
Kuiper, E. M., B. E. Hansen, R. A. de Vries, J. W. den Ouden-Muller, T. J. van Ditzhuijsen, E. B. 
Haagsma, M. H. Houben, B. J. Witteman, K. J. van Erpecum and H. R. van Buuren (2009). 
"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical 
response to ursodeoxycholic acid." Gastroenterology 136(4): 1281-1287. 
Kuipers, F., T. Claudel, E. Sturm and B. Staels (2004). "The Farnesoid X Receptor (FXR) as 
modulator of bile acid metabolism." Rev Endocr Metab Disord 5(4): 319-326. 
Kurzawa-Akanbi, M., P. S. Hanson, P. G. Blain, D. J. Lett, I. G. McKeith, P. F. Chinnery and C. 
M. Morris (2012). "Glucocerebrosidase Mutations alter the endoplasmic reticulum and 
lysosomes in Lewy body disease." Journal of Neurochemistry 123(2): 298-309. 
 216 
Lai, C. H. and K. H. Kuo (2005). "The critical component to establish in vitro BBB model: 
Pericyte." Brain Res Brain Res Rev 50(2): 258-265. 
Lan, R. Y., T. L. Salunga, K. Tsuneyama, Z. X. Lian, G. X. Yang, W. Hsu, Y. Moritoki, A. A. 
Ansari, C. Kemper, J. Price, J. P. Atkinson, R. L. Coppel and M. E. Gershwin (2009). "Hepatic 
IL-17 responses in human and murine primary biliary cirrhosis." J Autoimmun 32(1): 43-51. 
Lawson, L. J., V. H. Perry and S. Gordon (1992). "Turnover of resident microglia in the normal 
adult mouse brain." Neuroscience 48(2): 405-415. 
Layden, T. J. and J. L. Boyer (1978). "Influence of bile acids on bile canalicular membrane 
morphology and the lobular gradient in canalicular size." Lab Invest 39(2): 110-119. 
Lazaridis, K. N., B. D. Juran, G. M. Boe, J. P. Slusser, M. De Andrade, H. A. Homburger, K. 
Ghosh, E. R. Dickson, K. D. Lindor and G. M. Petersen (2007). "Increased prevalence of 
antimitochondrial antibodies in first-degree relatives of patients with primary biliary 
cirrhosis." Hepatology 46(3): 785-792. 
LeSage, G. D., A. Benedetti, S. Glaser, L. Marucci, Z. Tretjak, A. Caligiuri, R. Rodgers, J. L. 
Phinizy, L. Baiocchi, H. Francis, J. Lasater, L. Ugili and G. Alpini (1999). "Acute carbon 
tetrachloride feeding selectively damages large, but not small, cholangiocytes from normal 
rat liver." Hepatology 29(2): 307-319. 
Leuschner, U., H. Fischer, W. Kurtz, S. Güldütuna, K. Hübner, A. Hellstern, M. Gatzen and M. 
Leuschner (1989). "Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled 
double-blind trial." Gastroenterology 97(5): 1268-1274. 
Li, Y., K. Jadhav and Y. Zhang (2013). "Bile acid receptors in non-alcoholic fatty liver disease." 
Biochem Pharmacol 86(11): 1517-1524. 
Liddelow, S. A., K. A. Guttenplan, L. E. Clarke, F. C. Bennett, C. J. Bohlen, L. Schirmer, M. L. 
Bennett, A. E. Münch, W.-S. Chung, T. C. Peterson, D. K. Wilton, A. Frouin, B. A. Napier, N. 
Panicker, M. Kumar, M. S. Buckwalter, D. H. Rowitch, V. L. Dawson, T. M. Dawson, B. Stevens 
and B. A. Barres (2017). "Neurotoxic reactive astrocytes are induced by activated microglia." 
Nature 541(7638): 481-487. 
Limbad, C., T. R. Oron, F. Alimirah, A. R. Davalos, T. E. Tracy, L. Gan, P.-Y. Desprez and J. 
Campisi (2020). "Astrocyte senescence promotes glutamate toxicity in cortical neurons." 
PloS one 15(1): e0227887-e0227887. 
Lin, H., S. Patel, V. S. Affleck, I. Wilson, D. M. Turnbull, A. R. Joshi, R. Maxwell and E. A. Stoll 
(2017). "Fatty acid oxidation is required for the respiration and proliferation of malignant 
glioma cells." Neuro-Oncology 19(1): 43-54. 
Lindgren, S., H. Glaumann, S. Almer, A. Bergquist, E. Bjornsson, U. Broome, A. Danielsson, B. 
Lebrun, H. Prytz and R. Olsson (2009). "Transitions between variant forms of primary biliary 
cirrhosis during long-term follow-up." Eur J Intern Med 20(4): 398-402. 
Liu, X., P. Invernizzi, Y. Lu, R. Kosoy, Y. Lu, I. Bianchi, M. Podda, C. Xu, G. Xie and F. Macciardi 
(2010). "Genome-wide meta-analyses identify three loci associated with primary biliary 
cirrhosis." Nature genetics 42(8): 658-660. 
Long, R. G., P. J. Scheuer and S. Sherlock (1977). "Presentation and course of asymptomatic 
primary biliary cirrhosis." Gastroenterology 72(6): 1204-1207. 
Lu, C.-b., Z.-h. Wang, Y.-h. Zhou and M. Vreugdenhil (2012). "Temperature- and 
concentration-dependence of kainate-induced γ oscillation in rat hippocampal slices under 
submerged condition." Acta Pharmacologica Sinica 33(2): 214-220. 
Lu, C. B., M. Vreugdenhil and E. C. Toescu (2012). "The effect of aging-associated impaired 
mitochondrial status on kainate-evoked hippocampal gamma oscillations." Neurobiol Aging 
33(11): 2692-2703. 
 217 
Lu, W.-Y., T. G. Bird, L. Boulter, A. Tsuchiya, A. M. Cole, T. Hay, R. V. Guest, D. Wojtacha, T. Y. 
Man, A. Mackinnon, R. A. Ridgway, T. Kendall, M. J. Williams, T. Jamieson, A. Raven, D. C. 
Hay, J. P. Iredale, A. R. Clarke, O. J. Sansom and S. J. Forbes (2015). "Hepatic progenitor cells 
of biliary origin with liver repopulation capacity." Nature cell biology 17(8): 971-983. 
Ludwig, J. (1987). "New concepts in biliary cirrhosis." Semin Liver Dis 7(4): 293-301. 
Ludwig, J., E. R. Dickson and G. S. McDonald (1978). "Staging of chronic nonsuppurative 
destructive cholangitis (syndrome of primary biliary cirrhosis)." Virchows Arch A Pathol Anat 
Histol 379(2): 103-112. 
Mably, A. J., B. J. Gereke, D. T. Jones and L. L. Colgin (2017). "Impairments in spatial 
representations and rhythmic coordination of place cells in the 3xTg mouse model of 
Alzheimer's disease." Hippocampus 27(4): 378-392. 
Maciel-Baron, L. A., S. L. Morales-Rosales, A. A. Aquino-Cruz, F. Triana-Martinez, S. Galvan-
Arzate, A. Luna-Lopez, V. Y. Gonzalez-Puertos, N. E. Lopez-Diazguerrero, C. Torres and M. 
Konigsberg (2016). "Senescence associated secretory phenotype profile from primary lung 
mice fibroblasts depends on the senescence induction stimuli." Age (Dordr) 38(1): 26. 
Magen, I., Y. Avraham, Z. Ackerman, L. Vorobiev, R. Mechoulam and E. M. Berry (2009). 
"Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation." 
Journal of Hepatology 51(3): 528-534. 
MahmoudianDehkordi, S., M. Arnold, K. Nho, S. Ahmad, W. Jia, G. Xie, G. Louie, A. Kueider-
Paisley, M. A. Moseley, J. W. Thompson, L. St John Williams, J. D. Tenenbaum, C. Blach, R. 
Baillie, X. Han, S. Bhattacharyya, J. B. Toledo, S. Schafferer, S. Klein, T. Koal, S. L. Risacher, M. 
A. Kling, A. Motsinger-Reif, D. M. Rotroff, J. Jack, T. Hankemeier, D. A. Bennett, P. L. De 
Jager, J. Q. Trojanowski, L. M. Shaw, M. W. Weiner, P. M. Doraiswamy, C. M. van Duijn, A. J. 
Saykin, G. Kastenmüller, R. Kaddurah-Daouk, I. Alzheimer's Disease Neuroimaging and C. the 
Alzheimer Disease Metabolomics (2019). "Altered bile acid profile associates with cognitive 
impairment in Alzheimer's disease-An emerging role for gut microbiome." Alzheimer's & 
dementia : the journal of the Alzheimer's Association 15(1): 76-92. 
Mapstone, M., A. K. Cheema, M. S. Fiandaca, X. Zhong, T. R. Mhyre, L. H. MacArthur, W. J. 
Hall, S. G. Fisher, D. R. Peterson, J. M. Haley, M. D. Nazar, S. A. Rich, D. J. Berlau, C. B. Peltz, 
M. T. Tan, C. H. Kawas and H. J. Federoff (2014). "Plasma phospholipids identify antecedent 
memory impairment in older adults." Nature Medicine 20(4): 415-418. 
Maragakis, N. J. and J. D. Rothstein (2006). "Mechanisms of Disease: astrocytes in 
neurodegenerative disease." Nature Clinical Practice Neurology 2(12): 679-689. 
Mathiisen, T. M., K. P. Lehre, N. C. Danbolt and O. P. Ottersen (2010). "The perivascular 
astroglial sheath provides a complete covering of the brain microvessels: an electron 
microscopic 3D reconstruction." Glia 58(9): 1094-1103. 
McMaster, P. D. (1922). "DO SPECIES LACKING A GALL BLADDER POSSESS ITS FUNCTIONAL 
EQUIVALENT?" The Journal of experimental medicine 35(2): 127-140. 
McMillin, M., G. Frampton, R. Tobin, G. Dusio, J. Smith, H. Shin, K. Newell-Rogers, S. Grant 
and S. DeMorrow (2015). "TGR5 signaling reduces neuroinflammation during hepatic 
encephalopathy." Journal of neurochemistry 135(3): 565-576. 
Mells, G. F., G. Pells, J. L. Newton, A. J. Bathgate, A. K. Burroughs, M. A. Heneghan, J. M. 
Neuberger, D. B. Day, S. J. Ducker, R. N. Sandford, G. J. Alexander, D. E. J. Jones and U.-P. 
Consortium (2013). "Impact of primary biliary cirrhosis on perceived quality of life: The UK-
PBC national study." Hepatology 58(1): 273-283. 
 218 
Meng, Z., Y. Wang, L. Wang, W. Jin, N. Liu, H. Pan, L. Liu, L. Wagman, B. M. Forman and W. 
Huang (2010). "FXR regulates liver repair after CCl4-induced toxic injury." Mol Endocrinol 
24(5): 886-897. 
Metcalf, J. and O. James (1997). "The geoepidemiology of primary biliary cirrhosis." Semin 
Liver Dis 17(1): 13-22. 
Milani, S., H. Herbst, D. Schuppan, K. Y. Kim, E. O. Riecken and H. Stein (1990). "Procollagen 
expression by nonparenchymal rat liver cells in experimental biliary fibrosis." 
Gastroenterology 98(1): 175-184. 
Min, S. S., H. Y. Quan, J. Ma, J.-S. Han, B. H. Jeon and G. H. Seol (2009). "Chronic brain 
inflammation impairs two forms of long-term potentiation in the rat hippocampal CA1 
area." Neuroscience Letters 456(1): 20-24. 
Monfort, P., M.-D. Muñoz and V. Felipo (2005). "Chronic hyperammonemia in vivo impairs 
long-term potentiation in hippocampus by altering activation of cyclic GMP-dependent-
protein kinase and of phosphodiesterase 5." Journal of Neurochemistry 94(4): 934-942. 
Montagne, A., S. R. Barnes, M. D. Sweeney, M. R. Halliday, A. P. Sagare, Z. Zhao, A. W. Toga, 
R. E. Jacobs, C. Y. Liu, L. Amezcua, M. G. Harrington, H. C. Chui, M. Law and B. V. Zlokovic 
(2015). "Blood-brain barrier breakdown in the aging human hippocampus." Neuron 85(2): 
296-302. 
Montagnese, S., L. M. Nsemi, N. Cazzagon, S. Facchini, L. Costa, N. V. Bergasa, P. Amodio and 
A. Floreani (2013). "Sleep-wake profiles in patients with primary biliary cirrhosis." Liver 
International 33(2): 203-209. 
Montes, S., M. Alcaraz-Zubeldia, P. Muriel and C. Rıós (2001). "Striatal manganese 
accumulation induces changes in dopamine metabolism in the cirrhotic rat." Brain Research 
891(1): 123-129. 
Montgomery, S. M. and G. Buzsáki (2007). "Gamma oscillations dynamically couple 
hippocampal CA3 and CA1 regions during memory task performance." Proceedings of the 
National Academy of Sciences of the United States of America 104(36): 14495-14500. 
Morishita, H., J. H. Cabungcal, Y. Chen, K. Q. Do and T. K. Hensch (2015). "Prolonged Period 
of Cortical Plasticity upon Redox Dysregulation in Fast-Spiking Interneurons." Biol Psychiatry 
78(6): 396-402. 
Mosher, V. A. L., M. G. Swain, J. X. Q. Pang, G. G. Kaplan, K. A. Sharkey, G. M. MacQueen and 
B. G. Goodyear (2017). "Primary Biliary Cholangitis Alters Functional Connections of the 
Brain's Deep Gray Matter." Clinical and translational gastroenterology 8(7): e107-e107. 
Mosher, V. A. L., M. G. Swain, J. X. Q. Pang, G. G. Kaplan, K. A. Sharkey, G. M. MacQueen and 
B. G. Goodyear (2018). "Magnetic resonance imaging evidence of hippocampal structural 
changes in patients with primary biliary cholangitis." Clinical and translational 
gastroenterology 9(7): 169-169. 
Mouri, S., H. E. Mourabit, C. Bouzbib, A. Schaefer, C. Housset, N. Weiss and D. Thabut 
(2017). "Implication of the Blood-Brain Barrier in the Physiopathology of Hepatic 
Encephalopathy in Cirrhosis." Journal of Clinical and Experimental Hepatology 7: S45-S46. 
Mouries, J., P. Brescia, A. Silvestri, I. Spadoni, M. Sorribas, R. Wiest, E. Mileti, M. Galbiati, P. 
Invernizzi, L. Adorini, G. Penna and M. Rescigno (2019). "Microbiota-driven gut vascular 
barrier disruption is a prerequisite for non-alcoholic steatohepatitis development." Journal 
of Hepatology 71(6): 1216-1228. 
Mudaliar, S., R. R. Henry, A. J. Sanyal, L. Morrow, H. U. Marschall, M. Kipnes, L. Adorini, C. I. 
Sciacca, P. Clopton, E. Castelloe, P. Dillon, M. Pruzanski and D. Shapiro (2013). "Efficacy and 
 219 
safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes 
and nonalcoholic fatty liver disease." Gastroenterology 145(3): 574-582.e571. 
Munoz-Espin, D. and M. Serrano (2014). "Cellular senescence: from physiology to 
pathology." Nat Rev Mol Cell Biol 15(7): 482-496. 
Munoz-Lorente, M. A., A. C. Cano-Martin and M. A. Blasco (2019). "Mice with hyper-long 
telomeres show less metabolic aging and longer lifespans." Nat Commun 10(1): 4723. 
Nakamura, M., H. Kondo, T. Mori, A. Komori, M. Matsuyama, M. Ito, Y. Takii, M. Koyabu, T. 
Yokoyama and K. Migita (2007). "Anti-gp210 and anti-centromere antibodies are different 
risk factors for the progression of primary biliary cirrhosis." Hepatology 45(1): 118-127. 
Nakamura, M., Y. Takii, M. Ito, A. Komori, T. Yokoyama, Y. Shimizu-Yoshida, M. Koyabu, M. 
Matsuyama, T. Mori, T. Kamihira, M. Daikoku, K. Migita, H. Yatsuhashi, N. Nozaki, S. 
Shimoda and H. Ishibashi (2006). "Increased expression of nuclear envelope gp210 antigen 
in small bile ducts in primary biliary cirrhosis." J Autoimmun 26(2): 138-145. 
Nation, D. A., M. D. Sweeney, A. Montagne, A. P. Sagare, L. M. D'Orazio, M. Pachicano, F. 
Sepehrband, A. R. Nelson, D. P. Buennagel, M. G. Harrington, T. L. S. Benzinger, A. M. Fagan, 
J. M. Ringman, L. S. Schneider, J. C. Morris, H. C. Chui, M. Law, A. W. Toga and B. V. Zlokovic 
(2019). "Blood-brain barrier breakdown is an early biomarker of human cognitive 
dysfunction." Nature medicine 25(2): 270-276. 
Navawongse, R. and H. Eichenbaum (2013). "Distinct pathways for rule-based retrieval and 
spatial mapping of memory representations in hippocampal neurons." J Neurosci 33(3): 
1002-1013. 
Nelson, G., J. Wordsworth, C. Wang, D. Jurk, C. Lawless, C. Martin-Ruiz and T. von Zglinicki 
(2012). "A senescent cell bystander effect: senescence-induced senescence." Aging Cell 
11(2): 345-349. 
Nevens, F., P. Andreone, G. Mazzella, S. I. Strasser, C. Bowlus, P. Invernizzi, J. P. Drenth, P. J. 
Pockros, J. Regula, U. Beuers, M. Trauner, D. E. Jones, A. Floreani, S. Hohenester, V. Luketic, 
M. Shiffman, K. J. van Erpecum, V. Vargas, C. Vincent, G. M. Hirschfield, H. Shah, B. Hansen, 
K. D. Lindor, H. U. Marschall, K. V. Kowdley, R. Hooshmand-Rad, T. Marmon, S. Sheeron, R. 
Pencek, L. MacConell, M. Pruzanski and D. Shapiro (2016). "A Placebo-Controlled Trial of 
Obeticholic Acid in Primary Biliary Cholangitis." N Engl J Med 375(7): 631-643. 
Newton, J. L., N. Bhala, J. Burt and D. E. Jones (2006). "Characterisation of the associations 
and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life 
measure." J Hepatol 44(4): 776-783. 
Newton, J. L., K. G. Hollingsworth, R. Taylor, A. M. El-Sharkawy, Z. U. Khan, R. Pearce, K. 
Sutcliffe, O. Okonkwo, A. Davidson, J. Burt, A. M. Blamire and D. Jones (2008). "Cognitive 
impairment in primary biliary cirrhosis: symptom impact and potential etiology." Hepatology 
48(2): 541-549. 
Niedermeyer, E. (1997). "Alpha rhythms as physiological and abnormal phenomena." Int J 
Psychophysiol 26(1-3): 31-49. 
Nozaki, Y., K. Harada, T. Sanzen and Y. Nakanuma (2013). "PPARgamma ligand attenuates 
portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in 
primary biliary cirrhosis." Med Mol Morphol 46(3): 153-159. 
Nunes, A. F., J. D. Amaral, A. C. Lo, M. B. Fonseca, R. J. S. Viana, Z. Callaerts-Vegh, R. D’Hooge 
and C. M. P. Rodrigues (2012). "TUDCA, a Bile Acid, Attenuates Amyloid Precursor Protein 
Processing and Amyloid-β Deposition in APP/PS1 Mice." Molecular Neurobiology 45(3): 440-
454. 
 220 
O'Keefe, J. and J. Dostrovsky (1971). "The hippocampus as a spatial map. Preliminary 
evidence from unit activity in the freely-moving rat." Brain Research 34(1): 171-175. 
Oakley, F., M. Meso, J. P. Iredale, K. Green, C. J. Marek, X. Zhou, M. J. May, H. Millward-
Sadler, M. C. Wright and D. A. Mann (2005). "Inhibition of inhibitor of κB kinases stimulates 
hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis." 
Gastroenterology 128(1): 108-120. 
Ognjanovski, N., S. Schaeffer, J. Wu, S. Mofakham, D. Maruyama, M. Zochowski and S. J. 
Aton (2017). "Parvalbumin-expressing interneurons coordinate hippocampal network 
dynamics required for memory consolidation." Nature Communications 8(1): 15039. 
Ogrodnik, M., S. Miwa, T. Tchkonia, D. Tiniakos, C. L. Wilson, A. Lahat, C. P. Day, A. Burt, A. 
Palmer, Q. M. Anstee, S. N. Grellscheid, J. H. J. Hoeijmakers, S. Barnhoorn, D. A. Mann, T. G. 
Bird, W. P. Vermeij, J. L. Kirkland, J. F. Passos, T. von Zglinicki and D. Jurk (2017). "Cellular 
senescence drives age-dependent hepatic steatosis." Nat Commun 8: 15691. 
Ott, P. and F. S. Larsen (2004). "Blood–brain barrier permeability to ammonia in liver failure: 
a critical reappraisal." Neurochemistry International 44(4): 185-198. 
Palmela, I., F. L. Cardoso, M. Bernas, L. Correia, A. R. Vaz, R. F. Silva, A. Fernandes, K. S. Kim, 
D. Brites and M. A. Brito (2011). "Elevated levels of bilirubin and long-term exposure impair 
human brain microvascular endothelial cell integrity." Curr Neurovasc Res 8(2): 153-169. 
Palmela, I., L. Correia, R. F. Silva, H. Sasaki, K. S. Kim, D. Brites and M. A. Brito (2015). 
"Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption 
by unconjugated bilirubin: an in vitro study." Front Neurosci 9: 80. 
Palmela, I., L. Correia, R. F. M. Silva, H. Sasaki, K. S. Kim, D. Brites and M. A. Brito (2015). 
"Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption 
by unconjugated bilirubin: an in vitro study." Frontiers in neuroscience 9: 80-80. 
Palmela, I., H. Sasaki, F. L. Cardoso, M. Moutinho, K. S. Kim, D. Brites and M. A. Brito (2012). 
"Time-dependent dual effects of high levels of unconjugated bilirubin on the human blood-
brain barrier lining." Front Cell Neurosci 6: 22. 
Paolicelli, R. C., G. Bolasco, F. Pagani, L. Maggi, M. Scianni, P. Panzanelli, M. Giustetto, T. A. 
Ferreira, E. Guiducci, L. Dumas, D. Ragozzino and C. T. Gross (2011). "Synaptic pruning by 
microglia is necessary for normal brain development." Science 333(6048): 1456-1458. 
Pekny, M. and M. Nilsson (2005). "Astrocyte activation and reactive gliosis." Glia 50(4): 427-
434. 
Pellicciari, R., S. Fiorucci, E. Camaioni, C. Clerici, G. Costantino, P. R. Maloney, A. Morelli, D. J. 
Parks and T. M. Willson (2002). "6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent 
and selective FXR agonist endowed with anticholestatic activity." J Med Chem 45(17): 3569-
3572. 
Pells, G., G. F. Mells, M. Carbone, J. L. Newton, A. J. Bathgate, A. K. Burroughs, M. A. 
Heneghan, J. M. Neuberger, D. B. Day, S. J. Ducker, U.-P. Consortium, R. N. Sandford, G. J. 
Alexander and D. E. J. Jones (2013). "The impact of liver transplantation on the phenotype of 
primary biliary cirrhosis patients in the UK-PBC cohort." Journal of hepatology 59(1): 67-73. 
Pietersen, A. N., N. Patel, J. G. Jefferys and M. Vreugdenhil (2009). "Comparison between 
spontaneous and kainate-induced gamma oscillations in the mouse hippocampus in vitro." 
Eur J Neurosci 29(11): 2145-2156. 
Pollak, Y., H. Ovadia, E. Orion, J. Weidenfeld and R. Yirmiya (2003). "The EAE-associated 
behavioral syndrome: I. Temporal correlation with inflammatory mediators." Journal of 
Neuroimmunology 137(1): 94-99. 
 221 
Poo, J. L., G. Feldmann, S. Erlinger, A. Braillon, C. Gaudin, M. Dumont and D. Lebrec (1992). 
"Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by 
bile duct ligation in the rat." Gastroenterology 102(5): 1752-1759. 
Poordad, F. F. (2007). "The burden of hepatic encephalopathy." Alimentary pharmacology & 
therapeutics 25: 3-9. 
Post, S. M., H. Duez, P. P. Gervois, B. Staels, F. Kuipers and H. M. Princen (2001). "Fibrates 
suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated 
downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression." 
Arterioscler Thromb Vasc Biol 21(11): 1840-1845. 
Poupon, R. E., B. Balkau, E. Eschwège and R. Poupon (1991). "A multicenter, controlled trial 
of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group." N Engl J 
Med 324(22): 1548-1554. 
Poupon, R. E., A. M. Bonnand, Y. Chretien and R. Poupon (1999). "Ten-year survival in 
ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study 
Group." Hepatology 29(6): 1668-1671. 
Poupon, R. E., Y. Chrétien, O. Chazouillères, R. Poupon, J. Chwalow and P. B. C. S. G. and the 
French (2004). "Quality of life in patients with primary biliary cirrhosis." Hepatology 40(2): 
489-494. 
Powell, B. R., N. R. Buist and P. Stenzel (1982). "An X-linked syndrome of diarrhea, 
polyendocrinopathy, and fatal infection in infancy." The Journal of pediatrics 100(5): 731-
737. 
Prince, M. I., A. Chetwynd, W. L. Craig, J. V. Metcalf and O. F. W. James (2004). 
"Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom 
progression in a large population based cohort." Gut 53(6): 865. 
Prince, M. I., A. Chetwynd, P. Diggle, M. Jarner, J. V. Metcalf and O. F. James (2001). "The 
geographical distribution of primary biliary cirrhosis in a well-defined cohort." Hepatology 
34(6): 1083-1088. 
Puglielli, L., R. E. Tanzi and D. M. Kovacs (2003). "Alzheimer's disease: the cholesterol 
connection." Nature Neuroscience 6(4): 345-351. 
Pullinger, C. R., C. Eng, G. Salen, S. Shefer, A. K. Batta, S. K. Erickson, A. Verhagen, C. R. 
Rivera, S. J. Mulvihill, M. J. Malloy and J. P. Kane (2002). "Human cholesterol 7alpha-
hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype." The Journal of 
clinical investigation 110(1): 109-117. 
Quinn, M., M. McMillin, C. Galindo, G. Frampton, H. Y. Pae and S. DeMorrow (2014). "Bile 
acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent 
mechanisms." Digestive and liver disease : official journal of the Italian Society of 
Gastroenterology and the Italian Association for the Study of the Liver 46(6): 527-534. 
R. Pacheco-Rivera, J. A.-R., M.C. Garcia de Leon, M. Shibayama and J. Serrano-Luna (2017). 
Liver Pathophysiology - Chapter 23. E. S. T. Pablo Muriel. ProQuest Ebook Central. 
Ramos Pittol, J. M., A. Milona, I. Morris, E. C. L. Willemsen, S. W. van der Veen, E. Kalkhoven 
and S. W. C. van Mil (2020). "FXR Isoforms Control Different Metabolic Functions in Liver 
Cells via Binding to Specific DNA Motifs." Gastroenterology 159(5): 1853-1865.e1810. 
Ricci, P., A. F. Hofmann, L. Hagey, R. A. Jorgensen, E. R. Dickson and K. D. Lindor (1998). 
"Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary 
cirrhosis." Digestive diseases and sciences 43(6): 1292-1295. 
Ridlon, J. M., D. J. Kang and P. B. Hylemon (2006). "Bile salt biotransformations by human 
intestinal bacteria." J Lipid Res 47(2): 241-259. 
 222 
Robel, S., B. Berninger and M. Götz (2011). "The stem cell potential of glia: lessons from 
reactive gliosis." Nature Reviews Neuroscience 12(2): 88-104. 
Robson, E., C. Tweedy, N. Manzanza, J.-P. Taylor, P. Atkinson, F. Randall, A. Reeve, G. J. 
Clowry and F. E. N. LeBeau (2018). "Impaired Fast Network Oscillations and Mitochondrial 
Dysfunction in a Mouse Model of Alpha-synucleinopathy (A30P)." Neuroscience 377: 161-
173. 
Rodrigues, C. M., G. Fan, P. Y. Wong, B. T. Kren and C. J. Steer (1998). "Ursodeoxycholic acid 
may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial 
transmembrane potential and reactive oxygen species production." Mol Med 4(3): 165-178. 
Rogers, A. B. and R. Z. Dintzis (2012). Liver and Gallbladder. Comparative Anatomy and 
Histology: 193-201. 
Roskams, T. (2003). "Progenitor cell involvement in cirrhotic human liver diseases: from 
controversy to consensus." Journal of hepatology 39(3): 431-434. 
Roskams, T. A., N. D. Theise, C. Balabaud, G. Bhagat, P. S. Bhathal, P. Bioulac-Sage, E. M. 
Brunt, J. M. Crawford, H. A. Crosby, V. Desmet, M. J. Finegold, S. A. Geller, A. S. Gouw, P. 
Hytiroglou, A. S. Knisely, M. Kojiro, J. H. Lefkowitch, Y. Nakanuma, J. K. Olynyk, Y. N. Park, B. 
Portmann, R. Saxena, P. J. Scheuer, A. J. Strain, S. N. Thung, I. R. Wanless and A. B. West 
(2004). "Nomenclature of the finer branches of the biliary tree: canals, ductules, and 
ductular reactions in human livers." Hepatology 39(6): 1739-1745. 
Roy, D. S., A. Arons, T. I. Mitchell, M. Pignatelli, T. J. Ryan and S. Tonegawa (2016). "Memory 
retrieval by activating engram cells in mouse models of early Alzheimer’s disease." Nature 
531(7595): 508-512. 
Rubin, L. L., D. E. Hall, S. Porter, K. Barbu, C. Cannon, H. C. Horner, M. Janatpour, C. W. Liaw, 
K. Manning, J. Morales and et al. (1991). "A cell culture model of the blood-brain barrier." J 
Cell Biol 115(6): 1725-1735. 
Rudic, J. S., G. Poropat, M. N. Krstic, G. Bjelakovic and C. Gluud (2012). "Ursodeoxycholic 
acid for primary biliary cirrhosis." The Cochrane database of systematic reviews 12(12): 
CD000551-CD000551. 
Rustenhoven, J., D. Jansson, L. C. Smyth and M. Dragunow (2017). "Brain pericytes as 
mediators of neuroinflammation." Trends in pharmacological sciences 38(3): 291-304. 
Santello, M., C. Calì and P. Bezzi (2012). "Gliotransmission and the tripartite synapse." Adv 
Exp Med Biol 970: 307-331. 
Sasaki, M., M. Hsu, M. M. Yeh and Y. Nakanuma (2015). "In recurrent primary biliary 
cirrhosis after liver transplantation, biliary epithelial cells show increased expression of 
mitochondrial proteins." Virchows Arch 467(4): 417-425. 
Sasaki, M., H. Ikeda, H. Haga, T. Manabe and Y. Nakanuma (2005). "Frequent cellular 
senescence in small bile ducts in primary biliary cirrhosis: a possible role in bile duct loss." 
The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland 
205(4): 451-459. 
Sasaki, M., H. Ikeda, J. Yamaguchi, M. Miyakoshi, Y. Sato and Y. Nakanuma (2010). "Bile 
Ductular Cells Undergoing Cellular Senescence Increase in Chronic Liver Diseases Along With 
Fibrous Progression." American Journal of Clinical Pathology 133(2): 212-223. 
Sasaki, M., H. Ikeda, J. Yamaguchi, S. Nakada and Y. Nakanuma (2008). "Telomere 
shortening in the damaged small bile ducts in primary biliary cirrhosis reflects ongoing 
cellular senescence." Hepatology 48(1): 186-195. 
 223 
Sasaki, M., M. Miyakoshi, Y. Sato and Y. Nakanuma (2010). "Modulation of the 
microenvironment by senescent biliary epithelial cells may be involved in the pathogenesis 
of primary biliary cirrhosis." J Hepatol 53: 318-325. 
Sasaki, M., Y. Sato and Y. Nakanuma (2020). "Increased p16INK4a-expressing senescent bile 
ductular cells are associated with inadequate response to ursodeoxycholic acid in primary 
biliary cholangitis." Journal of Autoimmunity 107: 102377. 
Scoville, W. B. and B. Milner (1957). "Loss of recent memory after bilateral hippocampal 
lesions." J Neurol Neurosurg Psychiatry 20(1): 11-21. 
Sederberg, P. B., A. Schulze-Bonhage, J. R. Madsen, E. B. Bromfield, D. C. McCarthy, A. 
Brandt, M. S. Tully and M. J. Kahana (2007). "Hippocampal and neocortical gamma 
oscillations predict memory formation in humans." Cereb Cortex 17(5): 1190-1196. 
Seibenhener, M. L. and M. C. Wooten (2015). "Use of the Open Field Maze to measure 
locomotor and anxiety-like behavior in mice." Journal of visualized experiments : JoVE(96): 
e52434-e52434. 
Sell, S. (1998). "Comparison of liver progenitor cells in human atypical ductular reactions 
with those seen in experimental models of liver injury." Hepatology 27(2): 317-331. 
Selmi, C., F. Cavaciocchi, A. Lleo, C. Cheroni, R. De Francesco, S. A. Lombardi, M. De Santis, F. 
Meda, M. G. Raimondo, C. Crotti, M. Folci, L. Zammataro, M. J. Mayo, N. Bach, S. Shimoda, 
S. C. Gordon, M. Miozzo, P. Invernizzi, M. Podda, R. Scavelli, M. R. Martin, M. F. Seldin, J. M. 
LaSalle and M. E. Gershwin (2014). "Genome-Wide Analysis of DNA Methylation, Copy 
Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary 
Cirrhosis." Frontiers in Immunology 5(128). 
Selmi, C., M. J. Mayo, N. Bach, H. Ishibashi, P. Invernizzi, R. G. Gish, S. C. Gordon, H. I. 
Wright, B. Zweiban, M. Podda and M. E. Gershwin (2004). "Primary biliary cirrhosis in 
monozygotic and dizygotic twins: genetics, epigenetics, and environment." 
Gastroenterology 127(2): 485-492. 
Sengillo, J. D., E. A. Winkler, C. T. Walker, J. S. Sullivan, M. Johnson and B. V. Zlokovic (2013). 
"Deficiency in Mural Vascular Cells Coincides with Blood–Brain Barrier Disruption in A 
lzheimer's Disease." Brain pathology 23(3): 303-310. 
Shepherd, J., C. J. Packard, H. G. Morgan, J. L. Third, J. M. Stewart and T. V. Lawrie (1979). 
"The effects of cholestyramine on high density lipoprotein metabolism." Atherosclerosis 
33(4): 433-444. 
Sinal, C. J., M. Tohkin, M. Miyata, J. M. Ward, G. Lambert and F. J. Gonzalez (2000). 
"Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid 
homeostasis." Cell 102(6): 731-744. 
Singer, W. (1999). "Neuronal synchrony: a versatile code for the definition of relations?" 
Neuron 24(1): 49-65, 111-125. 
Smogorzewska, A. and T. de Lange (2002). "Different telomere damage signaling pathways 
in human and mouse cells." EMBO J 21(16): 4338-4348. 
Smyk, D. S., E. I. Rigopoulou, A. Pares, C. Billinis, A. K. Burroughs, L. Muratori, P. Invernizzi 
and D. P. Bogdanos (2012). "Sex differences associated with primary biliary cirrhosis." Clin 
Dev Immunol 2012: 610504. 
Sofroniew, M. V. (2009). "Molecular dissection of reactive astrogliosis and glial scar 
formation." Trends Neurosci 32(12): 638-647. 
Sohal, V. S., F. Zhang, O. Yizhar and K. Deisseroth (2009). "Parvalbumin neurons and gamma 
rhythms enhance cortical circuit performance." Nature 459(7247): 698-702. 
 224 
Solá, S., J. D. Amaral, P. M. Borralho, R. M. Ramalho, R. E. Castro, M. r. M. Aranha, C. J. Steer 
and C. M. P. Rodrigues (2006). "Functional Modulation of Nuclear Steroid Receptors by 
Tauroursodeoxycholic Acid Reduces Amyloid β-Peptide-Induced Apoptosis." Molecular 
Endocrinology 20(10): 2292-2303. 
Solá, S., R. E. Castro, P. A. Laires, C. J. Steer and C. M. P. Rodrigues (2003). 
"Tauroursodeoxycholic Acid Prevents Amyloid-β Peptide-Induced Neuronal Death Via a 
Phosphatidylinositol 3-Kinase-Dependent Signaling Pathway." Molecular Medicine 9(9): 226-
234. 
Song, P., Y. Zhang and C. D. Klaassen (2011). "Dose-response of five bile acids on serum and 
liver bile Acid concentrations and hepatotoxicty in mice." Toxicological sciences : an official 
journal of the Society of Toxicology 123(2): 359-367. 
Soto, C. (2003). "Unfolding the role of protein misfolding in neurodegenerative diseases." 
Nature Reviews Neuroscience 4(1): 49-60. 
Staels, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf and J. C. Fruchart (1998). 
"Mechanism of action of fibrates on lipid and lipoprotein metabolism." Circulation 98(19): 
2088-2093. 
Steffenach, H.-A., R. S. Sloviter, E. I. Moser and M.-B. Moser (2002). "Impaired retention of 
spatial memory after transection of longitudinally oriented axons of hippocampal CA3 
pyramidal cells." Proceedings of the National Academy of Sciences of the United States of 
America 99(5): 3194-3198. 
Steward, O., E. R. Torre, R. Tomasulo and E. Lothman (1992). "Seizures and the regulation of 
astroglial gene expression." Epilepsy Res Suppl 7: 197-209. 
Stojancevic, M., K. Stankov and M. Mikov (2012). "The impact of farnesoid X receptor 
activation on intestinal permeability in inflammatory bowel disease." Canadian journal of 
gastroenterology = Journal canadien de gastroenterologie 26(9): 631-637. 
Strautnieks, S. S., A. F. Kagalwalla, M. S. Tanner, A. S. Knisely, L. Bull, N. Freimer, S. A. 
Kocoshis, R. M. Gardiner and R. J. Thompson (1997). "Identification of a Locus for 
Progressive Familial Intrahepatic Cholestasis PFIC2on Chromosome 2q24." The American 
Journal of Human Genetics 61(3): 630-633. 
Strazzabosco, M. and L. Fabris (2012). "Development of the bile ducts: essentials for the 
clinical hepatologist." Journal of hepatology 56(5): 1159-1170. 
Stroup, D., M. Crestani and J. Y. Chiang (1997). "Identification of a bile acid response 
element in the cholesterol 7 alpha-hydroxylase gene CYP7A." Am J Physiol 273(2 Pt 1): 
G508-517. 
Suzuki, W. A. and H. Eichenbaum (2000). "The neurophysiology of memory." Ann N Y Acad 
Sci 911: 175-191. 
Tabibian, J. H., S. P. O'Hara, P. L. Splinter, C. E. Trussoni and N. F. LaRusso (2014). 
"Cholangiocyte senescence by way of N-ras activation is a characteristic of primary 
sclerosing cholangitis." Hepatology 59(6): 2263-2275. 
Tag, C. G., S. Sauer-Lehnen, S. Weiskirchen, E. Borkham-Kamphorst, R. H. Tolba, F. Tacke and 
R. Weiskirchen (2015). "Bile duct ligation in mice: induction of inflammatory liver injury and 
fibrosis by obstructive cholestasis." J Vis Exp(96). 
Tahamtan, M., I. Aghaei, V. Pooladvand, V. Sheibani, M. Khaksari and M. Shabani (2017). 
"Characterization of the CA1 pyramidal neurons in rat model of hepatic cirrhosis: insights 
into their electrophysiological properties." Metabolic Brain Disease 32(3): 881-889. 
 225 
Takano, S., Y. Ito, O. Yokosuka, M. Ohto, K. Uchiumi, K. Hirota and M. Omata (1994). "A 
multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis 
C." Hepatology 20(3): 558-564. 
Tarter, R. E., A. M. Hegedus, D. H. Van Thiel, N. Edwards and R. R. Schade (1987). 
"Neurobehavioral correlates of cholestatic and hepatocellular disease: differentiation 
according to disease specific characteristics and severity of the identified cerebral 
dysfunction." Int J Neurosci 32(3-4): 901-910. 
Theofilopoulos, S., Y. Wang, S. S. Kitambi, P. Sacchetti, K. M. Sousa, K. Bodin, J. Kirk, C. Saltó, 
M. Gustafsson and E. M. Toledo (2013). "Brain endogenous liver X receptor ligands 
selectively promote midbrain neurogenesis." Nature chemical biology 9(2): 126. 
Tort, A. B., R. W. Komorowski, J. R. Manns, N. J. Kopell and H. Eichenbaum (2009). "Theta–
gamma coupling increases during the learning of item–context associations." Proceedings of 
the National Academy of Sciences 106(49): 20942-20947. 
Traub, R. D., A. Bibbig, A. Fisahn, F. E. N. LeBeau, M. A. Whittington and E. H. Buhl (2000). "A 
model of gamma-frequency network oscillations induced in the rat CA3 region by carbachol 
in vitro." European Journal of Neuroscience 12(11): 4093-4106. 
Turner, I. B., M. Myszor, H. C. Mitchison, M. K. Bennett, A. D. Burt and O. F. W. James 
(1994). "A two year controlled trial examining the effectiveness of ursodeoxycholic acid in 
primary biliary cirrhosis." Journal of Gastroenterology and Hepatology 9(2): 162-168. 
Uhlhaas, P. J. and W. Singer (2006). "Neural Synchrony in Brain Disorders: Relevance for 
Cognitive Dysfunctions and Pathophysiology." Neuron 52(1): 155-168. 
Varadi, D. P. (1974). "Pruritus induced by crude bile and purified bile acids. Experimental 
production of pruritus in human skin." Arch Dermatol 109(5): 678-681. 
Verbeke, L., R. Farre, B. Verbinnen, K. Covens, T. Vanuytsel, J. Verhaegen, M. Komuta, T. 
Roskams, S. Chatterjee, P. Annaert, I. V. Elst, P. Windmolders, J. Trebicka, F. Nevens and W. 
Laleman (2015). "The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and 
Bacterial Translocation in Cholestatic Rats." The American Journal of Pathology 185(2): 409-
419. 
Victorelli, S. and J. F. Passos (2017). "Telomeres and Cell Senescence - Size Matters Not." 
EBioMedicine 21: 14-20. 
Võikar, V., E. Vasar and H. Rauvala (2004). "Behavioral alterations induced by repeated 
testing in C57BL/6J and 129S2/Sv mice: implications for phenotyping screens." Genes, Brain 
and Behavior 3(1): 27-38. 
von Zglinicki, T., G. Saretzki, W. Docke and C. Lotze (1995). "Mild hyperoxia shortens 
telomeres and inhibits proliferation of fibroblasts: a model for senescence?" Exp Cell Res 
220(1): 186-193. 
Vreugdenhil, M. and E. C. Toescu (2005). "Age-dependent reduction of gamma oscillations in 
the mouse hippocampus in vitro." Neuroscience 132(4): 1151-1157. 
Wahler, J. B., M. G. Swain, R. Carson, N. V. Bergasa and E. A. Jones (1993). "Blood-brain 
barrier permeability is markedly decreased in cholestasis in the rat." Hepatology 17(6): 
1103-1108. 
Wang, H., J. Chen, K. Hollister, L. C. Sowers and B. M. Forman (1999). "Endogenous bile acids 
are ligands for the nuclear receptor FXR/BAR." Mol Cell 3(5): 543-553. 
Wang, Y.-D., W.-D. Chen, M. Wang, D. Yu, B. M. Forman and W. Huang (2008). "Farnesoid X 
receptor antagonizes nuclear factor kappaB in hepatic inflammatory response." Hepatology 
(Baltimore, Md.) 48(5): 1632-1643. 
 226 
Warren, D. B., D. K. Chalmers, K. Hutchison, W. Dang and C. W. Pouton (2006). "Molecular 
dynamics simulations of spontaneous bile salt aggregation." Colloids and Surfaces A: 
Physicochemical and Engineering Aspects 280(1): 182-193. 
Washington, M. K. (2007). "Autoimmune liver disease: overlap and outliers." Mod Pathol 20 
Suppl 1: S15-30. 
Webster, C. R. and M. S. Anwer (1998). "Cyclic adenosine monophosphate-mediated 
protection against bile acid-induced apoptosis in cultured rat hepatocytes." Hepatology 
27(5): 1324-1331. 
Wei, Z., X.-C. Chen, Y. Song, X.-D. Pan, X.-M. Dai, J. Zhang, X.-L. Cui, X.-L. Wu and Y.-G. Zhu 
(2016). "Amyloid β Protein Aggravates Neuronal Senescence and Cognitive Deficits in 5XFAD 
Mouse Model of Alzheimer's Disease." Chinese medical journal 129(15): 1835-1844. 
Whittington, M. A., M. O. Cunningham, F. E. N. LeBeau, C. Racca and R. D. Traub (2011). 
"Multiple origins of the cortical gamma rhythm." Developmental Neurobiology 71(1): 92-
106. 
Whittington, M. A., R. D. Traub and J. G. Jefferys (1995). "Synchronized oscillations in 
interneuron networks driven by metabotropic glutamate receptor activation." Nature 
373(6515): 612-615. 
Wilhelmsson, U., E. A. Bushong, D. L. Price, B. L. Smarr, V. Phung, M. Terada, M. H. Ellisman 
and M. Pekny (2006). "Redefining the concept of reactive astrocytes as cells that remain 
within their unique domains upon reaction to injury." Proc Natl Acad Sci U S A 103(46): 
17513-17518. 
Wilson, J. D., C. A. Lindsey and J. M. Dietschy (1968). "Influence of dietary cholesterol on 
cholesterol metabolism." Ann N Y Acad Sci 149(2): 808-821. 
Witt-Sullivan, H., J. Heathcote, K. Cauch, L. Blendis, C. Ghent, A. Katz, R. Milner, S. C. Pappas, 
J. Rankin and I. R. Wanless (1990). "The demography of primary biliary cirrhosis in Ontario, 
Canada." Hepatology 12(1): 98-105. 
Wong, R. J., R. G. Gish and A. Ahmed (2014). "Hepatic encephalopathy is associated with 
significantly increased mortality among patients awaiting liver transplantation." Liver 
Transplantation 20(12): 1454-1461. 
Wright, G., N. A. Davies, D. L. Shawcross, S. J. Hodges, C. Zwingmann, H. F. Brooks, A. R. 
Mani, D. Harry, V. Stadlbauer and Z. Zou (2007). "Endotoxemia produces coma and brain 
swelling in bile duct ligated rats." Hepatology 45(6): 1517-1526. 
Wright, M. C., R. Issa, D. E. Smart, N. Trim, G. I. Murray, J. N. Primrose, M. J. P. Arthur, J. P. 
Iredale and D. A. Mann (2001). "Gliotoxin stimulates the apoptosis of human and rat hepatic 
stellate cells and enhances the resolution of liver fibrosis in rats." Gastroenterology 121(3): 
685-698. 
Wright, R. L. and C. D. Conrad (2005). "Chronic stress leaves novelty-seeking behavior intact 
while impairing spatial recognition memory in the Y-maze." Stress (Amsterdam, 
Netherlands) 8(2): 151-154. 
Wu, W.-B., R. Menon, Y.-Y. Xu, J.-R. Zhao, Y.-L. Wang, Y. Liu and H.-J. Zhang (2016). 
"Downregulation of peroxiredoxin-3 by hydrophobic bile acid induces mitochondrial 
dysfunction and cellular senescence in human trophoblasts." Scientific Reports 6(1): 38946. 
Wylot, B., K. Konarzewska, L. Bugajski, K. Piwocka and M. Zawadzka (2015). "Isolation of 
vascular endothelial cells from intact and injured murine brain cortex—technical issues and 
pitfalls in FACS analysis of the nervous tissue." Cytometry Part A 87(10): 908-920. 
Xu, M., T. Pirtskhalava, J. N. Farr, B. M. Weigand, A. K. Palmer, M. M. Weivoda, C. L. Inman, 
M. B. Ogrodnik, C. M. Hachfeld, D. G. Fraser, J. L. Onken, K. O. Johnson, G. C. Verzosa, L. G. P. 
 227 
Langhi, M. Weigl, N. Giorgadze, N. K. LeBrasseur, J. D. Miller, D. Jurk, R. J. Singh, D. B. Allison, 
K. Ejima, G. B. Hubbard, Y. Ikeno, H. Cubro, V. D. Garovic, X. Hou, S. J. Weroha, P. D. Robbins, 
L. J. Niedernhofer, S. Khosla, T. Tchkonia and J. L. Kirkland (2018). "Senolytics improve 
physical function and increase lifespan in old age." Nat Med 24(8): 1246-1256. 
Yamamoto, C. and H. McIlwain (1966). "ELECTRICAL ACTIVITIES IN THIN SECTIONS FROM 
THE MAMMALIAN BRAIN MAINTAINED IN CHEMICALLY-DEFINED MEDIA IN VITRO." Journal 
of Neurochemistry 13(12): 1333-1343. 
Yang, C. Y., X. Ma, K. Tsuneyama, S. Huang, T. Takahashi, N. P. Chalasani, C. L. Bowlus, G. X. 
Yang, P. S. Leung, A. A. Ansari, L. Wu, R. L. Coppel and M. E. Gershwin (2014). "IL-12/Th1 and 
IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy." 
Hepatology 59(5): 1944-1953. 
Yang, F., X. Huang, T. Yi, Y. Yen, D. D. Moore and W. Huang (2007). "Spontaneous 
development of liver tumors in the absence of the bile acid receptor farnesoid X receptor." 
Cancer Res 67(3): 863-867. 
Yang, Y., M. Zhang, G. Eggertsen and J. Y. Chiang (2002). "On the mechanism of bile acid 
inhibition of rat sterol 12alpha-hydroxylase gene (CYP8B1) transcription: roles of alpha-
fetoprotein transcription factor and hepatocyte nuclear factor 4alpha." Biochim Biophys 
Acta 1583(1): 63-73. 
Yasoshima, M., N. Kono, H. Sugawara, K. Katayanagi, K. Harada and Y. Nakanuma (1998). 
"Increased expression of interleukin-6 and tumor necrosis factor-alpha in pathologic biliary 
epithelial cells: in situ and culture study." Laboratory investigation; a journal of technical 
methods and pathology 78(1): 89-100. 
Younossi, Z. M., V. Ratziu, R. Loomba, M. Rinella, Q. M. Anstee, Z. Goodman, P. Bedossa, A. 
Geier, S. Beckebaum, P. N. Newsome, D. Sheridan, M. Y. Sheikh, J. Trotter, W. Knapple, E. 
Lawitz, M. F. Abdelmalek, K. V. Kowdley, A. J. Montano-Loza, J. Boursier, P. Mathurin, E. 
Bugianesi, G. Mazzella, A. Olveira, H. Cortez-Pinto, I. Graupera, D. Orr, L. L. Gluud, J.-F. 
Dufour, D. Shapiro, J. Campagna, L. Zaru, L. MacConell, R. Shringarpure, S. Harrison, A. J. 
Sanyal, M. Abdelmalek, G. Abrams, H. Aguilar, A. Ahmed, E. Aigner, G. Aithal, A. Ala, W. 
Alazawi, A. Albillos, M. Allison, S. Al-Shamma, R. Andrade, P. Andreone, M. Angelico, V. 
Ankoma-Sey, Q. Anstee, R. Anty, V. Araya, J. I. Arenas Ruiz, P. Arkkila, M. Arora, T. Asselah, J. 
Au, O. Ayonrinde, R. J. Bailey, M. Balakrishnan, K. Bambha, M. Bansal, S. Barritt, J. Bate, J. 
Beato, S. Beckebaum, J. Behari, P. Bellot, Z. Ben Ari, M. Bennett, M. Berenguer, B. T. 
Beretta-Piccoli, T. Berg, M. Bonacini, L. Bonet, B. Borg, M. Bourliere, J. Boursier, W. 
Bowman, D. Bradley, M. Brankovic, M. Braun, J.-P. Bronowicki, S. Bruno, E. Bugianesi, C. Cai, 
J. L. Calleja Panero, E. Carey, M. Carmiel, J. A. Carrión, M. Cave, C. Chagas, T. Chami, A. 
Chang, A. Coates, J. Cobbold, K. Corey, L. Corless, H. Cortez-Pinto, J. Crespo, O. Cruz Pereira, 
V. de Ledinghen, A. deLemos, M. Diago, J.-F. Dufour, P. Dugalic, W. Dunn, M. Elkhashab, M. 
Epstein, M. D. Escudero-Garcia, O. Etzion, L. Evans, R. Falcone, C. Fernandez, J. Ferreira, S. 
Fink, K. Finnegan, R. Firpi-Morell, A. Floreani, T. Fontanges, R. Ford, E. Forrest, A. Fowell, A. 
L. Fracanzani, S. Francque, B. Freilich, J. Frias, M. Fuchs, J. Fuentes, M. Galambos, J. Gallegos, 
A. Geerts, A. Geier, J. George, M. Ghali, R. Ghalib, P. Gholam, P. Gines, N. Gitlin, L. L. Gluud, 
T. Goeser, J. Goff, S. Gordon, F. Gordon, O. Goria, S. Greer, A. Grigorian, H. Gronbaek, M. 
Guillaume, N. Gunaratnam, D. Halegoua-De Marzio, B. Hameed, S. Hametner, J. Hamilton, S. 
Harrison, M. Hartleb, T. Hassanein, D. Häussinger, P. Hellstern, R. Herring, E. Heurich, C. 
Hezode, H. Hinrichsen, P. Holland Fischer, Y. Horsmans, J. Huang, A. Jakiche, L. Jeffers, B. 
Jones, R. Jorge, F. Jorquera, A. Kahraman, K. Kaita, N. Karyotakis, Z. Kayali, S. Kechagias, T. 
Kepczyk, M. Khalili, H. Khallafi, J. Kluwe, W. Knapple, A. Kohli, K. Korenblat, K. Kowdley, A. 
 228 
Krag, R. Krause, A. Kremer, K. Krok, M. Krstic, M. Kugelmas, S. Kumar, D. Labarriere, M. Lai, 
P. Lampertico, E. Lawitz, A. Lee, V. Leroy, S. Lidofsky, T. H. Lim, J. Lim, D. Lipkis, E. Little, A. 
Lonardo, M. Long, R. Loomba, Y. Lurie, G. Macedo, M. Makara, B. Maliakkal, M. Manns, P. 
Manousou, P. Mantry, G. Marchesini, C. Marinho, P. Marotta, H.-U. Marschall, P. Mathurin, 
M. Mayo, G. Mazzella, M. McCullen, W. McLaughlin, R. Merriman, A. Modi, E. Molina, A. 
Montano-Loza, C. Monteverde, S. Moreea, C. Moreno, F. Morisco, A. Mubarak, B. 
Muellhaupt, S. Mukherjee, T. Müller, A. Nagorni, J. Naik, G. Neff, M. Nevah, P. Newsome, E. 
Nguyen-Khac, M. Noureddin, J. Oben, A. Olveira, H. Orlent, D. Orr, J. Orr, G. Ortiz-Lasanta, V. 
Ozenne, P. Pandya, A. Paredes, J. Park, J. Patel, K. Patel, M. Uta, H. Patton, M. Peck-
Radosavljevic, S. Petta, S. Pianko, A. Piekarska, N. Pimstone, P. Pockros, S. Pol, M. Porayko, J. 
Poulos, D. Pound, J. Pouzar, J. Presa Ramos, N. Pyrsopoulos, N. Rafiq, K. Muller, A. Ramji, V. 
Ratziu, R. Ravinuthala, C. Reddy, G. Reddy K G, K. R. Reddy K R, F. Regenstein, R. Reindollar, 
A. Riera, M. Rinella, J. Rivera Acosta, G. Robaeys, S. Roberts, F. Rodriguez-Perez, M. Romero-
Gomez, R. Rubin, M. Rumi, S. Rushbrook, C. Rust, M. Ryan, R. Safadi, A. Said, K. Salminen, D. 
Samuel, J. Santoro, A. Sanyal, S. Sarkar, C. Schaeffer, J. Schattenberg, I. Schiefke, E. Schiff, W. 
Schmidt, J. Schneider, J. Schouten, M. Schultz, G. Sebastiani, D. Semela, T. Sepe, A. Sheikh, 
M. Sheikh, D. Sheridan, K. Sherman, O. Shibolet, M. Shiffman, A. Siddique, C. Sieberhagen, S. 
Sigal, K. Sikorska, K. Simon, M. Sinclair, R. Skoien, J. Solis, S. Sood, B. Souder, J. Spivey, P. 
Stal, L. Stinton, S. Strasser, P. Svorcan, G. Szabo, A. Talal, E. Tam, B. Tetri, P. Thuluvath, H. 
Tobias, K. Tomasiewicz, D. Torres, M. Trauner, C. Trautwein, J. Trotter, E. Tsochatzis, E. 
Unitt, V. Vargas, I. Varkonyi, E. Veitsman, U. Vespasiani Gentilucci, D. Victor, J. Vierling, C. 
Vincent, A. Vincze, M. von der Ohe, N. Von Roenn, R. Vuppalanchi, M. Waters, K. Watt, M. 
Weltman, A. Wieland, G. Wiener, A. Williams A, J. Williams J, J. Wilson, M. Yataco, E. 
Yoshida, Z. Younes, L. Yuan, A. Zivony, D. Zogg, H. Zoller, F. Zoulim, E. Zuckerman and M. 
Zuin (2019). "Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim 
analysis from a multicentre, randomised, placebo-controlled phase 3 trial." The Lancet 
394(10215): 2184-2196. 
Zamanian, J. L., L. Xu, L. C. Foo, N. Nouri, L. Zhou, R. G. Giffard and B. A. Barres (2012). 
"Genomic Analysis of Reactive Astrogliosis." The Journal of Neuroscience 32(18): 6391. 
Zenouzi, R., J. von der Gablentz, M. Heldmann, M. Göttlich, C. Weiler-Normann, M. Sebode, 
H. Ehlken, J. Hartl, A. Fellbrich, S. Siemonsen, C. Schramm, T. F. Münte and A. W. Lohse 
(2018). "Patients with primary biliary cholangitis and fatigue present with depressive 
symptoms and selected cognitive deficits, but with normal attention performance and brain 
structure." PloS one 13(1): e0190005-e0190005. 
Zhang, L., Y. D. Wang, W. D. Chen, X. Wang, G. Lou, N. Liu, M. Lin, B. M. Forman and W. 
Huang (2012). "Promotion of liver regeneration/repair by farnesoid X receptor in both liver 
and intestine in mice." Hepatology 56(6): 2336-2343. 
Zhang, L.-N., T.-Y. Shi, X.-H. Shi, L. Wang, Y.-J. Yang, B. Liu, L.-X. Gao, Z.-W. Shuai, F. Kong, H. 
Chen, W. Han, S.-M. Han, Y.-Y. Fei, Q.-C. Cui, Q. Wang, M. Shen, D. Xu, W.-J. Zheng, Y.-Z. Li, 
W. Zhang, X. Zhang and F.-C. Zhang (2013). "Early biochemical response to ursodeoxycholic 
acid and long-term prognosis of primary biliary cirrhosis: Results of a 14-year cohort study." 
Hepatology 58(1): 264-272. 
Zhang, Y., Y. Chen, S. L. Bressler and M. Ding (2008). "Response preparation and inhibition: 
the role of the cortical sensorimotor beta rhythm." Neuroscience 156(1): 238-246. 
Zhang, Y., H. R. Kast-Woelbern and P. A. Edwards (2003). "Natural structural variants of the 
nuclear receptor farnesoid X receptor affect transcriptional activation." J Biol Chem 278(1): 
104-110. 
 229 
Zhang, Y., Y. Xiong and W. G. Yarbrough (1998). "ARF promotes MDM2 degradation and 
stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression 
pathways." Cell 92(6): 725-734. 
Zheng, C., K. W. Bieri, E. Hwaun and L. L. Colgin (2016). "Fast Gamma Rhythms in the 
Hippocampus Promote Encoding of Novel Object-Place Pairings." eNeuro 3(2): 
ENEURO.0001-0016.2016. 
Zhou, J., N. Huang, Y. Guo, S. Cui, C. Ge, Q. He, X. Pan, G. Wang, H. Wang and H. Hao (2019). 
"Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis." Acta 
Pharmaceutica Sinica B 9(3): 526-536. 
Zimmermann, H. and J. Reichen (1992). "Ursodeoxycholate has no beneficial effect on liver 
function or histology in biliary cirrhosis in the rat." Journal of hepatology 16(3): 355-359. 
 
